


CURRICULUM VITAE

DATE: October 16, 2017

NAME: John Paul Bilezikian



EDUCATION:

Harvard College Cambridge, Massachusetts	B.A. (Magna Cum Laude in Biochemistry)	1965
---	--	------

College of Physicians & Surgeons Columbia University, New York, New York	M.D.	1969
---	------	------

POSITIONS HELD:

Intern and Assistant Resident	Medical Service Presbyterian Hospital New York, New York	1969-1971
----------------------------------	--	-----------

Clinical Associate (USPHS)	Section of Mineral Metabolism Metabolic Diseases Branch National Institutes of Health Bethesda, Maryland	1971-1973
-------------------------------	---	-----------

Senior Resident	Medical Service Presbyterian Hospital New York, New York	1973-1974
-----------------	--	-----------

Chief Resident	Medical Service Presbyterian Hospital New York, New York	1974-1975
----------------	--	-----------

Assistant Professor of Medicine	Department of Medicine College of Physicians & Surgeons Columbia University	1975-1980
Assistant Attending Physician	Presbyterian Hospital New York, New York	1975-1980
Associate Attending Physician	Presbyterian Hospital New York, New York	1980-1985
Associate Professor of Medicine	Department of Medicine College of Physicians & Surgeons Columbia University	1980-1981
Associate Professor of Medicine and of Pharmacology	Department of Medicine and Pharmacology College of Physicians & Surgeons Columbia University	1981-1985
Director, Metabolic Bone Diseases Program	Department of Medicine College of Physicians & Surgeons Columbia University	1982-
Associate Professor of Medicine and of Pharmacology (with tenure)	Department of Medicine and Pharmacology College of Physicians & Surgeons Columbia University	1982-1985
Attending Physician	Presbyterian Hospital New York, New York	1985-
Professor of Medicine and Pharmacology	Department of Medicine and Pharmacology College of Physicians & Surgeons Columbia University	1985-

Chief, Division of Endocrinology	Department of Medicine College of Physicians & Surgeons Columbia University	1987-2015
Director, Medical House Staff Training Program	Department of Medicine College of Physician & Surgeons Columbia University	1990-1996
Associate Chair	Department of Medicine College of Physicians & Surgeons Columbia University	1996-2003
Vice Chair, International Education and Research	Department of Medicine College of Physicians & Surgeons Columbia University	2015-

OTHER APPOINTMENTS:

Molly Bern Senior Investigator	New York Heart Association	1975-1979
Cardiovascular and Pulmonary Study Section	National Institutes of Health	1982
Chairman, Resident Selection Committee	Medical Service Presbyterian Hospital New York, New York	1980-1995
Editor	ENDOCRINOLOGY	1983-1987
General Medicine B Study Section (Member)	National Institutes of Health	1983-1987
Chairman,	American Society for Bone and	1985-1995

Publications Committee	Mineral Research	
Chairman, Program Committee	10th Meeting of the American Society for Bone and Mineral Research	1988
Councillor	American Society for Bone and Mineral Research	1987-1990
Executive Editor	TRENDS IN ENDOCRINOLOGY AND METABOLISM Elsevier	1989-1998
General Medicine B Study Section	National Institutes of Health	1990
Advisory Committee	Endocrinology Research Program NIDDK; NIH	1991-1993
Advisory Medical Panel	The Paget Foundation (for Paget's disease of bone and related disorders)	1991-
Program Committee	Ninth International Congress of Endocrinology (Nice, France)	1992
Editorial Board	Journal of Women's Health	1992-
Editorial Review Committee	The Paget Foundation (for Paget's disease of bone and related disorders)	1992-
Central Committee	International Congress of Endocrinology	1992-2000
Publications Committee	The Endocrine Society	1993

Associate Editor	Journal of Clinical Endocrinology and Metabolism	1994-1999
Chair	Consensus Development Conference on Optimal Calcium Intake National Institutes of Health	1994
Special Study Section	Basic Osteoporosis: New Experimental Strategies (BONES Initiative): National Institutes of Health	1994
General Medicine B Study Section	National Institutes of Health	1995
Member	Subspecialty Board on Endocrinology: Diabetes and Metabolism, American Board of Internal Medicine	1995-2001
Member	Special Grants Review Committee National Institutes of Arthritis, Musculoskeletal and Skin Diseases	1995-1998
Steering Committee	World Foundation for Medical Studies in Female Health	1995-2004
Chair	Command Osteoporosis Integration Panel: U.S. Army Medical Research and Materiel	1996
Orthopedic and Musculoskeletal Study Section	National Institutes of Health	1996 1997
Board Member	Endocrine Fellows Foundation	1996-
Co-Chair	City-wide Conference on Osteoporosis Peking Union Medical College Beijing, China	1996
Co-Chair	City-wide Conference on Osteoporosis	1996

Shanghai Second Medical University
Shanghai, China

Editorial Advisory Board	Prevention	1997-2003
Board of Trustees	International Society for Clinical Densitometry	1997-2003
Associate Director	Partnership for Women's Health at Columbia	1997-2004
Wellcome Visiting Professorship Committee	Federation of American Societies for Experimental Biology (FASEB)	1997-2000
Member	Committee on Body Composition, Nutrition and Health of Military Women Institute of Medicine National Academy of Sciences	1997-1998
Member	Board of Directors, International Society of Clinical Densitometry	1997-2003
Associate Editor	Journal of Clinical Densitometry	1998-1999
Editorial Board	Women's Health in Primary Care	1998-2005
Editorial Board	American Journal of Medicine	1998-2004
Associate Editor	The Journal of Gender Specific Medicine	1998-2004
Member, Development Committee	World Federation on Osteoporosis	1998
Editorial Board	Trends in Endocrinology and Metabolism	1998-1999
Chair	Greater New York Regional	1998-2006

	Osteoporosis Board	
Founding Member	Association for Patient-Oriented Research	1998-
Member	Osteoporosis Research and Advisory Group	1998-2002
Scientific Committee	International Symposium on Thyroid and Parathyroid Tumors, Pisa, Italy	1999
Planning Committee	Consensus Development Conference on Osteoporosis; National Institutes of Health	1999
Member	Panel, Clinical Consensus on Multiple Endocrine Neoplasia Syndromes Type 1 and 2	1999
PRESIDENT	International Society for Clinical Densitometry	1999-2001
Member	International Scientific Committee Third International Congress on Osteoporosis, Xi'an, P.R. China	1999
Member	Journals Steering Committee The Endocrine Society	1999-2004
Member	Board of Governance International Osteoporosis Foundation	1999-2016
Member	Committee of Scientific Advisors International Osteoporosis Foundation	1999-
EDITOR-IN-CHIEF	JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM	2000-2004
Member	Advisory Board: Women in Transition:	2000

The Crucial Years before the Menopause
NIH

Member	International Advisory Board 1 st International Conference on Osteoporosis in Men, Siena, Italy	2001
Member	Scientific Committee International Congress on Glucocorticoid- Induced Osteoporosis, Mantova, Italy	2001
Member	Board of Trustees National Osteoporosis Foundation	2001-2004
Member	Institute for Endocrine Health Advisory Board	2001-
Co-Chair	Workshop on Asymptomatic Primary Hyperparathyroidism National Institutes of Health	2002
Member	Recent Advances Committee for Endocrinology American Board of Internal Medicine	2002-2003
Member	International Advisory Board II International Congress on Osteoporosis in Men, Genoa, Italy	2003
Panelist	Position Development Conference Int'l Society of Clinical Densitometry	2003
Member	Editorial Board Yonsei Medical Journal	2003-
Editor	Clinical Cases in Bone and Mineral Metabolism	2003-

Member	Steering Committee World Congress on Osteoporosis Rio de Janeiro, Brazil	2003-2004
Member	Editorial Board Current Osteoporosis Reports	2003-
Member	International Relations Committee International Society of Clinical Densitometry	2003-2006
Member	Academic Relations Task Force American Association of Clinical Endocrinologists	2003-2004
Chair	Board of Directors Endocrine Fellows Foundation	2003-
Co-Director	Symposia: Osteoporosis and Its Treatment Brazilian Society of Bone and Mineral Research	2004
Member	Scientific Program Committee International Osteoporosis Foundation Meeting Toronto, Canada	2004- 2006
Section Editor	Journal of Women's Health	2005-
Member	Board of Directors International Society for Clinical Densitometry	2005-
Editorial Board	Arquivos Brasileiros de Endocrinologia e Metabologia	2005
Councillor	The Endocrine Society	2005-2008

Moderator	Position Development Conference International Society for Clinical Densitometry	2005
Member	Women in Bone and Mineral Research Committee, ASBMR	2005-2010
Member	Editorial Board The Armenian Medical Review	2005-
Member	Editorial Board Journal of Clinical Densitometry	2005-
Associate Editor	Osteoporosis International	2006-2007
Member	Board of Directors The Paget Foundation	2006-2012
Medical Advisor	Board of Directors Hypoparathyroidism Association	2006-
Co-Director	Annual Fellows' Forum in Metabolic Bone Diseases, ASBMR	2006-
Co-Director	American Society of Bone and Mineral Research/Japan Osteoporosis Society Joint Symposium, Tokyo	2006
Chair	ASBMR Symposium: Targeting Bone Remodeling for the Treatment of Osteoporosis, Hawaii	2007
Chair	International Relations Committee International Society for Clinical Densitometry	2007-2009

Co-Chair	Bisphosphonates and Osteonecrosis of the Jaw New York Academy of Sciences	2007
Co-Moderator	Position Development Conference International Society for Clinical Densitometry	2007
Editorial Board	Clinical and Translational Science	2007-
Member	International Board of Medical Advisors Yerevan State Medical University Yerevan, Armenia	2007-
Director	Annual Symposia on Osteoporosis Yerevan State Medical University and American University of Armenia, Yerevan, Armenia	2007-
Senior Associate Editor	Journal of Bone and Mineral Research	2008-2013
Nominating Committee	American Society for Bone and Mineral Research	2008
Co-Chair	3 rd International Workshop on Asymptomatic Primary Hyperparathyroidism	2008
International Advisor	Chinese Journal of Osteoporosis and Bone Mineral Research	2008-
Member	Committee of the Scientific Advisors of F.I.R.M.O. (Fondazione Italiana per la Ricerca sulle Malattie dell'Osso.	2008-
Advisory Board	Armenian American Wellness Center Yerevan, Armenia	2008-

Co-Chair	Skeletal Endocrinology 3 rd International Meeting Brescia, Italy	2009
External Review Committee	University of Alabama Center for Metabolic Bone Diseases	2009
Co-Chair	Parathyroids, 2010 Pisa, Italy	2010
Member	Armenian Medical World Congress '09 Honorary Committee	2009
Member	ASBMR Clinician Outreach Taskforce	2009
Member	Scientific Committee 5 th International Conference on Osteoporosis and Skeletal Research, China	2010
Moderator	Leadership Round Table on Skeletal Health Yerevan, Armenia	2010-
Co-Moderator	ISCD and IOF FRAX Initiative and ISCD 2010 FRAX Position Development Conference, Bucharest, Romania	2010
Editorial Board	Endocrine	2011-
Editorial Board	BoneKEY	2011-
Working Groups	International Osteoporosis Foundation Education; Rare Bone Diseases; Glucocorticoid Induced Osteoporosis; Compliance with Therapy	2011-
International Advisory Board	Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group	2011-

Co-Chair	International Symposium on Primary Hyperparathyroidism and Osteoporosis Bucharest, Romania	2011
Co-Moderator	ISCD Position Development Conference Body Composition, Sao Paulo, Brazil	2012
Member	ASBMR Working Group on Outreach to Chinese Bone Scientists	2012-
Member	Osteoporosis & Bone Scientific Committee American Association of Clinical Endocrinologists	2012-
Member	Scientific Committee, Armenian World Medical Congress	2013
Co-Moderator	Position Development Conference ISCD	2013
Member	Scientific Statement Task Force The Endocrine Society	2013-2015
Executive Advisory Editor	Bone Research	2013-
International Member Scientific Advisory Committee	31 st Brazilian Congress of Endocrinology, Curitiba, Brazil	2014
Chair	“Insights on Hypoparathyroidism: applying evidence to reduce the burden of disease and improve patient outcomes.” American Thyroid Association	2014
Member	Finance Committee, American Society for Bone and Mineral Research	2014-
Member	Program Advisory Committee: Annual	2014-2015

Member	Meeting of the American Society for Bone and Mineral Research Bone Working Group Endocrine Society	2014-
Member	Bone and Parathyroid Scientific Committee American Association of Clinical Endocrinologists	2014-
Co-Chair	1 st International Conference on the Diagnosis, Management, and Treatment of Hypoparathyroidism Florence, Italy	2015
Member	Expert Panel, Position Development Conference of the International Society of Clinical Densitometry	2015
Co-Chair	Skeletal Endocrinology Brescia, Italy	2015
Member	Nominating Committee American Society for Bone and Mineral Research	2015
Faculty Member	Wu Family China Center for Health Initiatives, Columbia University Medical Center	2015-
Member	Nominating Committee Endocrine Society	2016-
Co-Director	3 rd International Osteoporosis Summit of Eastern European and Central Asian Countries of the International Osteoporosis Foundation Yerevan, Armenia	2016
Chair	Search Committee for Editor-in-Chief of Journal of Bone and Mineral Research and JBMR Plus	2016
Editorial Board	Osteoporosis and Sarcopenia	2016-
Editorial Board	Endocrinology and Metabolism	2016-
Member, ex officio	Publications Committee American Society for Bone	2016-

MENTORSHIP

Dr. Bilezikian has mentored over 70 individuals many of whom have gone on to distinguish themselves in Endocrinology and in the field of Metabolic Bone Diseases both at his institution, the College of Physicians and Surgeons, at other national institutions and internationally. The reach of Dr. Bilezikian's mentorship activities extends far beyond the borders of the United States including: Armenia, Australia, Argentina, Brazil, Canada, China, France, Germany, Greece, Italy, Japan, Korea, Iran and Lebanon. A partial listing follows:

At the College of Physicians and Surgeons, Columbia University

Elizabeth Shane, MD, Professor of Medicine; Vice-Dean for Student Research

Shonni Silverberg, MD Professor of Medicine

Susan Steinberg, MD, Professor of Pharmacology

Felicia Cosman, MD, Professor of Medicine, Director of Research, National Osteoporosis Foundation and co-Editor-in-Chief of Osteoporosis International

Jack Tohme, MD, Associate Professor of Medicine

Susan Thys-Jacobs, MD, Assistant Professor of Medicine

Mishaela Rubin MD, MS, Associate Professor of Medicine

Marcella Walker MD, MS, Associate Professor of Medicine

Natalie Cusano, MD, MS, Assistant Professor of Medicine

Aline Costa, MD, Associate Research Scientist

Leonardo Bandeira, MD, Post-doctoral Research Fellow

At other institutions in the United States:

Evelyn Horn, MD, Professor of Clinical Medicine, Weill-Cornell University Medical College

Steven Grinspoon, MD, Professor of Medicine, Harvard Medical School

Lorraine Fitzpatrick, MD, Former Professor of Medicine Mayo Medical School and Chief Medical Officer, Radius Pharmaceuticals

Carly Rochester MD, Associate Professor, Yale University School of Medicine

Linda Kupfer, PhD, Senior Policy Analyst, Fogarty International Center, National Institutes of Health

Daniel Coleman, PhD, Associate Director, Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals

Shira Rhode, PhD, Director, Worldwide Regulatory Strategy Pfizer Pharmaceuticals

Monica Girotra, MD, Associate Professor of Medicine, Memorial Sloan Kettering Cancer Center

Sherry Liu, PhD, Assistant Professor of Bioengineering, University of Pennsylvania School of Medicine

Mariam Manoukian, MD, Assistant Clinician, Stanford University School of Medicine

At institutions outside the United States:

Markus Seibel, MD, Professor of Medicine, University of Sydney, Sydney, Australia

Liu JanMin, MD, Professor and Director of Metabolic Bone Diseases Research, Second Medical Institute of Shanghai, Ru Jin Hospital, Shanghai China

Kazuhido Ogino, MD, Professor of Endocrinology and Cardiology, Tattori Medical School, Japan

Amy Han, PhD, National Institute of Toxicological Research, Food and Drug Administration, Seoul, Korea

Frederick Chan, MD, Assistant Professor, Hong Kong University School of Medicine, Queen Elizabeth Hospital, Hong Kong, China

Andrew Ho, MD, Assistant Professor, Endocrinology New Territories Medical School, Hong Kong, China

Laura Masi, MD, Associate Professor, Division of Metabolic Bone Diseases, University of Florence, Florence Italy

Carolina Moreira, MD, PhD, Assistant Professor, Director of Metabolic Bone Diseases, Federal University of Curitiba, Curitiba Brazil

Barbara Silva, MD, PhD, Professor of Medicine, University Bel Horizonte, Felicio Rocho Hospital and Santa Casa de Belo Horizonte, Brazil

Henrique Arante, MD, Federal University of Sao Paulo, Sao Paulo, Brazil

Cristiana Cipriani, Assistant Professor of Medicine, University of Rome, Rome, Italy

Silvia Civiastelli, MD, Instructor, University of Bresica, Brescia, Italy

Maria Belen Zanchetta, MD, University of Buenos Aires, Buenos Aires, Argentina

Stephanie Boutroy, PhD, Assistant Professor, University Claude Bernard, Lyon, France

Nicholas Hutchings, Fulbright Scholar, American University of Armenia, Yerevan, Armenia

Monika Pawlowka, Assistant Professor of Medicine, University of British Columbia, British Columbia, Canada

Vahe Krmoyan, MPH candidate, American University of Armenia, Yerevan, Armenia

Yu-Kwang Donovan Tay, MBBS, Consultant, Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, Singapore

AWARDS, DISTINCTIONS AND HONOR SOCIETIES:

L.J. Henderson Prize, Biochemistry, Harvard College	1965
Alpha Omega Alpha (Columbia University, Physicians & Surgeons Chapter)	1968
J. Murray Steele Award, New York Heart Association	1976
Steven Triennial Prize, College of Physicians & Surgeons	1977
Research Career Development Award, National Institutes of Health	1977-1982
President, Alumni Association,	1987-1989

College of Physicians & Surgeons	
Silver Medal, College of Physicians & Surgeons Alumni Association	1991
Lillian Clark Visiting Professor in Mineral Metabolism The University of Texas, Southwestern Medical Center at Dallas	1992
Alumni Medal, Alumni Federation of Columbia University	1993
President, American Society for Bone and Mineral Research	1995-1996
Doody Award: THE PARATHYROIDS (For Best Health Science Books)	1994-1995
William Resnick Memorial Lecture, Stamford Hospital Stamford, CT	1995
Society for Clinical Densitometry (First Honorary Member)	1995
Visiting Professor in Endocrinology, Department of Medicine University of Maryland	1995
Endocrine Fellows Foundation Visiting Lectureship Award	1996
The MacPherson Visiting Professor and Physician-in-Chief Pro Tem Deaconess Hospital, Harvard Medical School, Boston, MA	1996
Visiting Professor Hong Kong University Medical School, Hong Kong	1996
Visiting Professor and John Edson Lecturer Long Island College Hospital	1997
Doody Award: PRINCIPLES OF BONE BIOLOGY	1996-1997

(For Best Health Science Books)

Visiting Professor, Bone and Mineral Metabolism Beth Israel Hospital, Harvard Medical School, Boston	1997
Mayo Clinic Distinguished Lecturer in Medical Science Rochester, Minnesota	1997
ASBMR Abstract Presentation Award: Outstanding Research in the Pathophysiology of Osteoporosis (shared with Drs. A. Morishima and M. Grumbach)	1997
Plenary Lecturer: 27th Annual Meeting of the Endocrine Society of India	1997
DISTINGUISHED PHYSICIAN AWARD, Endocrine Society	1998
Neil Auerbach Memorial Lecturer, Norwalk Hospital	1998
Boy Frame Distinguished Lecturer, Henry Ford Hospital	1998
Featured Lecturer, 3rd International Congress on Osteoporosis Xian, China	1999
Invited Speaker, 13th Annual Smithwick Symposium, Boston University	1999
Plenary Lecturer, Swiss Bone and Mineral Society, Berne, Switzerland	1999
Tisdale Lecturer, University of Vermont Medical School	1999
Invited Speaker, 4th International Conference on New Actions of Parathyroid Hormone, Malta	1999
HONORARY PROFESSOR OF THE MEDICAL FACULTY UNIVERSITY OF HEIDELBERG	1999-
Honorary Member, Sociedade Brasileira para o Estudo do Metabolismo Osseo e Mineral	1999-

Featured Speaker, First Congress of the Brazilian Society of Bone and Mineral Metabolism and Sixth International Symposium on Metabolic Bone Diseases, Recife, Brazil	1999
Speaker, NIH Consensus Development Conference on Osteoporosis	2000
Featured Speaker, IV Argentine Osteoporosis Congress and II Mercosur Congress of Metabolic Bone and Mineral Diseases, Buenos Aires	2000
First Distinguished Lecturer in Musculoskeletal Medicine University of Western Ontario, Ontario, Canada	2000
THE FREDERIC C. BARTTER AWARD for Excellence in Clinical Investigation American Society for Bone and Mineral Research	2000
Plenary Lecturer, Korean Society of Menopause Seoul, Korea	2000
Invited Featured Lecturer, NIH Inter-Institute Endocrine Grand Rounds: A Tribute to Gerald D. Aurbach	2000
Featured Speaker, V Congreso Iberoamericano SIBOMM; Buenos Aires, Argentina	2000
Founder and Director, Endocrine Fellows Foundation Preceptorship in Osteoporosis and Metabolic Bone Diseases, Columbia University, Division of Endocrinology	2000-
Frank and Sheila Thompson Lecturer in Endocrinology Texas A&M University, Health Science Center, Temple Campus	2001
Plenary Lecturer, Endocrine Society, 83 rd Annual Meeting	2001
Invited Speaker, First International Conference on Osteoporosis in Men Siena, Italy	2001

Plenary Speaker, 2 nd International Greater China Congress of Endocrinology, Hong Kong, China	2001
Invited Speaker, Second International Congress on Glucocorticoid-Induced Osteoporosis, Mantova, Italy	2001
MASTER, American College of Endocrinology	2001
Visiting Professor, Division of Mineral Metabolism Barnes-Jewish Hospital, Washington University School of Medicine St. Louis, MO	2001
Featured Speaker, VIII Simposio Internacional de Doencas Metabolicas Osseas, Recife, Brazil	2001
Invited Speaker, Third International Conference on Cancer-Induced Bone Diseases, Hyogo, Japan	2001
Featured Speaker, 8 th Annual Meeting of the Canarian Society of Internal Medicine, Gran Canaria, Spain	2001
Honorary Member, Belgian Bone Club	2001
Visiting Professor, Division of Endocrinology and Metabolism University of Louisville Health Sciences Center	2002
Magistral Lecturer: Osteoporosis, Brescia University, Brescia, Italy	2002
Featured Speaker, Annual Meeting of the Sociedad Chilena de Osteologia y Metabolismo Mineral, Santiago, Chile	2002
Invited Speaker, 25 th Brazilian Congress of Endocrinology and Metabolism, Brazil	2002
Beverly Towery Lecture, University of Louisville School of Medicine	2002
Featured Speaker, First Annual Symposium: Duke Center for Bone and Mineral Disorders	2002

Invited Speaker, 6 th European Congress of Endocrinology Lyon, France	2003
Invited Speaker, Third International Congress on Glucocorticoid-induced Osteoporosis. Turin, Italy	2003
Invited Speaker, Second International Congress on Osteoporosis in Men Genoa, Italy	2003
Invited Speaker, 12 th Balkan Congress of Endocrinology and 30 th Panhellenic Congress of Endocrinology and Metabolism Thessaloniki, Greece	2003
Invited Speaker, 3 rd Brazilian Congress of Bone and Mineral Research Recife, Brazil, 1 st Joint Meeting of the Brazilian Society of Endocrinology and Metabolism/AACE, Porto de Galinhas, Brazil	2003
Co-Author: ASBMR designation of seminal paper of the first two decades of the J Bone Min Res: Skeletal Disease in Primary Hyperparathyroidism 4:283-291, 1989.	2003
Featured Speaker, 9 th Annual Meeting of the Spanish Society of Bone and Mineral Research, Gran Canaria, Spain	2003
Keynote Speaker, 9 th Annual Meeting of the International Society for Clinical Densitometry, Los Angeles, California	2003
Consultant, NIH Osteoporosis and Related Bone Diseases National Resource Center	2003-
Co-Chair, State of the Art in the Management of Osteoporosis, A Symposium of the Office of Women's Health U.S. Department of Health and Human Services	2003
Participant, Surgeon General's Report on Osteoporosis and Bone Health	2003
ASBMR Abstract Presentation Award: Outstanding Research in the Treatment of Osteoporosis (shared with Drs. Black, Ensrud, Greenspan, McGowan,	2003

Lang, Garnero, and Rosen)

The Sixth Annual John G. Haddad, Jr. Memorial Lecturer, University of Pennsylvania	2003
Co-Chair, Skeletal Endocrinology (Workshop), Garda Lake, Italy	2003
Invited Speaker, 26th Brazilian Congress of Endocrinology and Metabolism, Brazil	2004
Plenary Lecturer, 9 th International Workshop on Multiple Endocrine Neoplasia, NIH	2004
International Leadership and Service Award, Brazilian Society of Endocrinology and Metabolism and the Brazilian Society of Densitometry	2004
Top 5% of Extramural NIH Grantees over past 25 years (1979-2004)	2004
Plenary Lecturer, 9 th Armenian Medical World Congress, San Francisco	2005
Invited Speaker, Society for Endocrinology, Metabolism and Diabetes of South Africa	2005
Plenary Lecturer, Endo-Recife, Recife, Brazil	2005
Invited Speaker, Bone and Tooth Society, England	2005
Invited Speaker, 2 nd Joint Clinical Update Endocrinology Symposium, Puerto Rico Society of Endocrinology and Diabetes	2005
Invited Speaker, National Osteoporosis Foundation, International Symposium on Osteoporosis	2005
Visiting Professor, Walter Reed Army Medical Center, Endocrinology Division	2005

JOHN P. McGOVERN COMPLEAT PHYSICIAN AWARD Houston Academy of Medicine	2005
Honorary Advisor, Osteoporosis Society of Hong Kong	2005-
Visiting Professor, Bone and Mineral Unit, Division of Endocrinology, Oregon Health & Science University	2005
Invited Speaker, Sociedad Argentina de Osteoporosis, Buenos Aires, Argentina	2006
Invited Speaker, Brazilian Endocrine Society and Endo-Recife, Recife, Brazil	2006
FIRST ANNUAL GLOBAL LEADERSHIP AWARD OF THE INTERNATIONAL SOCIETY OF CLINICAL DENSITOMETRY	2006
LIFETIME ACHIEVEMENT AWARD, ARMENIAN AMERICAN MEDICAL SOCIETY OF CALIFORNIA	2006
Visiting Professor, Division of Rheumatology and Bone Center, University of Alabama, Birmingham	2006
Founder and Director, Annual Symposium for Fellows training in Osteoporosis and Metabolic Bone Diseases, Endocrine Fellows Foundation and ASBMR	2006-
DOROTHY L. AND DANIEL H. SILBERBERG PROFESSORSHIP DEPARTMENT OF MEDICINE, COLLEGE OF PHYSICIANS & SURGEONS, COLUMBIA UNIVERSITY	2007-
Plenary Speaker, 13 th Annual Meeting of the Paulista Society of Rheumatology, Sao Paulo, Brazil	2007
Visiting Professor, Joan C. Edwards School of Medicine, West Virginia	2007

Invited Speaker, VII Congress of the IberoAmerican Society of Osteology and Mineral Metabolism, Santiago, Chile	2007
Chair, ASBMR Symposium: Targeting Bone Remodeling for the Treatment of Osteoporosis	2007
Organizer, Osteoporosis Training Course, Yerevan, Armenia	2007
Invited Speaker, The 3 rd International Conference on Osteoporosis and Bone Research, Shanghai, China	2007
Chair, International Relations Committee, International Society of Clinical Densitometry	2007-
Plenary Speaker, 2 nd International Medical Congress Yerevan, Armenia	2007
Jack W. Coburn Endowed Lectureship, American Society of Nephrology	2007
The 2008 Doctor Lila A. Wallis Distinguished Visiting Professor in Women's Health, Weill-Cornell Medical College, New York	2008
Plenary Speaker, International Osteoporosis Foundation Biennial Scientific Congress, Bangkok, Thailand	2008
Plenary Speaker, International Society of Clinical Densitometry Annual Meeting, San Francisco	2008
Featured Speaker, 14 th Annual Course on Diagnostic Imaging, Radiomagem, Porto Alegre, Brazil	2008
Featured Speaker, China Forum, Johns Hopkins School of Medicine, Division of Endocrinology	2008
Featured Speaker, Canadian Endocrine Update, McMaster University,	2008

Hamilton, Ontario, Canada

Featured Speaker, EndoRecife 2008, Recife, Brazil 2008

Plenary Speaker, International Conference on Osteoporosis and Bone Research 2008, Beijing, China 2008

State-of-the-Art Lecturer, American College of Rheumatology, San Francisco, CA 2008

Plenary Speaker, Australian & New Zealand Bone and Mineral Society, Melbourne, Australia 2008

Plenary Speaker, Endocrine Society of Australia, Melbourne, Australia 2008

Plenary Program Speaker, American Society for Bone and Mineral Research, Montreal, Canada 2008

Plenary Speaker, Osteomen: 4th International Conference on Osteoporosis in Men, S. Margherita Ligure, Italy 2008

Invited Speaker, International Society of Endocrinology, Rio de Janeiro 2008

Grollman Visiting Professor and Lectureship, University of Texas Southwestern, Department of Medicine 2008

LIFETIME ACHIEVEMENT AWARD
THE ARMENIAN AMERICAN HEALTH PROFESSIONALS ORGANIZATION 2008

OUTSTANDING ACHIEVEMENT AWARD
Brazilian Society for Endocrinology and Metabolism 2008

North American Menopause Society/GlaxoSmithKline Consumer HealthCare Calcium Research Award 2008

Plenary Speaker, ECCEO9 – IOF Ninth Congress, Athens, Greece	2009
Plenary Speaker, 18 th Annual Meeting of the American Association of Clinical Endocrinologists	2009
Invited Speaker, European Calcified Tissue Society, Vienna, Austria	2009
Plenary Speaker, EndoRecife, Recife, Brazil	2009
Plenary Speaker, XX Congress of the Chilean Endocrinology and Diabetes Society	2009
Invited Speaker, 6 th International Congress on Glucocorticoid Induced Osteoporosis, Siena, Italy	2009
Plenary Speaker, Tenth Armenian Medical World Congress, New York	2009
Invited Speaker, 10 th Annual Santa Fe Bone Symposium, Santa Fe, New Mexico	2009
GIDEON A. RODAN EXCELLENCE IN MENTORSHIP AWARD American Society for Bone and Mineral Research	2009
Invited Speaker, European Congress of Endocrinology	2010
Invited Speaker, International Congress of Endocrinology, Kyoto, Japan	2010
Plenary Lecturer, International Osteoporosis Foundation World Congress Florence, Italy	2010
Invited Speaker, 11 th Annual Santa Fe Bone Symposium, Santa Fe, NM	2010
Richard J. Kritchman Distinguished Lecturer, New York Downtown Hospital	2010

Annual Lind Lecturer, Bryn Mawr Hospital, PA	2010
Distinguished Service Award, Yerevan State Medical University, Yerevan, Armenia	2010
Plenary Speaker, 5 th International Conference on Osteoporosis and Bone Research, Shenzhen, China	2010
Invited Speaker, 9 th Annual Meeting of the Chinese Endocrine Society, Dalian, China	2010
Invited Speaker, 29 th Brazilian Congress of Endocrinology, Gramado, Brazil	2010
Co-Moderator, ISCD-IOF FRAX Initiative and ISCD Position Development Conference on FRAX, Bucharest, Romania	2010
Invited Plenary Speaker, 22 nd Annual Meeting of the Japanese Society for Kidney Disease, Tokyo, Japan	2011
Invited Speaker, 7 th St. Michael's Hospital Osteoporosis and Metabolic Bone Disease Outreach Symposium, Toronto Canada	2011
Invited Speaker, 7 th International Congress on Glucocorticoid-Induced Osteoporosis, Padua, Italy	2011
Plenary Speaker, ENDO-11: The Endocrine Society's 93 rd Annual Meeting Boston, MA	2011
Plenary Speaker, 3 rd International Medical Congress of Armenia, Yerevan, Armenia	2011
Invited Speaker, ENDORECIFE 2011, Brazilian Society of Endocrinology and Metabology – Chapter Pernambuco, Pernambuco, Brazil.	2011

Invited Speaker, BRADOO, Belo Horizonte, Brazil	2011
Invited Speaker, 5 th European Osteoporosis Summit, Slovak Republic	2011
Plenary Lecturer, 21 st Annual Meeting of the American Association of Clinical Endocrinologists, Philadelphia	2012
Featured Speaker, 15 th Congress of the Lebanese Society of Endocrinology, Diabetes and Lipids, Beirut, Lebanon	2012
Plenary Lecturer, National Clinical Update in Endocrinology and Metabolism Brescia, Italy	2012
Keynote Speaker, Second Biennial Symposium on Advances in the Diagnosis and Treatment of Parathyroid Disease, Thomas Jefferson University, Philadelphia, PA	2012
Plenary Lecturer, 30 th Brazilian Congress of Metabiology and Endocrinology Goiania, Brazil	2012
Distinguished Service Award, The Hypoparathyroidism Association	2012
David Jacobs Memorial Lecturer, Lenox Hill Hospital, NY	2012
Honorary Member, Brazilian Society of Endocrinology, Diabetes, and Metabolism	2012
Peter Heimann Distinguished Lecturer, International Association of Endocrine Surgeons, Helsinki, Finland	2013
Invited Speaker, 8 th International Congress of Glucocorticoid-Induced Osteoporosis and Other Drug Induced Osteoporosis, Pisa, Italy	2013
Plenary Lecturer, 2 nd Joint Meeting of the International Bone and Mineral Society and the Japanese Society of Bone and Mineral Research, Kobe, Japan	2013
Invited Speaker, 5 th Russian Congress on Osteoporosis and other Metabolic Skeletal Diseases, Moscow, Russia	2013

Invited Speaker, 14 th Annual Scientific Meeting of the Osteoporosis Society of Hong Kong, Hong Kong, China	2013
Plenary Lecturer, 18 th National Congress of Endocrinology & Metabolism, The Argentine Society of Endocrinology, Buenos Aires, Argentina	2013
Featured Lecturer, 6 th Joint SPED-AACE Convention, Puerto Rico	2013
Keynote Speaker, Inaugural International Chinese Musculoskeletal Research Society Conference, Suzhou, China	2013
Featured Speaker, Lebanese Osteoporosis Prevention Society and Pan Arab Osteoporosis Society	2014
Featured Speaker, 2 nd International Conference of the Saudi Osteoporosis Society, Riyadh, Saudi Arabia	2014
Featured Speaker, Japanese Society for Bone and Mineral Research Osaka, Japan	2014
Lecturer, Distinguished Lecture Series in Nutritional Sciences, Columbia University, New York	2014
LAUREATE DISTINGUISHED EDUCATOR AWARD The Endocrine Society	2014
Featured Speaker, 6 th Congress of Traumatologists and Orthopaedic Surgeons of Republic of Armenia	2014
HONORARY MEMBER, BRAZILIAN SOCIETY OF ENDOCRINOLOGY AND METABOLISM	2014
John Bilezikian Bone Densitometry Center, Opened at Gyumri Medical Center, Gyumri, Armenia	2014

OSCAR GLUCK HUMANITARIAN AWARD INTERNATIONAL SOCIETY FOR CLINICAL DENSITOMETRY	2015
Featured Speaker, Association des médecins endocrinologues du Québec	2015
FIRST GLOBAL EDUCATOR AWARD McMASTER UNIVERSITY, ONTARIO, CANADA	2015
Featured Speaker, Third Annual Robert Levin Lecture, Boston University, Department of Medicine	2015
Paul Dalgin Memorial Lecture, Stamford Hospital, Stamford, CT	2015
Plenary Speaker, Zhejiang University School of Medicine Annual Meeting, Pediatric Society, Hangzhou, China	2015
Plenary Speaker, 6 th Brazilian Congress on Bone Densitometry and Bone Metabolism (BRADOO), Curitiba, Brazil	2015
Guest Faculty, 5 th Annual Review of Endocrinology and Diabetes University of Pernambuco, Recife, Brazil	2015
Plenary Speaker, National Osteoporosis Society of U.K. Birmingham, England	2016
Plenary Speaker, 9 th International Congress on Glucocorticoid-induced Osteoporosis, Rome, Italy	2016
Ray A. and Robert L. Kroc Lecture Ohio State University School of Medicine	2016
Speaker, National Osteoporosis Foundation Annual Meeting (USA)	2016
Featured Speaker, 35 th Annual Meeting of the Korean Endocrine Society	2016

and 2016 Seoul International Congress of Endocrinology	
John Leonard Lecturer University of Washington Medical Center, Seattle, Washington	2016
Invited Speaker, Joint Meeting Brazilian Society of Orthopedic Surgeons & American Society for Bone and Mineral Research, Fortaleza, Brazil	2016
Plenary Speaker, Joint Meeting, 17 th International Congress of Endocrinology and the 15 th Annual Meeting of the China Society of Endocrinology, Beijing, China	2016
Keynote Speaker, Russian Association on Osteoporosis, Kazan, Russia	2016
Plenary Speaker, 7 th Brazilian Congress on Bone Densitometry and Bone Metabolism (BRADOO), Joinville, Brazil	2016
Director, International Summit on Osteoporosis of Central Asian and Eastern European Countries, Yerevan, Armenia	2016
Invited Speaker, 7 th Emirates Diabetes and Endocrine Congress, Dubai	2017
Invited Speaker, Ukraine Osteoporosis Society	2017
Invited Speaker, 14 th Bone Biology Forum, Chiba, Japan	2017
Invited Speaker, 17 th Congress of the Italian Society of Osteoporosis and Mineral Metabolism, Bologna, Italy	2017
HONORARY MEMBER, Russian Osteoporosis Association	2017
Commendation Award, Endocrine Fellows Foundation for 10 Years of Leadership, EFF Forum on Metabolic Bone Diseases	2017

HONORARY PhD DEGREE, Doctor Honoris Causa, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania	2017
Guest Speaker, The 3 rd International Symposium on the Calcium-Sensing Receptor, Florence, Italy	2017
HONORARY PhD DEGREE, Doctor Honoris Causa in Clinical and Translational Medicine, University of Pisa, Pisa, Italy	2017
Lectio Magistralis, University of Pisa, Pisa, Italy	2017
The 5 th Annual H. Ralph Schumacher Lecture, Philadelphia Rheumatism Society	2017
Plenary Speaker, Armenia Medical World Congress Buenos Aires, Argentina	2017
Magistrale Lettura Iperparatiroidismo: una malattia in evoluzione, Hyperparathyroidism Congress, Rome, Italy	2017
Invited Speaker, 1 st European Symposium on Hypoparathyroidism, Vienna, Austria	2017
Visiting Professor, Yerevan State Medical University, Yerevan, Armenia	2017-

BOARD CERTIFICATIONS:

Diplomate, Internal Medicine American Board of Internal Medicine	1975
Diplomate, Endocrinology and Metabolism American Board of Internal Medicine	1977

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS:

American Federation for Clinical Research	1974
Endocrine Society	1977
American Society for Bone and Mineral Research	1979

American Society for Pharmacology & Experimental Therapeutics	1980
The American Society for Clinical Investigation	1980
Fellow, American College of Physicians	1982
American Heart Association	1987
International Bone and Mineral Society	1989
Association of Program Directors in Internal Medicine	1990
Association of American Physicians	1993
Fellow, New York Academy of Medicine	1994
American Association of Clinical Endocrinologists	1994
International Society for Clinical Densitometry	1995
Fellow, American College of Endocrinology	1995
Association of Program Directors in Endocrinology and Metabolism	1995
Association of Osteobiology	1999
Member, North American Menopause Society	2001
Member, National Bone Health Alliance (NBHA) Institute for Clinical and Economic Review (ICER) Working Group	2016-

BOOKS AND MONOGRAPHS:

Associate Editor	PRINCIPLES AND PRACTICE OF ENDOCRINOLOGY AND METABOLISM, First Edition (Becker KL, Editor) JB Lippincott	1990
Co-Editor	NIH Proceedings of the Consensus Development Conference on the Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism. Journal of Bone and Mineral Research	1991
Editor-in-Chief	THE PARATHYROIDS: BASIC AND CLINICAL CONCEPTS Raven Press	1994
Associate Editor	PRINCIPLES AND PRACTICE OF ENDOCRINOLOGY AND METABOLISM Second Edition, (Becker KL, Editor) JB Lippincott	1995
Co-Editor	PRINCIPLES OF BONE BIOLOGY (Raisz LG, Rodan GA, Co-Editors) Academic Press	1996
Guest Editor	CURRENT OPINION IN ENDOCRINOLOGY AND DIABETES (Kohler PO, Editor) Rapid Science Publishers	1996 1997
Guest Editor	TRENDS IN ENDOCRINOLOGY AND METABOLISM	1996 1997

Co-Editor	(Catt KJ, Editor) Elsevier THE AGING SKELETON (Rosen CJ, Glowacki J, Co-Editors) Academic Press	1999
Co-Editor	DYNAMICS OF BONE AND CARTILAGE METABOLISM (Seibel MJ, Robins SP, Co-Editors) Academic Press	1999
Editor	QUESTIONS AND ANSWERS ON PRIMARY HYPERPARATHYROIDISM (A Publication of The Paget Foundation)	2000
Associate Editor	PRINCIPLES AND PRACTICE OF ENDOCRINOLOGY AND METABOLISM, Third Edition (Becker KL, Editor) Lippincott, Williams & Wilkins	2001
Editor-in-Chief	THE PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 2nd Edition (Marcus R, Levine MA, Co-Editors) Academic Press	2001
Co-Editor	PRINCIPLES OF BONE BIOLOGY, 2nd Edition (Raisz LG, Rodan GA, Co-Editors) Academic Press	2002
Guest Editor	ENDOCRINE AND METABOLISM CLINICS OF NORTH AMERICA “OSTEOPOROSIS”	2003
Guest Editor	THE ENDOCRINOLOGIST: DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS	2003
Guest Editor	OSTEOPOROSIS TODAY	2003

Volume #3, #1

Section Editor	GENDER SPECIFIC MEDICINE (Marianne Legato, Editor) Elsevier, San Diego	2004
Associate Editor	ENCYCLOPEDIA OF ENDOCRINE DISEASES (Martini L. Editor) Academic Press	2004
Guest Editor	Journal of Endocrinological Investigation Vol 28, Supplement to #8	2005
Co-Editor	DYNAMICS OF BONE AND CARTILAGE METABOLISM, 2 nd Edition (Seibel MJ, Robins SP, Co-Editors) Elsevier, San Diego	2006
Guest Editor	Brazilian Archives of Endocrinology and Metabolism 50 Issue #4 Special Issue: Disorders of Bone and Mineral Metabolism (F. Bandeira & JLC Borges, co-editors)	2006
Co-Editor	Principles of Bone Biology (Martin TJ, Raisz LG, co-editors) Elsevier, San Diego	2008
Guest Editor	Brazilian Archives of Endocrinology and Metabolism 50 Issue #4 Special Issue: Disorders of Bone and Mineral Metabolism (F. Bandeira & JLC Borges, co-editors)	2009
Co-Editor	Osteoporosis in Men (Orwoll E, Vanderschueren D, co-editors)	2010

Guest Editor	Brazilian Archives of Endocrinology and Metabolism 54 Issue #2 Special Issue: Osteoporosis and Related Disorders (F. Bandeira & M. Lazaretta-Castro, co-editors)	2010
Section Editor	Oxford Textbook of Endocrinology and Diabetes, 2 nd Edition (Wass JAH and Stewart P, eds), Oxford University Press, Oxford, England	2011
Issue Editor	Bisphosphonates and Osteonecrosis of the Jaw (JP Bilezikian, JT Grbic, eds) Annals of the New York Academy of Sciences, vol. 1218	2011
Editor-in-Chief	Hypoparathyroidism: Endocrine Society and Projects in Knowledge	2014
Editor-in-Chief	THE PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3 rd Edition (Marcus R, Levine M, Marcocci C, Potts JT Jr, Silverberg SJ, co-editors) Elsevier, San Diego, CA	2015
Editor-in-Chief	Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism Wiley-Blackwell, Boston, MA	2016-
Co-Editor	Frontiers of Hormone Research Vitamin D, Karger, Switzerland (Chigo E, Guaraldi F, Benso, A, series eds)	2016-
Section Editor	Oxford Textbook of Endocrinology and Metabolism	2016-

Editorial Board	Osteoporosis and Sarcopenia	2016-
Editorial Board	Endocrinology and Metabolism	2016-
Co-Editor	Emerging Aspects of Vitamin D in Clinical Medicine (Bilezikian JP and Giustina A, editors-in-chief)	2016-
Editor-in-Chief	Hypoparathyroidism: Endocrine Society and Projects in Knowledge	2017
Issue Co-Editor	Endocrinology of Bone Current Opinion in Endocrine and Metabolic Research	2018

PUBLICATIONS:

1. Bilezikian JP, Kaempfer ROR and Magasanik B: Mechanism of tryptophanase induction in *E. coli*. *J Mol Biol* 14:494-505, 1967.
2. Wells SA, Ketcham AS, Marx SJ, Powell D, Bilezikian JP, Shimkin PM, Potts JT, Pearson KD and Doppman JL: The pre-operative localization of hyperfunctioning parathyroid tissue: Radioimmunoassay of parathyroid hormone in plasma from selectively catheterized thyroid veins. *Ann Surg* 177:93-98, 1973.
3. Bilezikian JP, Aurbach GD, Connor TB, Pachas WN, Aptekar R, Wells SA and Decker JL: Pseudogout following parathyroidectomy. *Lancet* 1:445-447, 1973.
4. Bilezikian JP, Pearson KD, Powell D, Ketcham AS, Doppman JL and Aurbach GD: Selective venous catheterization of the neck: Localization of a parathyroid adenoma with anomalous drainage by non-thyroidal veins. *J Clin Endo Metab* 36:826-829, 1973.
5. Marx SJ, Powell D, Shimkin PM, Wells SA, Ketcham AS, McGuigan JE, Bilezikian JP and Aurbach GD: Familial hyperparathyroidism. *Ann Int Med* 78:371-377, 1973.
6. Doppman JL, Wells SA, Shimkin PM, Pearson KD, Bilezikian JP, Heath DA, Powell D, Ketcham AS and Aurbach GD: Parathyroid localization by angiographic techniques in patients with previous neck surgery. *Brit J Roentgen* 46:403-418, 1973.
7. Bilezikian, JP and Aurbach, GD: Binding of catecholamines to a beta-adrenergic receptor of the turkey erythrocyte: Relationship to adenylate cyclase activity. *J Biol Chem* 248:5575-5583, 1973.
8. Bilezikian JP and Aurbach GD: A beta-adrenergic receptor of the turkey erythrocyte: Effect of temperature, detergents, and proteases. *J Biol Chem* 248:5584-5589, 1973.
9. Gardner JD, Klaeveman HL, Bilezikian JP and Aurbach GD: Effect of beta-adrenergic catecholamines upon sodium transport in the turkey erythrocyte. *J Biol Chem* 248:5590-5596, 1973.
10. Bilezikian, JP, Heath, DA and Doppman, JL: Selective thyroid venous catheterization in the localization of parathyroid adenoma. *Lancet* 1:1441-1442, 1973.

11. Bilezikian JP, Doppman JL, Shimkin PM, Powell D, Wells SA, Heath DA, Ketcham AD, Monchik J, Mallette LE, Potts JT and Aurbach GD: Preoperative localization of abnormal parathyroid tissue: Cumulative experience with venous sampling and arteriography. *Am J Med* 55: 505-514, 1973.
12. Aurbach GD, Mallette LE, Patten BM, Heath DA, Doppman JL and Bilezikian JP: Hyperparathyroidism: Recent studies. *Ann Int Med* 79:566-581, 1973.
13. Wells SA, Doppman JL, Bilezikian JP, Shimkin PM, Powell D, Ketcham AS and Aurbach GD: Repeated neck exploration in patients with primary hyperparathyroidism: Use of selective thyroid arteriography, selective venous sampling, and parathyroid hormone radioimmunoassay in localizing lesions. *Surgery* 74:678-686, 1973.
14. Gardner JD, Klaeveman HL, Bilezikian JP and Aurbach GD: Effect of catecholamines upon sodium transport in the turkey erythrocyte II. *Endocrinology* 95:499-507, 1974.
15. Patten, BM, Bilezikian JP, Mallette LE, Prince A, Engel WK and Aurbach GD: The neuromuscular disease of hyperparathyroidism. *Ann Int Med* 80:182-194, 1974.
16. Gardner JD, Klaeveman HL, Bilezikian JP and Aurbach GD: The effect of ouabain on catecholamine-stimulated sodium transport in the turkey erythrocyte. *J Biol Chem* 249:516-520, 1974.
17. Bilezikian JP and Aurbach GD: The effect of nucleotides on the expression of beta-adrenergic adenylate cyclase activity in turkey erythrocytes. *J Biol Chem* 249:157-161, 1974.
18. Aurbach, GD, Bilezikian JP, Klaeveman HL and Gardner JD: The beta-adrenergic receptor and cyclic-AMP-mediated sodium transport in the avian erythrocyte. In: *Endocrinology, 1973*, (S. Taylor, Ed.), Medical Books, Ltd., London 343-348, 1974.
19. Mallette LE, Bilezikian JP, Heath DA and Aurbach GD: Hyperparathyroidism: A review of 52 cases. *Medicine* 53:127-147, 1974.
20. Mallette LE, Bilezikian JP, Ketcham AS and Aurbach GD: Parathyroid carcinoma and familial hyperparathyroidism. *Am J Med* 57:642-648, 1974.

21. Wells SA, Johnsrude IS, Ellis GJ, Bilezikian JP, Johnson C, Peete WPK, Shingleton WW and McPherson HT: Preoperative localization of hyperfunctioning parathyroid tissue utilizing parathyroid hormone radioimmunoassay of plasma from selectively catheterized thyroid veins. *North Carolina Med J* 35:678-682, 1974.
22. Bilezikian JP: Hypercalcemia: The changing clinical profile. *Resident and Staff Physician* 77-83, 1976.
23. Bilezikian, JP: The interrelationship between beta-adrenergic receptors and adenylate cyclase activity in the turkey erythrocyte. In: *Modern Pharmacology* (GS Levey, Ed.), Marcel Dekker, Inc., New York 349-371, 1976.
24. Bilezikian JP and Spiegel AM: Identification and uncoupling of beta-adrenergic receptors during maturation of the mammalian erythrocyte. *Bull NY Acad Sci* 53:302-303, 1977.
25. Antman EM and Bilezikian JP: Asymptomatic hyperparathyroidism. *J Am Med Assoc* 237:2186-2187, 1977.
26. Schnur MJ, Appel GB and Bilezikian JP: Primary hyperparathyroidism and benign monoclonal gammopathy. *Arch Int Med* 137:1201-1203, 1977.
27. Bilezikian JP, Spiegel AM, Brown EM and Aurbach GD: Identification and persistence of beta-adrenergic receptors during maturation of the rat reticulocyte. *Mol Pharmacol* 13:775-785, 1977.
28. Bilezikian JP, Spiegel AM, Gammon DE and Aurbach GD: The role of guanyl nucleotides in the expression of catecholamine responsive adenylate cyclase during maturation of the rat reticulocyte. *Mol Pharmacol* 13:786-795, 1977.
29. Derenoncourt FJ, Bilezikian JP, Feind CR, Weber CJ, Hardy MA and Reemtsma K: Long-term maintenance of responsive human parathyroid adenomas in organ culture. *Surgical Forum* 28:107-109, 1977.
30. Schonberg M, Bilezikian JP, Apfelbaum M and Benn RC: Beta-adrenergic receptors and myogenesis. *J Cyclic Nucleotide Res*, 4:55-69, 1978.

31. Bilezikian JP, Dornfeld AM and Gammon DE: The structure and activity of beta-adrenergic amines I. binding to the beta receptor and activation of adenylate cyclase. *Biochem Pharmacol* 27:1445-1454, 1978.
32. Bilezikian JP, Dornfeld AM and Gammon DE: The structure and activity of beta-adrenergic amines II. binding to the beta receptor and inhibition of adenylate cyclase. *Biochem Pharmacol* 27:1455-1461, 1978.
33. Bilezikian JP: Disassociation of beta-adrenergic receptors from hormone responsiveness during maturation of the rat reticulocyte. *Biochem Biophys Acta* 542:263-273, 1978.
34. Bilezikian JP and Gammon DE: The effect of age on beta-adrenergic receptors and adenylate cyclase in rat erythrocytes. *Life Sci* 23:253-260, 1978.
35. Bilezikian JP, Canfield RE, Jacobs TP, Polay JS, D'Adamo AP, Eisman JA and DeLuca HF: The response of 1-alpha, 25-dihydroxyvitamin D3 to hypocalcemia in human subjects. *N Engl J Med* 299:437-441, 1978.
36. Bilezikian JP, Loeb JN and Gammon DE: The influence of hyperthyroidism and hypothyroidism on the beta-adrenergic responsiveness of the turkey erythrocyte. *J Clin Invest* 63:184-192, 1979.
37. Bilezikian JP: Parathyroid hormone and calcium. *LAB* 79:27-31, 1979.
38. Bilezikian JP, Gammon DE, Rochester CL and Shand DG: A radioreceptor assay for propranolol. *Clin Pharm Therap* 26:173-180, 1979.
39. Bilezikian JP, Loeb JN and Gammon DE: Induction of sustained hyperthyroidism and hypothyroidism in the turkey: Physiological and Biochemical Observations. *Poultry Science* 59:628-634, 1980.
40. Shane E, McClane KA, Olarte MR and Bilezikian JP: Hypoparathyroidism and elevated muscle enzymes. *Neurology* 30:192-195, 1980.
41. Omrani GR, Gammon DE and Bilezikian JP: Regulation of catecholamine-responsive adenylate cyclase activity in rat reticulocyte membranes by endogenous factors: General characteristics and resolution into protein and nucleotide components. *Biochim Biophys Acta* 629:455-469, 1980.

42. Schonberg M, Krichevsky A and Bilezikian JP: Increasing number of beta-adrenergic receptors in differentiating muscle cells. *Life Sci* 26:1287-1292, 1980.
43. Furukawa H, Bilezikian JP and Loeb JN: Effects of ouabain and isoproterenol on potassium influx in the turkey erythrocyte: Quantitative relation of Ligand binding and cyclic AMP generation. *Biochim Biophys Acta* 598:345-356, 1980.
44. Rochester CL, Gammon DE, Shane E and Bilezikian JP: A radioreceptor assay for propranolol and 4-hydroxypropranolol. *Clin Pharm Therap* 28:32-39, 1980.
45. Lau YH, Robinson RB, Rosen MR and Bilezikian JP: Subclassification of Beta-adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. *Circ Res* 47:41-47, 1980.
46. Furukawa H, Bilezikian JP and Loeb JN: Kinetics and thermodynamics of ouabain binding by intact turkey erythrocytes. *J Gen Physiol* 76:499-516, 1980.
47. Furukawa H, Loeb JN and Bilezikian JP: Beta-adrenergic receptors and isoproterenol-stimulated potassium transport in erythrocytes from normal and hypothyroid turkeys: Quantitative relation between receptor occupancy and physiologic responsiveness. *J Clin Invest* 66:1057-1064, 1980.
48. Derenoncourt, FJ, Bilezikian JP, Feind CR, Gammon DE, Shane E, Krutzik S, Hardy MR, Weber C and Reemtsma KR: The influence of beta-adrenergic catecholamines upon cyclic AMP and parathyroid hormone secretion in human parathyroid glands. *J Surg Res* 30:86-95, 1981.
49. Shane E, Gammon DE and Bilezikian JP: Guanine nucleotide-induced shift in binding affinity for beta-adrenergic agonists in rat reticulocyte and turkey erythrocyte membranes. *Biochem Pharmacol* 30:531-535, 1981.
50. Nash MA, Jacobs SG, Koutsoyiannis ML and Bilezikian JP: Hyperphosphatemia with insufficient parathyroid response in renal failure. *J Pediat* 98:247-250, 1981.
51. Jacobs TP, Siris ES, Bilezikian JP, Baquiran DC, Shane E and Canfield RE: Hypercalcemia of malignancy: Treatment with intravenous dichloromethylene diphosphonate. *Ann Int Med* 94:312-316, 1981.

52. Schonberg M, Smith TJ, Krichevsky A and Bilezikian JP: Glucocorticoids enhance glucose uptake and affect beta-adrenergic responsiveness in muscle cell cultures. *Cell Differentiation* 10:101-107, 1981.
53. Shane E, Gammon DE and Bilezikian JP: A cellular activator of catecholamine-sensitive adenylate cyclase in rat reticulocytes and erythrocytes: Changes during reticulocyte development and effects on the beta receptor. *Arch Biochem Biophys* 208:418-425, 1981.
54. Shane E, Baquiran DC and Bilezikian JP: Effects of dichloromethylene diphosphonate on serum and urine calcium in primary hyperparathyroidism. *Ann Int Med* 95:23-27, 1981.
55. Ball WJ Jr, Tse-Eng D, Wallick ET, Bilezikian JP, Schwartz A and Butler VP Jr: Effect of quinidine on the digoxin receptor in vitro. *J Clin Invest* 68:1065-1074, 1981.
56. Smith TJ, Dana R, Krichevsky A, Bilezikian JP and Schonberg M: Inhibition of beta-adrenergic responsiveness in muscle cell cultures by dexamethasone. *Endocrinology* 109:2110-2116, 1981.
57. Furukawa H, Bilezikian JP and Loeb JN: Potassium fluxes in the rat reticulocyte: Quabain sensitivity and changes during maturation. *Biochim Biophys Acta* 649:625-632, 1981.
58. Bilezikian JP: The medical management of primary hyperparathyroidism. *Ann Int Med* 96:198-202, 1982.
59. Bilezikian JP and Loeb JN: Mechanisms of altered beta-adrenergic responsiveness in the hyperthyroid and hypothyroid turkey erythrocyte. *Life Sci* 30:663-673, 1982.
60. Ragavan VV, Smith JE and Bilezikian JP: Vitamin A toxicity and hypercalcemia. *Am J Med Sci* 283:161-164, 1982.
61. Shane E and Bilezikian JP: Parathyroid carcinoma: A review of 62 patients. *Endocrine Reviews* 3:218-226, 1982.
62. Shane E, Jacobs TP, Siris ES, Steinberg SF, Stoddart K, Canfield RE and Bilezikian JP: Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate. *Am J Med* 72:939-944, 1982.

63. Bilezikian JP. Primary hyperparathyroidism: Surgical vs. medical management. *Drug Therapy* 7:41-48, 1982.
64. Canfield RE, Siris ES, Jacobs TP, Bilezikian JP, Shane E, Steinberg SF and Armstrong EG: Clinical experience with dichloromethylene diphosphonate in multiple myeloma, breast cancer, hypercalcemia of malignancy and hyperparathyroidism. In: *Proceedings of Symposium CEMO IV, Diphosphonates and Bone*, (Donath A and Courvoisier B, eds.) Editions Medicine et Hygiene, Geneva 264-274, 1982.
65. Morris SA and Bilezikian JP: Conditions associated with the appearance of guanine nucleotide-dependent adenylate cyclase activity in turkey erythrocyte membranes. *Biochem Pharmacol* 31:2783-2790, 1982.
66. Furukawa H, Loeb JN and Bilezikian JP: Catecholamine-stimulated potassium transport in erythrocytes from normal and hyperthyroid turkeys: Quantitative relation between beta-adrenergic receptor occupancy and physiological responsiveness. *Endocrinology* 111:1891-1896, 1982.
67. Kupfer LE, Robinson RB and Bilezikian JP: Identification of alpha1-adrenergic receptors in cultured rat myocardial cells with a new iodinated alpha1 adrenergic antagonist [125I]IBE 2254. *Circ Res* 51:250-254, 1982.
68. Steinberg SF and Bilezikian JP: Identification and characterization of Alpha1-adrenergic receptors in rat myocardium with a new iodinated radioligand, [125I]IBE 2254. *J Mol Cell Cardiol* 14:601-610, 1982.
69. Bilezikian JP: Hypercalcemia. In: *Current Therapy in Endocrinology 1983-1984*. (DT Krieger and CW Bardin, eds.) 272-277, 1983; and In: *Current Therapy in Internal Medicine 1984-1985*. (Bayless TM, Brain MC and RM Cherniak, Eds.) 513-518, BC Decker, Inc., Philadelphia, 1984.
70. Morris SA and Bilezikian JP: Evidence that forskolin activates turkey erythrocyte adenylate cyclase through a non-catalytic site. *Arch Biochem Biophys* 220:628-636, 1983.
71. Steinberg SF and Bilezikian JP: Total and free propranolol levels in sensitive and resistant patients. *Clin Pharm Therap* 33:163-171, 1983.

72. Schonberg M, Morris SA, Krichevsky A and Bilezikian JP: The use of [125I] iodocyanopindolol as a specific probe for beta-adrenergic receptors in differentiating cultured rat skeletal muscle. *Cell Differentiation* 12:321-327, 1983.
73. Morris SA, Schonberg M, Krichevsky A and Bilezikian JP: Desensitization of cultured muscle cells to isoproterenol. *Biochim Biophys Acta* 762:344-354, 1983.
74. Bilezikian JP, Shane E, Morris SA and Steinberg SF: Exogenous and endogenous regulation of adrenergic receptors: Applicability to selected clinical problems. In: *Principles of Receptorology* (Agarwal KN ed.) Walter de Gruyter & Co., Berlin 545-592, 1983.
75. Bilezikian JP and Loeb JN: The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. *Endocrine Reviews* 4:378-388, 1983.
76. Bilezikian JP: Medical approaches to the management of primary hyperparathyroidism. In: *Proceedings of the Symposium on Clinical Disorders of Bone and Mineral Metabolism* (Frame B and JT Potts, Jr., Eds.) Excerpta Medica, Amsterdam, 139-161, 1983.
77. Merlini G, Fitzpatrick LA, Siris ES, Bilezikian JP, Birken S, Beychok S and Osserman EF: A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. *J Clin Immunol* 4:185-196, 1984.
78. Steinberg SF, Jaffe EA and Bilezikian JP: Endothelial cells contain beta-adrenergic receptors. *Naunyn-Schmiedeberg's Arch Pharmacol* 325:310-313, 1984.
79. Morris SA, Rowin KW, Tanowitz HB, Wittner M and Bilezikian JP: Alteration of the pattern of beta-adrenergic desensitivation in cultured L6E9 muscle cells infected with *Trypanosoma cruzi*. *Mol and Biochem Parasitol* 13:227-234, 1984.
80. Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV and Bilezikian JP: The Influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. *New Engl J Med*, 310:1221-1225, 1984.
81. Halper JP, Mann JJ, Weksler ME, Bilezikian JP, Sweeney JA, Brown RP and Golbourne T: Beta-adrenergic receptor and cyclic AMP levels in intact Human lymphocytes: Effects of age and gender. *Life Sci* 35:855-863, 1984.

82. Shane E, Yeh M, Feigin A and Bilezikian JP: Reticulocyte cytosol activator protein: Its actions upon the beta-adrenergic receptor and the N proteins of adenylate cyclase. *J Receptor Research*, 4:475-486, 1984.
83. Bilezikian JP: Surgery or no surgery for primary hyperparathyroidism. *Annals of Int Med*, 102:402-403, 1985.
84. Bilezikian JP: Hyper- and hypoparathyroidism. In: *Conn's Current therapy* (RE Rakel, Ed.) WB Saunders Co., Philadelphia, 491-494, 1985.
85. Shane E and Bilezikian JP: Parathyroid carcinoma. In: *Current Therapy in Endocrinology and Metabolism*, 1985-1986. (DT Krieger and CW Bardin, Eds.). BC Decker, Inc., Philadelphia, 347-349, 1985.
86. Shane E, Yeh M, Feigin AS, Owens JM and Bilezikian JP: Cytosol activator protein from rat reticulocytes requires the stimulatory guanine nucleotide binding protein for its actions on adenylate cyclase. *Endocrinology*, 117:255-263, 1985.
87. Shane E, Yeh M, Feigin AS, Owens JM and Bilezikian JP: Reticulocyte cytosol activator protein: Effects upon the stimulatory and inhibitory regulatory proteins of adenylate cyclase. *Endocrinology*, 117:264-270, 1985.
88. Clemens TL, Silverberg S, Dempster DW, Shane E, Segre GV, Williams S, Lindsay R and Bilezikian JP: Oral phosphate depresses serum 1,25-dihydroxyvitamin D concentrations in osteoporotic subjects. In: *Vitamin D: Chemical, Biochemical and Clinical Update* (AW Norman, K Schaefer, HG Grigoleit, DV Herrath, Eds.) Walker de Gruyter, New York, 1010-1011, 1985.
89. Steinberg SF, Drugge ED, Bilezikian JP and Robinson RB: Acquisition by cardiac myocytes of a pertussis toxin-specific regulatory protein linked to the alpha1-receptor. *SCIENCE*, 230:186-188, 1985.
90. Mann JJ, Brown RP, Halper JP, Sweeney JA, Kocsis JH, Stokes PE and Bilezikian JP: Reduced sensitivity of lymphocyte beta-receptors in patients with endogenous depression and psychomotor agitation. *N Eng J Med* 313:715-720, 1985.
91. Morris SA and Bilezikian JP: The regulation of adenylate cyclase activity in turkey erythrocyte membranes by forskolin. *Arch Biochem Biophys* 243:678-689, 1985.

92. Shane E, Avioli RC, Greene VS, Yeh M, Owens J, Bell NH, and Bilezikian JP: Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase by a cytosol protein activator from rat reticulocytes. *J Bone Min Res* 1:41-50, 1986.
93. Morris SA and Bilezikian JP: Modifications of the adenylate cyclase complex during differentiation of cultured myoblasts. *J Cellular Physiol* 127:28-38, 1986.
94. Shane E and Bilezikian JP: "Calcium, phosphate , and magnesium metabolism," and "Disorders of calcium, phosphate, and magnesium metabolism." In: *Fluid and Electrolyte Management in Critical Care*. (Askanazi J, Starker PM and Weissman C Eds.) Butterworth, Stoneham, MA, 81-92, 337-353, 1986.
95. Kupfer LE, Bilezikian JP and Robinson RB: Regulation of alpha and beta adrenergic receptors by triiodothyronine in cultured rat myocardial cells. *Naunyn-Schmiedeberg's Arch Pharmacol* 334:275-281, 1986.
96. Steinberg SF, Chow Y and Bilezikian JP: Regulation of rat heart membrane adenylate cyclase by magnesium and manganese. *J Pharmacol Expt'l Ther* 237:764-772, 1986.
97. Silverberg SJ, Shane E, Clemens TL, Dempster DW, Segre GV, Lindsay R and Bilezikian JP: The effect of oral phosphate on major indices of skeletal metabolism in normal subjects. *J Bone Min Res* 1:383-388, 1986.
98. Bilezikian JP: Defining the role of adrenergic receptors in human physiology. In: *Adrenergic Receptors in Man* (Insel, PA Ed.), Marcel Dekker, New York, 36-68, 1987.
99. Bilezikian JP: "Hypercalcemia," "Primary Hyperparathyroidism" and "Hypocalcemia." In: *Internal Medicine*, 2nd Edition (Stein JH Editor-in-Chief); Little-Brown, Boston, 2086-2092; 2123-2128, 1987.
100. Fitzpatrick LA and Bilezikian JP: Acute primary hyperparathyroidism. *Am J Med* 82:275-282, 1987.
101. Siris ES, Clemens TL, Dempster DW, Shane E, Segre GV, Lindsay R and Bilezikian JP: Tumor induced osteomalacia: Kinetics of calcium, phosphorus and vitamin D metabolism and characteristics of bone histomorphometry. *Am J Med* 82:307-312, 1987.

102. Steinberg SF, Chow Y and Bilezikian JP: Stimulatory and inhibitory regulation of myocardial adenylate cyclase by 5'-guanylyl-imidodiphosphate. *Biochem Pharmacol* 36:757-764, 1987.
103. Bilezikian JP: "Clinical disorders of the parathyroid glands" In: *Clinical Endocrinology of Calcium Metabolism* (Raisz LG and Martin TJ, Eds.), Marcel Dekker, NY, 53-97, 1987.
104. Buchtal SD, Bilezikian JP and Danilo P Jr: Alpha-adrenergic receptors in the adult neonatal and fetal canine heart. *Dev Pharmacol and Therap* 10:90-99, 1987.
105. Steinberg SF, Chow YK, Robinson RB and Bilezikian JP: A pertussis toxin substrate regulates alpha1-adrenergic dependent phosphatidylinositol hydrolysis in cultured rat myocytes. *Endocrinology* 120:1889-1896, 1987.
106. Steinberg SF, Bilezikian JP and Al-Awqati Q: Fura-2 fluorescence is localized to mitochondria in endothelial cells. *Am J Physiol* 22:744-747, 1987.
107. Kassotis J, Steinberg SF, Ross S, Bilezikian JP and Robinson RB: An inexpensive dual-excitation apparatus for fluorescence microscopy. *Pflugers Archives European J of Pharmacology* 409:47-51, 1987.
108. Morris SA and Bilezikian JP: The influence of EDTA on adenylate cyclase activity during preparation of membranes from rat and mouse myocardium. *Biochim Biophys Acta* 931:234-241, 1987.
109. Morris SA, Bilezikian JP, Tanowitz H and Wittner M: Infection of L6E9 myoblasts with *T. cruzi* alters adenylate cyclase activity and guanine nucleotide binding proteins. *J Cell Physiol* 133:64-71, 1987.
110. Bilezikian JP: Primary hyperparathyroidism: Entering the third generation. *Cases in Metabolic Bone Disease* (Rogosin Institute) 2:1-11, 1987.
111. Robinson RB, Kupfer LE and Bilezikian JP: "Alpha and beta-adrenergic receptors in cultured heart cells." In: *The Heart Cell in Culture*, (Pinson A, Ed.), CRC Press, Inc., Cleveland, OH, 143-159, 1987.

112. Steinberg SF, Chow YK and Bilezikian JP: Cyclic AMP and guanine nucleotide regulatory proteins. In: *The Liver: Biology and Pathobiology* (Arias IM, Jakoby WB, Popper H, Schachter D and Shafritz DA, Eds.), Raven Press 769-776, 1988.
113. Rosen MR, Steinberg SF, Chow Y, Bilezikian JP and Danilo P: The role of a pertussis-toxin sensitive protein in the modulation of canine Purkinje fiber automaticity. *Circ Res* 62:315-323, 1988.
114. Morris SA, Tanowitz HB, Factor SM, Bilezikian JP and Wittner M: Myocardial adenylate cyclase activity in acute murine Chagas' disease. *Circ Res* 62:800-810, 1988.
115. Shane E and Bilezikian JP: Parathyroid carcinoma In: *Textbook of Uncommon Cancer*. (Williams CJ, Krikorian JC, Green MR and Raghavan D Eds.) John Wiley, New York, 763-771, 1988.
116. Morris SA, Tanowitz H, Hatcher V, Bilezikian JP and Wittner M: Alterations in intracellular calcium following infection of human endothelial cells with *Trypanosoma cruzi*. *Mol Biochem Parasitol* 29:213-221, 1988.
117. Bilezikian JP, Steinberg SF, Horn EM, Robinson RB and Rosen MR: G protein-adrenergic interactions in the heart. *Mol and Cell Biochem* 82:5-11, 1988.
118. Horn EM, Corwin SJ, Steinberg S, Chow YK, Neuberger GW, Cannon PJ, Powers ER and Bilezikian JP: Reduced lymphocyte nucleotide regulatory proteins and beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy. *Circulation* 78:1373-1379, 1988.
119. Horn EM and Bilezikian JP: Endocrine modulation of the lymphocyte beta-adrenergic receptor complex. *Progress in Catecholamine Research* 42:561-567, 1988.
120. Bilezikian JP: Disorders of calcium and the parathyroid glands. IN: *Metabolic Bone and Mineral Disorders* (Manolagas S and Olefsky J Eds.), *Contemporary Issues in Endocrinology and Metabolism*, Churchill-Livingston, New York 5:63-101, 1988.
121. Bilezikian JP and Shane E: Osteoporosis: An update on risk factors and treatment options. *The Female Patient* 13:31-45, 1988; *Physician's Assistant* 12:41-55, 1988.
122. Bilezikian JP: Hypercalcemia. *Disease-A-Month* 34:737-799, 1988.

123. Bilezikian JP and Martin TJ: Parathyroid hormone related disorders. *Henry Ford Hospital Med J* 36:159-161, 1988; and In: *Clinical Disorders of Bone and Mineral Metabolism* (Kleerekoper M and Krane S Eds.) Mary Ann Liebert, New York, 303-309, 1989.
124. Rosen MR, Robinson RB, Cohen IS and Bilezikian JP: Developmental changes in alpha-adrenergic modulation of cardiac rhythm. In: *Physiology and Pathophysiology of the Heart*; 2nd Edition (Sperelakis N, Ed), Kluwer, Boston, 413-422, 1989.
125. Weinstock RS, Golland RS, Shane E, Clemens TL, Lindsay R and Bilezikian JP: Bone mineral density in women with Type II Diabetes mellitus. *J Bone Min Res* 4:97-101, 1989.
126. Silverberg SJ, Shane E, de la Cruz L, Segre GV, Clemens TL and Bilezikian JP: Abnormalities in parathyroid hormone secretion and 1,25-dihydroxyvitamin D3 formation in osteoporosis. *N Eng J Med* 320:277-281, 1989.
127. Horn EM, Johnson NJ, Bilezikian JP and Rosen MR: Developmental changes in the electrophysiological properties and the beta-adrenergic receptor-effector complex in atrial fibers of the canine coronary sinus. *Circ Res* 65:325-333, 1989.
128. Bilezikian JP, Silverberg SJ and Shane E: Primary hyperparathyroidism in the 1980's. In: *Clinical Disorders of Bone and Mineral Metabolism* (Kleerekoper M and Krane S, Eds.), Mary Ann Liebert, New York 359-365, 1989.
129. Morris SA, Weiss LM, Factor SM, Bilezikian JP, Tanowitz HB and Wittner M: Verapamil ameliorates clinical, pathological and biochemical manifestations of experimental Chagasic cardiomyopathy in mice. *J Am Coll Cardiology* 14:782-789, 1989.
130. Bilezikian JP: Etiologies and therapy of hypercalcemia. *Endocrinology and Metabolism Clinics of North America*. 18:389-414, 1989.
131. Cosman F, Morrow B, Kopal M and Bilezikian JP: Stimulation of inositol phosphate formation in ROS 17/2.8 cell membranes by guanine nucleotide, calcium and parathyroid hormone. *J Bone Min Res* 4:413-420, 1989.
132. Silverberg SJ, Shane E, De La Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL and Bilezikian JP: Skeletal disease in primary hyperparathyroidism. *J Bone Min Res* 4:283-291, 1989.

133. Turken SA, Cafferty M, Silverberg SJ, de la Cruz L, Cimino C, Lange DJ, Lovelace RE and Bilezikian JP: Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. *Am J Med* 87:553-557, 1989.
134. Bilezikian JP: Primary hyperparathyroidism. *Trends in Endocrinol and Metab* 1:3-6, 1989.
135. Han HM, Robinson RB, Bilezikian JP and Steinberg SF: Developmental changes in guanine nucleotide regulatory proteins in the rat myocardial alpha1-adrenergic receptor complex. *Circ Res* 65:1763-1773, 1989.
136. Tanowitz H, Morris SA, Weiss LM, Bilezikian JP, Factor SM and Wittner M: Effect of verapamil on the development of chronic experimental Chagas' disease. *Am J Trop Med Hyg* 41:643-649, 1989.
137. Morris SA, Bilezikian JP, Hatcher V, Weiss L, Tanowitz HB and Wittner M: *Trypanosoma cruzi*: Infection of cultured human endothelial cells alters inositol phosphate synthesis. *Experimental Parasitol* 69:330-339, 1989.
138. Parisien MV, Dempster DW, Shane E, Silverberg SJ, Lindsay R and Bilezikian JP: Structural parameters of iliac bone biopsies in primary hyperparathyroidism. In: *Bone Morphometry* (Takahashi HE, Ed.) Nishimura, Nigata, Japan, 228-231, 1990.
139. Rosen MR, Bilezikian JP, Cohen IS and Robinson RB: Alpha-adrenergic modulation of cardiac rhythm. In: *Cardiac Electrophysiology from Cell to Bedside* (Zipes DP and Jalife J Eds.), WB Saunders, Philadelphia, PA 300-304, 1990.
140. Bilezikian JP: Primary hyperparathyroidism. IN: *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. (Favus, MJ, Ed.) William Byrd Press, Richmond, VA 109-111, 1990.
141. Bilezikian JP: Primary hyperparathyroidism. *Sandorama* 2:28-32, 1990.
142. Bilezikian JP: "Hypercalcemia", "Primary hyperparathyroidism" and "Hypocalcemia". In: *Internal Medicine, 3rd Edition* (Stein JH, Editor-in-Chief): Little-Brown, Boston, pp 2331-2339; 2372-2378, 1990.

143. Horn EM, Bilezikian JP: Mechanisms of abnormal transmembrane signaling of the beta-adrenergic receptor in congestive heart failure. In: Role of the Sympathetic Nervous System in Congestive Heart Failure: Basic Mechanisms and Clinical Directions. (Packer M, Ed.) *Circulation* 82:(Suppl) I26-I35, 1990.
144. Fitzpatrick LA, Bilezikian JP: Primary hyperparathyroidism. In: Principles and Practice of Endocrinology and Metabolism (Becker KL, Ed.), JB Lippincott, Philadelphia, PA, 430-437, 1990.
145. Bilezikian JP: Parathyroid hormone-related peptide in sickness and in health. *N Eng J Med* 322:1151-1153, 1990.
146. Tohme JT, Bilezikian JP, Clemens TL, Silverberg SJ, Shane E, Lindsay R: Suppression of parathyroid hormone secretion with oral calcium in normal subjects and in patients with primary hyperparathyroidism. *J Clin Endocrinol and Metab* 70:951-956, 1990.
147. Coleman DT, Bilezikian JP: Parathyroid hormone stimulates phospholipase C activity in canine renal cortical membranes. *J Bone Min Res* 5:299-306, 1990.
148. Han HM, Bilezikian JP, Robinson RB: Functional uncoupling of the inhibitory alpha1-adrenergic response from a guanine nucleotide regulatory protein in innervated cultured cardiac cells by potassium depolarization. *J Mol Cell Cardiology* 22:49-56, 1990.
149. Parisien MV, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP, Dempster DW: The histomorphometry of bone in primary hyperparathyroidism: Preservation of cancellous bone structure. *J Clin Endocrinol and Metab* 70:930-938, 1990.
150. Parisien MV, Silverberg SJ, Shane E, Dempster DW, Bilezikian JP: Bone disease in primary hyperparathyroidism. *Endocrinology and Metabolism Clinics of North America* 19:19-34, 1990.
151. Morris SA, Wittner M, Weiss L, Hatcher VB, Tanowitz HB, Bilezikian JP, Gordon PB: Extracellular matrix derived from *T. cruzi* infected endothelial cells directs phenotypic expression. *J. Cell Physiol* 145:340-346, 1990.

152. Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D, Clemens TL, Bilezikian JP: Nephrolithiasis and bone involvement in primary hyperparathyroidism. *Am J Med* 89:327-334, 1990.
153. Morris SA, Wittner M, Tanowitz H, Bilezikian JP: Pathophysiological insights into the cardiomyopathy of Chagas' disease. *Circulation* 82:1900-1909, 1990.
154. Steinberg SF, Bilezikian JP: Receptor-effector coupling and second messenger systems. In: *Cardiac Electrophysiology: A Textbook* (MR Rosen, MJ Janse and AL Wit, eds) Futura Publishing Co., Inc. Mt. Kisco, NY 793-802, 1990.
155. Tanowitz HB, Burns ER, Sinha AK, Kahn NN, Morris SA, Factor SM, Hatcher VB, Bilezikian JP, Baum SG, Wittner M: Enhanced platelet adherence and aggregation in Chagas' disease: A potential pathogenic mechanism for cardiomyopathy. *Am J Trop Med Hyg* 43:274-281, 1990.
156. Brown SL, Bilezikian JP: AIDS and training in internal medicine. *N Eng J Med* 323:1567-1568, 1990.
157. Parisien M, Recker RR, Silverberg SJ, Shane E, Mellish RW, Lindsay R, Bilezikian JP, Dempster DW: Cancellous bone structure in postmenopausal women with primary hyperparathyroidism. In: *Third International Symposium on Osteoporosis* (Christiansen C and Overgaard K, eds.) Osteopress ApS, Copenhagen 1139-1140, 1990.
158. Bilezikian JP: Primary hyperparathyroidism. In: *Current Therapy in Endocrinology and Metabolism; 4th Edition* (C.W. Bardin, Ed) BC Decker, Inc. Philadelphia 448-452, 1991.
159. Bilezikian JP: Measurements of parathyroid hormone-related peptide in the circulation. *Trends in Endocrinology and Metabolism* 2:1-3, 1991.
160. Bilezikian JP: Diagnostic and therapeutic considerations in hypercalcemia of malignancy. *Oncology Update* 1:10-11, 1991.
161. Coleman DT, Morrow BS, Bilezikian, JP: Effects of guanine nucleotides and parathyroid hormone on inositol 1,4,5-trisphosphate metabolism in canine renal cortical tubular cell membranes. *J Bone Min Res* 6:599-608, 1991.

162. Tohme JF, Seibel MJ, Silverberg SJ, Robins SP, Bilezikian JP: Biochemical markers of bone metabolism. *Z Rheumatol* 50:133-141, 1991.
163. Morris SA, Tanowitz HB, Bilezikian JP, Wittner M: Modulations of host cell metabolism by *Trypanosoma cruzi*. *Parasitology Today* 7:82-87, 1991.
164. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW: Characterization and evaluation of asymptomatic primary hyperparathyroidism. *J Bone Min Res* 6:(Suppl II) 585-589, 1991.
165. Morris SA, Barr S, Klei TR, Weiss L, Tanowitz H, Wittner M, Bilezikian JP: Myocardial beta-adrenergic adenylate cyclase complex in a canine model of Chagasic cardiomyopathy. *Circ Res* 69:185-195, 1991.
166. Morris SA, Horn EM, Hawley T, Manning D, Bilezikian JP: The influence of detergents on the availability of pertussis toxin substrates. *Archiv Biochem Biophys* 290:86-92, 1991.
167. Horn EM, Danilo P, Apfelbaum MA, Barr ML, Pepino P, Powers ER, Smith CR, Rose EA, Bilezikian JP: Beta-adrenergic receptor sensitivity and guanine nucleotide regulatory proteins in transplanted human hearts and autotransplanted baboons. *Transplantation* 52:960-966, 1991.
168. Bilezikian JP: The hypercalcemic states: Their differential diagnosis and acute management. In: *Disorders of Bone and Mineral Metabolism* (Coe FL and Favus MJ, Eds.), Raven Press, New York 493-522, 1992.
169. Fitzpatrick LA, Coleman DT, Bilezikian JP: The target tissue actions of parathyroid hormone. In: *Disorders of Bone and Mineral Metabolism* (Coe FL and Favus MJ, eds), Raven Press, New York 123-148, 1992.
170. Bilezikian JP: In Memoriam: Gerald D. Aurbach. *J Bone Min Res* 7:IX-X, 1992.
171. Bilezikian JP: Clinical utility of assays for parathyroid hormone-related protein. *Clin Chem* 38:179-181, 1992.
172. Morris SA, Tanowitz HB, Makman M, Hatcher VB, Bilezikian JP, Wittner M: *T. cruzi*: Alteration of cAMP metabolism following infection of human endothelial cells. *Exp'tal Parasitology* 74:69-76, 1992.

173. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP: Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption in primary hyperparathyroidism. *J Clin Endocrinol Metab* 74:481-486, 1992.
174. Vulliamoz Y, Huber F, Bilezikian JP: Regulation of inositol 1,4,5-triphosphate metabolism by guanine nucleotides in membranes of cultured newborn rat cardiomyocytes. *Biochem Pharmacol* 43:1001-1007, 1992.
175. Ogawa S, Koga S, Kuwabara K, Brett J, Morrow B, Morris SA, Bilezikian JP, Silverstein SC, Stern D: Hypoxia-induced increased permeability of cultured bovine and aortic endothelial monolayers occurs through lowering of cellular cAMP levels and is modulated by glucocorticoids. *Am J Physiol (Cell Physiol)* 31:C546-C554, 1992.
176. Bilezikian JP, Silverberg SJ: Osteoporosis: a practical approach to the perimenopausal woman. *J Women's Health* 1:21-28, 1992.
177. Bilezikian JP: Management of acute hypercalcemia. *N Eng J Med* 326:1196-1203, 1992.
178. Parisien M, Mellish RWE, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster DW: Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. *J Bone Min Res* 7:913-920, 1992.
179. Seibel MJ, Robins SP, Bilezikian JP: Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. *Trends in Endocrinology and Metabolism* 3:263-270, 1992.
180. Grinspoon SK, Bilezikian JP: HIV infection and the endocrine system. *N Eng J Med* 327:1360-1365, 1992.
181. Wardlaw SL, Bilezikian JP: Hyperprolactinemia and osteopenia. *J Clin Endocrinol Metab* 75:690-691, 1992.
182. Oz HS, Wittner M, Tanowitz HB, Bilezikian JP, Saxon M, Morris SA: *Trypanosoma Cruzi*: Regulation of intracellular calcium homeostasis. *Experimental Parasitol* 74:390-399, 1992.

183. Glusman J, Morris SA, Rohde S, Chen G, Camacho JA, Bilezikian JP: Opposing influences of dexamethasone and retinoic acid on adenylate cyclase activity in ROS 17/2.8 cells. *Endocrinology* 132:261-268, 1993.
184. Shane E, Del C Rivas M, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP: Osteoporosis after cardiac transplantation. *Am J Med* 94:257-264, 1993.
185. Bilezikian JP: Hypercalcemia of malignancy: culprits, mechanisms and measurements. *Endocrine Fellows Foundation Conference Forum*: 3-4, 1993.
186. Bilezikian JP: Osteoporosis: On the verge of rational effective therapy. *Mt. Sinai J of Med* 60:87-94, 1993.
187. Bilezikian JP: Primary Hyperparathyroidism. IN: *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 2nd edition (Favus MJ, Ed) Raven Press, NY 155-159, 1993.
188. Tohme JF, Bilezikian JP: Hypocalcemic emergencies. *Endocrinology and Metabolism Clinics of North America* 22:363-376, 1993.
189. Nussbaum SR, Warrell RP, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ: Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. *J Clin Oncol* 11:1618-1623, 1993.
190. Grinspoon SK, Bilezikian JP: Endocrine abnormalities in HIV disease. *The AIDS Reader* 3:191-198, 1993.
191. Grinspoon SK, Bilezikian JP: Endocrine manifestations of AIDS. *Trends in Endocrinol and Metab* 4:315-317, 1993.
192. Bilezikian JP: Management of hypercalcemia. *J Clin Endocrinol and Metab* 77:1445-1449, 1993.
193. Morris SA, Bilezikian JP, Tanowitz H, Wittner M: Compromise of the microcirculation in Chagas' disease. *The Proceedings of the National Congress of Medicine II*, (Madoery RT et al., eds) 117-123, 1993.

194. Huan H, Tanowitz HB, Oz HS, Wittner M, Spray DC, Bilezikian JP, Morris SA: Evidence that myocardial pertussis toxin substrates are uniquely altered in acute murine Chagas' diseases in a manner unrelated to myocardial dysfunction. *J Mol Cell Cardiol* 25:1293-1304, 1993.
195. Morris SA, Florant G, Saxon M, Chen G, Bilezikian JP: Myocardial beta adrenergic receptor complex in hibernation. *Am J Physiol* 265:R1430-R1438, 1993.
196. Bilezikian JP: Hypercalcemia. In: *Current Therapy in Endocrinology and Metabolism* 5th Edition (CW Bardin, Ed) Mosby-Year Book, St. Louis, 511-514, 1994.
197. Bilezikian JP: "Hypercalcemia", "Hypocalcemia" and "Primary Hyperparathyroidism" in *Internal Medicine*, 4th Edition (JH Stein, Editor-in-Chief) Mosby, St. Louis, MO 1494-1497, 1497-1502, 1541-1548, 1994.
198. Grinspoon SK, Bilezikian JP: HIV infection and endocrine disease. *Current Opinion in Endocrinology and Diabetes* (Kohler PO, ed) Current Science, Philadelphia, 3-6, 1994.
199. Bilezikian JP, Marcus R, Levine MA: Preface to "The Parathyroids". In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds). Raven Press, NY xvii-xix, 1994.
200. Coleman DT, Fitzpatrick LA, Bilezikian JP: Biochemical mechanisms of parathyroid hormone action. In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds) Raven Press, NY 239-258, 1994.
201. Bilezikian JP, Singer FR: Acute management of hypercalcemia due to parathyroid hormone and parathyroid hormone-related protein. In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds) Raven Press, NY 359-372, 1994.
202. Bilezikian JP, Silverberg SJ, Gartenberg F, Kim TS, Jacobs T, Siris E, Shane E: Clinical presentation of primary hyperparathyroidism. In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds) Raven Press, NY 457-470, 1994.
203. Parisien M, Dempster DW, Shane E, Bilezikian JP: Histomorphometric analysis of bone in primary hyperparathyroidism. In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds) Raven Press, NY 493-504, 1994.

204. Bilezikian JP: Guidelines for the medical or surgical management of primary hyperparathyroidism. In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds) Raven Press, NY 567-574, 1994.
205. Silverberg SJ, Bilezikian JP: Parathyroid function and responsiveness in osteoporosis. In: *The Parathyroids* (Bilezikian JP, Marcus R, Levine MA, eds) Raven Press, NY 805-812, 1994.
206. Morris SA, Florant G, Saxon M, Chen G, Bilezikian JP: Myocardial beta-adrenergic receptor complex in hibernation. In: *Life in the Cold III: Ecological, Physiological and Molecular Mechanisms* (Carey C, Florant GL, Wunder BA, Horwitz B, eds) Westview Press (Boulder, Colorado) 305-325, 1994.
207. Grinspoon SK, Bilezikian JP: Metabolic and endocrinologic disturbances with HIV infection. *ENDOTrends* 4:1-3, 1994.
208. Bilezikian JP: Primary hyperparathyroidism: another important metabolic bone disease of women. *J Women's Health* 3:21-32, 1994.
209. Kleerekoper M, Bilezikian JP: Parathyroidectomy for non-traditional features of primary hyperparathyroidism. *Am J Medicine* 96:99-100, 1994.
210. Horwitz MJ, Bilezikian JP: Primary hyperparathyroidism and parathyroid hormone-related protein. *Current Opinion in Rheumatology* 6:321-328, 1994.
211. Grinspoon SK, Donovan DS, Bilezikian JP: Aetiology and pathogenesis of hormonal and metabolic disorders in HIV infection. In: *The Endocrinology and Metabolism of HIV Infection*. Bailliere's Clinical Endocrinology and Metabolism, Bailliere Tindall, London 735-755, 1994.
212. Noy A, Bilezikian JP: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. *J Clin Endocrinol and Metab* 79:1223-1231, 1994.
213. Siegel LM, Grinspoon SK, Garvey GJ, Bilezikian JP: Sepsis and adrenal function. *Trends in Endocrinol and Metab* 5:324-328, 1994.
214. Bilezikian JP: Major issues regarding estrogen replacement therapy in postmenopausal women. *J Women's Health* 4:273-282, 1994.

215. Bilezikian JP and Panel Members: Optimal Calcium Intake: Statement of the Consensus Development Panel on Optimal Calcium Intake. *J Am Med Assoc* 272:1942-1948, 1994.
216. Oz HS, Wittner M, Tanowitz H, Bilezikian JP, Morris SA: Trypanosoma cruzi: evidence for GTP binding proteins. *Am J Trop Med Hyg* 50:620-631, 1994.
217. Sun LS, Vulliamoz Y, Huber F, Bilezikian JP, Robinson RB: An excitatory muscarinic response in neonatal ventricular myocytes and its modulation by sympathetic innervation. *J Mol Cell Cardiol* 26:779-787, 1994.
218. Huan H, Wittner M, Tanowitz H, Bilezikian JP, Morris SA: Release of GTP binding protein alpha subunits from mouse myocardial membranes: basic properties and their alterations in acute immune Chagas' disease. *Cardiovasc Res* 29:350-358, 1995.
219. Rosen MR, Bilezikian JP, Cohen IS, Robinson RB: Alpha-adrenergic modulation of cardiac rhythm. In: *Cardiac Electrophysiology: From Cell to Bedside*; 2nd Edition (Zipes DP and Jalife J Eds), WB Saunders, Philadelphia, PA 435-440, 1995
220. Bilezikian JP: Hyperparathyroidism and hypoparathyroidism. In: *Conn's Current Therapy* (Rakel RE, ed) WB Saunders, Philadelphia, PA 565-569, 1995.
221. Rosen MR, Robinson RB, Cohen IS, Steinberg SF, Bilezikian JP: Alpha-adrenergic modulation of cardiac rhythm. In: *Physiology and Pathophysiology of the Heart*; 3rd Edition (Sperelakis N, Ed), Kluwer Academic Publishers, Boston 457-465, 1995.
222. Horn EM, Kukin ML, Neuberger GW, Goldsmith RL, McCarty M, Gratch M, Medina N, Yushak M, Packer M, Bilezikian JP: Lymphocyte G proteins reflect response to treatment in congestive heart failure. *Am Heart Journal* 129:98-106, 1995.
223. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, Bilezikian JP: Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. *J Clin Endocrinol & Metab* 80:723-728, 1995.
224. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, McMahon D, Bilezikian JP: Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. *J Clin Endocrinol & Metab* 80:729-734, 1995.

225. Wittner M, Morris SA, Christ GJ, Hatcher VB, Zeballos GA, Bilezikian JP, Weiss LM, Tanowitz HB: Trypanosoma cruzi: Indices of endothelin release from endothelial cells. *J Infectious Diseases* 171:493-497, 1995.
226. Epstein S, Shane E, Bilezikian JP: Organ transplantation and osteoporosis. *Current Opinion in Rheum* 7:255-261, 1995.
227. Silverberg SJ, Fitzpatrick LA, Bilezikian JP: Primary hyperparathyroidism. In: *Principles and Practice of Endocrinology and Metabolism*, 2nd Edition (Becker KL, ed) JB Lippincott, Philadelphia, PA 512-520, 1995.
228. Seibel MJ, Robins SP, Bilezikian JP: Biochemical markers of bone metabolism. In: *Principles and Practice of Endocrinology and Metabolism*, 2nd Edition (Becker KL, ed), JP Lippincott, Philadelphia, PA 498-508, 1995.
229. Siegel LM, Bilezikian JP: Metabolic bone diseases and disorders of the gastrointestinal tract. *Gastrointestinal Tract and the Endocrine System*. (Singer MV, Ziegler R, and Rohr G, eds) Kluwer Academic Publishers, The Netherlands 113-129, 1995.
230. Parisien M, Cosman F, Mellish RWE, Schnitzer M, Nieves J, Silverberg SJ, Shane E, Kimmel D, Recker RR, Bilezikian JP, Lindsay R, Dempster DW: Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. *J Bone Min Res* 10:1393-1399, 1995.
231. Ogino K, Burkhoff D, Bilezikian JP: The hemodynamic basis for the cardiac effect of parathyroid hormone and parathyroid hormone-related protein. *Endocrinology* 136:3024-3030, 1995.
232. Bilezikian JP: Viewpoint: Osteoporosis: Why calcium is important. *J Women's Health* 4:483-494, 1995.
233. Shane E, Bilezikian JP: Normal bone and mineral homeostasis. In: *Bisphosphonate on Bones* (Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, eds) Elsevier, Amsterdam, 3-21, 1995.
234. Bilezikian JP: Nephrolithiasis in primary hyperparathyroidism. In: *Kidney Stones: Medical and Surgical Treatment* (Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds) Lippincott-Raven, Philadelphia, 783-802, 1996.

235. Silverberg SJ, Fitzpatrick LA, Bilezikian JP: The role of parathyroid hormone and vitamin D in the pathogenesis of osteoporosis. In: Osteoporosis (Marcus R, Feldman D, Kelsey J, eds) Academic Press, San Diego, 715-726, 1996.
236. Koga S, Morris SA, Bilezikian JP, Chen G, Huang JX, Thompson WJ, Ashikaga T, Brett J, Stern D, Pinsky D: Tumor necrosis factor increases endothelial cell monolayer permeability and decreases thrombomodulin activity through activation of cyclic nucleotide phosphodiesterase and decreased intracellular cyclic AMP. *A J Physiology* 268:C1104-C1113, 1996.
237. Tohme JF, Bilezikian JP: Diagnosis and treatment of hypocalcemic emergencies. *The Endocrinologist* 6:10-18, 1996.
238. Bilezikian JP: Primary hyperparathyroidism. IN: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd Edition. (Favus MJ, ed) Lippincott-Raven Press, Philadelphia 181-186, 1996.
239. Bilezikian JP: Current and future non-hormonal approaches to the treatment of osteoporosis. *Int'l J Fertility* 41:148-155, 1996.
240. Chen G, Barr S, Walsh D, Rohde S, Brewer A, Bilezikian JP, Wittner M, Tanowitz H, Morris SA: Cardioprotective actions of verapamil on the beta-adrenergic receptor complex in acute canine Chagas' disease. *J Mol Cell Cardiol* 28:931-941, 1996.
241. Sun LS, Huber F, Robinson RB, Bilezikian JP, Steinberg SF, Vulliamoz Y: Muscarinic receptor heterogeneity in neonatal rat ventricular myocytes in culture. *J Cardiovasc Pharmacol* 27:455-461, 1996.
242. Silverberg SJ, Locker F, Bilezikian JP: Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. *J Clin Endocrinol Metab* 81:4007-4012, 1996.
243. Silverberg SJ, Bilezikian JP: Evaluation and management of primary hyperparathyroidism. *J Clin Endocrinol Metab* 81:2036-2040, 1996.
244. Morris SA, Bilezikian JP: Signal transduction in bone physiology: messenger systems for parathyroid hormone. In: Principles of Bone Biology (Bilezikian JP, Raisz LR, Rodan GA, eds) Academic Press, San Diego, 1203-1215, 1996.

245. Rodan GA, Raisz LR, Bilezikian JP: Pathophysiology of osteoporosis. In: Principles of Bone Biology (Bilezikian JP, Raisz LR, Rodan GA, eds) Academic Press, San Diego, 979-990, 1996.
246. Fitzpatrick LA, Bilezikian JP: Actions of parathyroid hormone. In: Principles of Bone Biology (Bilezikian JP, Raisz LR, Rodan GA, eds) Academic Press, San Diego 339-346, 1996.
247. Silverberg SJ, Bilezikian JP: Cytokines in primary hyperparathyroidism: factors that matter. *J Clin Endocrinol & Metab* 3448-3449, 1996.
248. Bilezikian JP, Silverberg SJ: Usefulness of bone mass measurements in primary hyperparathyroidism. *Current Opinion in Endocrinology and Diabetes* 3:514-520, 1996.
249. Thys-Jacobs S, Chan FKW, Koberle LMC, Bilezikian JP: Hypercalcemia due to vitamin D toxicity. In: *Vitamin D* (Feldman D, editor-in-chief) Academic Press, San Diego 883-901, 1997.
250. Chan FKW, Koberle LMC, Thys-Jacobs S, Bilezikian JP: Differential diagnosis, etiologies and management of hypercalcemia. *Current Problems in Surgery* 34:1-79, 1997.
251. Tohme JF, Bilezikian JP: Critical illness and calcium metabolism. In: *Endocrinology of Critical Disease* (Ober KP, ed.) Humana Press, Totowa, NJ 233-247, 1997.
252. Masi L, Bilezikian JP: Osteoporosis: New hope for the future. *Int'l J of Fertility* 42:245-254, 1997.
253. Seibel MJ, Robins SP, Bilezikian JP: Serum undercarboxylated osteocalcin and the risk of hip fracture. *J Clin Endocrinol & Metab* 82:717-718, 1997.
254. Bilezikian JP: Hypercalcemia and primary hyperparathyroidism. *Medicine Int'l* 25:64-67, 1997.
255. Hara M, Liu Y, Zhen L, Cohen IS, Yu H, Danilo P, Ogino K, Bilezikian JP, Rosen MR: The positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are due to increases in the current I_p , and the slope of the pacemaker potential. *Circulation* 96:3704-3709, 1997.

256. Locker FG, Silverberg SJ, Bilezikian JP: Optimal dietary calcium intake in primary hyperparathyroidism. *Am J Med* 102:543-550, 1997.
257. Huang H, Tanowitz HB, Bilezikian JP, Wittner M, Weiss LM, Morris SA: Myocardial G proteins in murine Chagas' disease. *J Parasitology* 663-670, 1997.
258. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP: Insulin-like growth factor-I in men with idiopathic osteoporosis. *J Clin Endocrinol & Metab* 82:2799-2806, 1997.
259. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: Still evolving? *J Bone Min Res* 12:856-862, 1997.
260. Silverberg SJ, Bone III HG, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Sanguinetti EL, Bilezikian JP: Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. *N Eng J Med* 337:1506-1510, 1997.
261. Rosen CJ, Bilezikian JP: Evolving towards a new paradigm for prevention of osteoporosis: the time is upon us. *J Clin Endocrinol & Metab*, 82:2782-2783, 1997.
262. Bilezikian JP, Silverberg SJ: Asymptomatic primary hyperparathyroidism. In: *Parathyroid Diseases: From the Gene to the Cure*. (Brandi ML, ed) Societa Editrice Europea di Nicodemo Maggiulli & C., Firenze, Italy, 73-90, 1997.
263. Bilezikian JP, Thakker RV: Hypoparathyroidism. *Current Opinion in Endocrinology and Diabetes* 4:427-432, 1997.
264. Bilezikian JP: Osteoporosis: The case for screening. *Osteoporosis: Index & Reviews* 2:2-7, 1997.
265. Bilezikian JP: "Hypercalcemia", "Hypocalcemia" and "Primary Hyperparathyroidism" in *Internal Medicine*, 5th Edition (JH Stein, Editor-in-Chief) Mosby, St. Louis, MO 1927-1930, 1930-1934, 1965-1971, 1998.
266. Kulak CAM, Bandeira C, Voss DM, Sobieszczyk SM, Bandeira F, Silverberg SJ, Bilezikian JP: Bone mass increases markedly following parathyroidectomy in osteitis fibrosa cystica. *J Clin Endocrinol & Metab* 83:732-735, 1998.

267. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. *J Clin Endocrinol & Metab* 83:1083-1088, 1998.
268. Rosen CJ, Donahue LR, Beamer WG, Adler RA, Kurland ES, Bilezikian JP: IGF-I and osteoporosis: lessons from mice and men. In: *Nutritional Symposium on Osteoporosis*. Springer-Verlag, Berlin 135-140, 1998.
269. Kulak CAM, Bilezikian JP: Practical approaches to the prevention of osteoporosis. *Int'l J of Fertility* 43:56-64, 1998.
270. Schneeman BO, Neisheim RO, Bilezikian JP, Butte NF, Butterfield GE, Heymsfield SB, Looker A, Matheson GO, Specker BL: Reducing stress fracture in physically active military women. Food and Nutrition Board, Institute of Medicine, National Academy Press, Washington D.C., 1998.
271. Bilezikian JP: Estrogens and postmenopausal osteoporosis. *J Bone Min Res* 13:774-776, 1998.
272. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP: An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: implications for genetic studies of bone mineral density. *J Clin Endocrinol Metab* 83:2286-2290, 1998.
273. Kurland ES, Chan FKW, Rosen CJ, Bilezikian JP: Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. *J Clin Endocrinol & Metab* 83:2576-2579, 1998.
274. Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. *N Engl J Med* 339:599-603, 1998.
275. Bilezikian JP: Importance of estrogens in skeletal health of men and women. In: *Metabolic Bone Disorders* (Mithal A, Rao DS, Zaide M, eds) Hindustani Book Depot, Lucknow, India, 169-180, 1998.
276. Bilezikian JP: Evolution of primary hyperparathyroidism: a global perspective. In: *Metabolic Bone Disorders* (Mithal A, Rao DS, Zaide M, eds) Hindustani Book Depot, Lucknow, India, 29-42, 1998.

277. Boncimino K, McMahon DJ, Adesso V, Bilezikian JP, Shane E: Magnesium deficiency and bone loss after cardiac transplantation. *J Bone Min Res* 14:295-303, 1999.
278. Bilezikian JP: Primary hyperparathyroidism. In: *The Bone and Mineral Manual: A Practical Guide* (Kleerekoper M, Siris E, McClung M, eds) Academic Press 30:141-142, 1999.
279. Morris SA, Shen H, Bex FJ, Bilezikian JP: Influence of anti-resorptive agent OST-766 on signal transduction pathways involved in parathyroid hormone action. *Calcif Tissue Int* 64:148-153, 1999.
280. Dempster DW, Parisien M, Silverberg SJ, Liang X-G, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP: On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. *J Clin Endocrinol & Metab* 84:1562-1566, 1999.
281. Staron RB, Greenspan R, Miller TT, Bilezikian JP, Shane E, Haramati N: Computerized bone densitometric analysis: operator-dependent errors. *Radiology* 211:467-470, 1999.
282. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP: Calcium dysregulation and the polycystic ovarian syndrome. *Steroids* 64:430-435, 1999.
283. Freda P, Bilezikian JP: The pituitary adrenal axis in HIV disease. *The AIDS Reader* 9:43-50, 1999.
284. Silverberg SJ, Bilezikian JP: Primary Hyperparathyroidism. In: *Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications* (Seibel MJ, Robins SP, Bilezikian JP, eds) Academic Press, San Diego 571-580, 1999.
285. Silverberg SJ, Bilezikian JP: Parathyroid hormone. In: *The Aging Skeleton* (Rosen CJ, Glowacki J, Bilezikian JP, eds) Academic Press, San Diego 175-184, 1999.
286. Bilezikian JP, Kurland ES, Rosen CJ: Idiopathic osteoporosis in men. In: *Osteoporosis in Men* (Orwoll E, editor) Academic Press, San Diego 395-416, 1999.

287. Bilezikian JP: Primary hyperparathyroidism. In: Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism, Fourth Edition (Favus M, editor) Lippincott, Williams & Wilkens 187-191, 1999.
288. Fitzpatrick LA, Bilezikian JP: Structure, function, and actions of parathyroid hormone. In: Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Applications (Seibel MJ, Robins SP, Bilezikian JP, eds.) Academic Press, San Diego 187-199, 1999.
289. Bilezikian JP: The role of estrogens in the skeletal health of men and women. Proceedings of the 3rd Int'l Congress on Osteoporosis. Xi'an, China 26-30, 1999.
290. Silverberg SJ, Bilezikian JP, Bone HG, Talpos GB, Horwitz M, Stewart AF: Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab 84:2275-2285, 1999.
291. Miller PD, Zapalowski C, Kulak CAM, Bilezikian JP: Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 84:1867-1871, 1999.
292. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP: Vitamin D insufficiency in primary hyperparathyroidism. Am J Med 107:561-567, 1999.
293. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP: A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New Eng J Med 341:1249 -1255, 1999.
294. Bilezikian JP, Kurland ES, Rosen CJ: Male skeletal health and osteoporosis. Trends in Endocrinol Metab 10:244-250, 1999.
295. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Rosen CJ, Watts NB: Practical clinical application of biochemical markers of bone turnover. J Clin Densitometry 2:323-342, 1999.
296. Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 84:3431-3434, 1999.
297. Bilezikian JP: Primary hyperparathyroidism: insights for the next millenium. Clinical Laboratory 45:403-407, 1999.

298. Rosen CJ, Bilezikian JP: Perplexing polymorphisms: D(i)ps, Sn(i)ps and Trips. *J Clin Endocrinol Metab* 84:4465-4466, 1999.
299. Kulak CAM, Bilezikian JP: Bone mass measurement in identification of women at risk for osteoporosis. *Int'l J of Fertility and Women's Health* 44:269-278, 1999.
300. Bilezikian JP: The importance of calcium in postmenopausal women. *Am J Therapeutics* 6:325-326, 1999.
301. Kulak CAM, Bilezikian JP: Bisphosphonates: characteristics and use in osteoporosis. In: *Osteoporosis* (Bandeira F, Macedo G, Caldas G, Griz L, Faria M, eds) Medsi, Rio de Janeiro, Brazil, 351-372, 2000.
302. Bilezikian JP: Gender-specificity and osteoporosis. *J Gender Specific Med* 3:6-14, 2000.
303. Bilezikian JP, Zapalowski C, Kulak CAM, Rosen C, Miller PD: Newer concepts in bone densitometry. In: *Osteoporosis* (Bandeira F, Macedo G, Caldas G, Griz L, Faria M, eds) Medsi, Rio de Janeiro, Brazil, 113-126, 2000.
304. Bilezikian JP, Meng X, Shi Y, Silverberg SJ: Primary hyperparathyroidism in women: New York and Beijing (A Tale of Two Cities). *Int'l J Fertility and Women's Health* 45:158-165, 2000.
305. Tohme JF, Bilezikian JP, Rodino MA: Treatment options for the osteoporotic woman. *EndoTrends* 7:1-6, 2000.
306. Bilezikian JP: A new look for the new millennium. *J Clin Endocrinol Metab* 85:3-4, 2000.
307. Bilezikian JP: Prevention and treatment of osteoporosis. *Columbia's Women's Health Program Monograph*, Postgraduate Institute for Medicine, Englewood, Colorado, 31-41, 2000.
308. Kulak CAM, Schussheim DH, McMahon DJ, Kurland E, Silverberg SJ, Siris ES, Bilezikian JP, Shane E: Osteoporosis and low bone mass in pre- and perimenopausal women. *Endocrine Practice* 6:296-304, 2000.

309. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP: Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers. *J Clin Endocrinol Metab* 85:3069-3076, 2000.
310. Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS, Harbison M, Berdon W, Oberfield SE: Osteoporosis: an unusual presentation of childhood Crohn's disease. *J Clin Endocrinol Metab* 85:2122-2126, 2000.
311. Khan A, Bilezikian JP: Primary hyperparathyroidism: pathophysiology and impact on bone. *Canadian Medical Association Journal* 163:184-187, 2000.
312. Mulder JE, Bilezikian JP: Management of hypercalcemia. *J Crit Care Med* 15:277-285, 2000.
313. Bilezikian JP: Primary hyperparathyroidism: when to observe and when to operate. In: *Endocrinology and Metabolism Clinics of North America* (Strewler GS, ed) 29:465-478, 2000.
314. Bilezikian JP, Silverberg SJ: Parathyroid hormone: does it have a role in the pathogenesis of osteoporosis? In: *Clinics in Laboratory Medicine* (Rosen CJ, ed) 20:559-567, 2000.
315. Bilezikian JP: Estrogens and fracture risk. *Menopause Management* 9:22-27, 2000.
316. Yu YH, Bilezikian JP: "Tachycardia-induced" cardiomyopathy secondary to thyrotoxicosis: a young man with unrecognized Graves' disease. *The Thyroid* 10:923-927, 2000.
317. Bilezikian JP, Silverberg SJ: Clinical spectrum of primary hyperparathyroidism. *Reviews in Endocrine & Metabolic Disorders* 1:237-245, 2000.
318. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. In: *Endocrinology, Fourth Edition* (DeGroot LJ, Jameson JL, eds) WB Saunders, Philadelphia, PA, 1075-1093, 2001.
319. Seibel MJ, Robins SP, Bilezikian JP: Markers of bone metabolism. In: *Principles and Practice of Endocrinology and Metabolism* (Becker KL, ed) Lippincott-Williams & Wilkins, Philadelphia, PA 548-556, 2001.

320. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. In: Principles and Practice of Endocrinology and Metabolism, 3rd Edition (Becker KL, ed) Lippincott-Williams & Wilkins, Philadelphia, PA 564-573, 2001.
321. Silverberg SJ, Bilezikian JP: Clinical presentation of primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine M, eds) Academic Press, San Diego, CA 349-360, 2001.
322. Parisien M, Dempster DW, Shane E, Bilezikian JP: Histomorphometric analysis of bone in primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine M, eds) Academic Press, San Diego, CA 423-436, 2001.
323. Mulder JE, Bilezikian JP: Acute management of hypercalcemia. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 729-742, 2001.
324. Silverberg SJ, Bilezikian JP: Clinical course of primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 387-398, 2001.
325. Silverberg SJ, Bilezikian JP: Parathyroid function and responsiveness in osteoporosis. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 843-852, 2001.
326. Mithal A, Bandeira F, Meng X, Silverberg S, Shi Y, Mishra SK, Griz L, Macedo G, Celdas G, Bandeira C, Bilezikian JP, Rao DS: Primary hyperparathyroidism in India, Brazil and China. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 375-386, 2001.
327. Rosen CJ, Bilezikian JP: Anabolic therapy for osteoporosis. *J Clin Endocrinol Metab* 86:957-964, 2001.
328. Bilezikian JP, Silverberg SJ: The role of parathyroid hormone and vitamin D in the pathogenesis of osteoporosis. In: Osteoporosis, 2nd Edition (Marcus R, Kelsey J, Feldman D, eds) Academic Press, San Diego, CA 2:71-84, 2001.
329. Bilezikian JP: Osteoporosis: What's new, what's next. *Menopause Management* 10 (Suppl I) 21-23, 2001.

330. Bilezikian JP: The role of estrogens in male skeletal development. *Reprod Fertil Dev* 13(4):253-259, 2001.
331. Shimoyama M, Ogino K, Uchida K, Furuse Y, Kinugasa Y, Taniguchi S, Igawa O, Hisatome I, Bilezikian JP, Shigemasa C: Fragment-specific actions of parathyroid hormone in isolated perfused rat hearts. *Calcif Tissue Int* 69:88-93, 2001.
332. Shimoyama M, Ogino K, Bilezikian JP, Uchida K, Furuse Y, Hisatome I, Shigemasa C: Signal transduction pathways and the chronotropic actions of parathyroid hormone (PTH) in isolated perfused rat hearts. *J Cardiovasc Pharmacol* 38:491-499, 2001.
333. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G, and the Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Fitzpatrick L, Favus M, Kiel D, Marcus R, Orwoll E, Schnitzner T, Black D: A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. *Osteo Int* 12:140-151, 2001.
334. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian JP, Lindsay R: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. *J Bone Min Res* 16:1846-1853, 2001.
335. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. *J Clin Endocrinol Metab* 86:5658-5671, 2001.
336. Bilezikian JP, Kurland ES: Therapy of male osteoporosis with parathyroid hormone. *Calcif Tissue Int* 69:248-251, 2001.
337. Rubin MR, LiVolsi VA, Bandeira F, Caldas G, Bilezikian JP: Tc-99m-Sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. *J Clin Endocrinol Metab* 86:5138-5141, 2001.
338. Bilezikian JP, Marcus R, Levine MA: Preface. In: *The Parathyroids*, 2nd Edition, (Bilezikian JP, Marcus R, Levine MA, eds) Academic Press, San Diego, CA XV - XVI, 2001.
339. Bilezikian JP: Hypercalcemia and primary hyperparathyroidism. *MEDICINE* 29: 12:54-57, 2001

340. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR: American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. *Endocr Pract* 7(4):293-312, 2001.
341. Bilezikian JP, Khosla S, Riggs BL: Estrogen effects on bone in the male skeleton. In: *Principles of Bone Biology*, 2nd edition (Bilezikian JP, Raisz LG, Rodan GA, eds) Academic Press 1467-1476, 2002.
342. Rodan GA, Raisz LG, Bilezikian JP: Pathophysiology of osteoporosis. In: *Principles of Bone Biology* 2nd Edition (Bilezikian JP, Raisz LG, Rodan GA, eds) Academic Press, San Diego, CA 1275-1290, 2002.
343. Hock JM, Fitzpatrick LA, Bilezikian JP: Actions of parathyroid hormone. In: *Principles of Bone Biology*, 2nd Edition (Bilezikian JP, Raisz LG, Rodan GA, eds) Academic Press, San Diego, CA 463-482, 2002.
344. Gao H, Bodine PV, Murrills R, Bex FJ, Bilezikian JP, Morris SA: PTH-dependent adenylyl cyclase activation in SaOs 2 cells: passage dependent effects on G protein interactions. *J Cell Physiol* 193:10-18, 2002.
345. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. In: *Oxford Textbook of Endocrinology and Diabetes* (Wass JAH, Shalet SM, eds) Oxford University Press, Oxford 619-632, 2002.
346. Bilezikian JP: Bisphosphonates: new dosing regimens and approaches to treatment. *Menopause Management* 11:22-23, 2002.
347. Bilezikian JP: Estrogens and postmenopausal osteoporosis: after all these years, Albright still had it right. *The Endocrinologist (Supplement)* (Kolb F, ed) 168-170, 2002.
348. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Black D, Favus MJ, Fitzpatrick L, Kiel DP, Marcus R, Orwoll E, Schnitzer T: Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. *Endocrine Reviews* 23:552-559, 2002.

349. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Favus M, Fitzpatrick L, Kiel D, Marcus R, Orwoll E, Schnitzner T: Meta-analysis of alendronate for the treatment of postmenopausal women. *Endocrine Reviews* 23:508-516, 2002.
350. Rubin MR, Cosman F, Lindsay R, Bilezikian JP: The anabolic effects of parathyroid hormone. *Osteoporosis International* 13:267-277, 2002.
351. Bilezikian JP: Editorial: Sometimes, Bigger is Better. *J Clin Endocrinol Metab* 87:1-2, 2002.
352. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism: epidemiology and clinical consequences. *Clinical Reviews in Bone and Mineral Metabolism* 1:25-34, 2002.
353. Bilezikian JP: PTH for osteoporosis treatment: an update. *Menopause Management* 11:22-30, 2002.
354. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Black DM, Favus M, Fitzpatrick L, Kiel D, Marcus R, Orwoll E, Schnitzner T: Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. *Endocrine Reviews* 23:540-551, 2002.
355. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Black DM, Favus M, Fitzpatrick L, Kiel D, Marcus R, Orwoll E, Schnitzner T: Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. *Endocrine Reviews* 23:517-523, 2002.
356. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Black DM, Favus M, Fitzpatrick L, Kiel D, Marcus R, Orwoll E, Schnitzner T: Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocrine Reviews* 23:529-539, 2002.

357. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen C, Bilezikian JP, Black DM, Favus M, Fitzpatrick L, Kiel D, Marcus R, Orwoll E, Schnitzner T: Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. *Endocrine Reviews* 23:524-528, 2002.
358. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, the Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group: Bilezikian JP, Black DM, Favus M, Fitzpatrick L, Kiel D, Marcus R, Orwoll E, Schnitzner T: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocrine Reviews* 23:570-578, 2002.
359. Bilezikian JP: Sex steroids, mice and men: when androgens and estrogens get very close to each other. *J Bone Min Research* 17:563-566, 2002.
360. Silverberg SJ, Brown, I, Bilezikian JP: Age as a criterion for surgery in primary hyperparathyroidism. *Am J Med* 113:681-684, 2002.
361. Cranney A, Tugwell P, Wells G, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen CJ, Bilezikian JP, Black DM, Favus M, Fitzpatrick LA, Kiel DP, Marcus R, Orwoll ES, Schnitzner TJ: Systematic reviews of randomized trials in osteoporosis: Introduction and methodology. *Endocrine Reviews* 23:496-507, 2002.
362. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G, The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group: Rosen CJ, Bilezikian JP, Favus MJ, Fitzpatrick LA, Kiel DP, Marcus R, Orwoll ES, Schnitzner T, Black DM: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. *Endocrine Reviews* 23:560-569, 2002.
363. Bell NH, Bilezikian JP, Bone III HG, Kaur A, Maragoto A, Santora AC: Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. *J Clin Endocrinol Metab* 87:2792-2797, 2002.
364. Ogino K, Ogura K, Furuse Y, Uchida K, Shimoyama M, Kinugawa T, Osaki S, Kato M, Igawa O, Hisatome I, Bilezikian JP, Shigemasa C: Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. *J Clin Endocrinol Metab* 87:4722-4728, 2002.

365. Rubin MR, Bilezikian JP: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. *J Clin Endocrinol Metab* 87:4033-4041, 2002.
366. Rubin MR, Bilezikian JP: The potential of parathyroid hormone as a therapy for osteoporosis. *Reproduction, Fertility and Development* 47:103-115, 2002.
367. Ettinger B, Bilezikian JP: Editorial: For osteoporosis, are two anti-resorptive drugs better than one? *J Clin Endocrinol Metab* 87;3:983-984, 2002.
368. Bilezikian JP, Mulder JE, Silverberg SJ: Hypercalcemic states: differential diagnosis and acute management. In: *Disorders of Bone and Mineral Metabolism, 2nd Edition*, (Coe, Favus eds) Lippincott, Williams & Wilkins, Philadelphia, PA 22:489-515, 2002.
369. Bilezikian JP: New treatment options for osteoporosis: PTH (1-34) teriparatide injection [rDNA origin]. *Current Research and Expert Commentary, Medical Education Network*, 2-8, 2002.
370. Rubin MR, Bilezikian JP: New anabolic therapies in osteoporosis. *Current Opinion in Rheumatology*, 14:433-440, 2002.
371. Bilezikian JP, Potts JT, Jr.: Primary hyperparathyroidism: new issues and new questions – Bridging the past with the future. *J Bone Min Res* 17 (Suppl 2) N57-N67, 2002.
372. Leib ES, Lenchik L, Bilezikian JP, Maricic MJ, Watts NB: Position Statements of the International Society of Clinical Densitometry: Methodology. *J Clin Densitometry* 5 (Suppl) S5-S11, 2002.
373. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. *J Bone Min Res* 17 (Suppl 2) N2-N11, 2002; *J Clin Endocrinol Metab* 87:5353-5361, 2002.
374. Miller PD, Bilezikian JP: Bone densitometry in asymptomatic primary hyperparathyroidism. *J Bone Min Res* 17 (Suppl 2) N98-N102, 2002.

375. Bilezikian JP, Miller P: BMD testing, bone quality and antiresorptive drug efficacy. *Osteoporosis Today* 2:1-2, 2002.
376. Bilezikian JP, Yoshimoto K, Pollak MR, Schipani E, Juppner H, Brown EM, Arnold A, Thakker RV: Genetic disorders of parathyroid hormone action. In: *Genetics in Endocrinology* (Baxter JD, Melmed S, New MI, eds) Lippincott, Williams & Wilkins, Philadelphia, PA 423-444, 2002.
377. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: Physiology and surgical indications. In: *Surgery of the Thyroid and Parathyroid Glands* (Randolph G, ed), Elsevier-Saunders, Philadelphia, PA 489-497, 2003.
378. Rubin MR, Bilezikian JP: Parathyroid hormone as a therapy for osteoporosis. In: *Osteoporosis: Scientific Principles and Clinical Practice* (Orwoll ES, Bliziotes M, eds) Humana Press, Totowa, NJ 493-522, 2003.
379. Bilezikian JP: The JCEM in 2003: Looking backwards and forwards. *JCEM* 88:1-2, 2003.
380. Bilezikian JP: Osteoporosis in men. In: *Endocrinologia e Diabetes* (Bandeira F, Macedo G, Caldas G, Griz L, Faria MS, eds) MEDSI, Rio de Janeiro, Brazil, 444-458, 2003.
381. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian JP, Lindsay R: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. *J Clin Endocrinol Metab* 88:1150-1156, 2003.
382. Rubin MR, Bilezikian JP: New anabolic therapies in osteoporosis. *Endocrinology and Metabolism Clinics of North America* 32:285-308, 2003.
383. Khosla S, Bilezikian JP: The role of estrogens in men; androgens in women. *Endocrinology and Metabolism Clinics of North America* 32:195-218, 2003.
384. Rubin MR, Bilezikian JP: The anabolic effects of parathyroid hormone therapy. In: *Clinics in Geriatric Medicine* 19:415-432, 2003.

385. Bilezikian JP: When should a gynecologist refer a patient for specialty care in osteoporosis? *International Journal of Fertility* 48:132-136, 2003.
386. Bilezikian JP: Identifying and treating patients at high risk for fractures. In: *Achieving Clinical and Cost-effectiveness in the Management of Osteoporosis. Managed Care Consultant* 3:10-16, 2003.
387. Bilezikian JP: Revised guidelines for the management of asymptomatic primary hyperparathyroidism. *EndoTrends* 9:6-7, 2003.
388. Siris ES, Bilezikian JP, Rubin MR, Black D, Bockman R, Bone HG, Hochberg MC, McClung MR, Schnitzler TJ: Pins and plaster aren't enough: A call for the evaluation and treatment of patients with osteoporotic fractures. *J Clin Endocrinol Metab* 88:3482-3486, 2003.
389. Silverberg SJ, Brown I, LoGerfo P, Gao P, Cantor T, Bilezikian JP: Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. *J Clin Endocrinol Metab* 88:4725-4730, 2003.
390. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M: The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab* 88:5644-5649, 2003.
391. Bilezikian JP, Silverberg SJ: Physiology of the parathyroid glands and pathophysiology of primary hyperparathyroidism. In: *Endocrine Surgery* (Schwartz, Pertsemlidis, Gagner, eds), Marcel Dekker, Inc. New York, NY 213-230, 2003.
392. Opatowsky AR, Bilezikian JP: Racial differences in the effect of early milk consumption on peak and postmenopausal bone mineral density. *J Bone Min Res* 18:1978-1988, 2003.
393. Khan AA, Hanley D, O'Brien C, Pasiaka J, Ste-Marie LG, Rotstein LE, Rosen I, Young JEM, Josse R, Bilezikian JP: Asymptomatic primary hyperparathyroidism: standards and guidelines for management. *Endocrine Practice* 9:400-405, 2003.
394. Bhagat G, Leffler D, Bilezikian JP, Green PH: Cystosarcoma phyllodes of the breast occurring in a child with subsequent diagnosis of celiac disease. *J Ped Gastroenterol Nutr* 36:644-646, 2003.

395. Bilezikian JP: Bone strength in primary hyperparathyroidism. *Osteoporosis Int'l* 14: (Suppl 5) 5113-5117, 2003.
396. Opotowsky AR, Su BW, Bilezikian JP: Height and lower extremity length as predictors of hip fracture: results of the NHANES I epidemiologic follow-up study. *J Bone Min Res* 18:1674-1681, 2003.
397. Silverberg SJ, Bilezikian JP: "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. *J Clin Endocrinol Metab* 88:5348-5352, 2003.
398. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *N Eng J Med* 349:1207-1215, 2003.
399. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In: *Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism, Fifth Edition* (Favus M, editor) Am Soc Bone Min Res, Washington D.C. 230-235, 2003.
400. Bilezikian JP: PTH for building bone in high-risk osteoporosis patients. *Osteoporosis Today* 3:1-2, 2003.
401. Bilezikian JP: The role of the endocrinologist in the treatment of osteoporosis. In: *The Endocrinologist* 13:(Suppl 2) S17-22, 2003.
402. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. *Endocr Practice* 9:544-564, 2003.
403. Canalis E, Bilezikian JP, Angeli A, Giustina A: Perspectives on glucocorticoid induced osteoporosis. *Bone* 34:593-598, 2004.
404. Bilezikian JP: The JCEM in 2004: Winding up while winding down. *J Clin Endocrinol Metab* 89:1-2, 2004.
405. Bilezikian JP: Overview of the qualities of bone that are responsible for bone strength. *CME Forum* 3:6-11, 2004.

406. Bilezikian JP, Silverberg SJ: Management of asymptomatic primary hyperparathyroidism. *N Eng J Med* 350:1746-1751, 2004.
407. Rubin MR, Bilezikian JP: Anabolic therapy of osteoporosis in women and in men. IN: *Principles of Gender-Specific Medicine* (ML Legato, ed) Elsevier, Academic Press, San Diego 995-1009, 2004.
408. Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. *J Clin Endocrinol Metab* 89:3319-3325, 2004.
409. Opotowsky AR, Bilezikian JP: Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: A prospective analysis of the NHANES I follow-up study. *Am J Med* 117:169-174, 2004.
410. Kurland ES, Heller SL, Diamond B, McMahon D, Cosman F, Bilezikian JP: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. *Osteoporosis Int'l* 15:992-997, 2004.
411. Khosla S, Bilezikian JP: The role of androgens and estrogens in the male skeleton. In: *Principles of Gender-Specific Medicine* (ML Legato, editor) Elsevier, Academic Press, San Diego 1021-1032, 2004.
412. Miller PD, Bilezikian JP, Deal C, Harris S, Pacifici R: Clinical use of teriparatide in the real world: initial insights. *Endocrine Practice* 10:139-148, 2004.
413. Silverberg SJ, Bilezikian JP: Asymptomatic primary hyperparathyroidism: a medical perspective. IN: *Surgical Clinics of North America*, (Clark O, Duh Q, Kebebew E, eds) 84:787-802, 2004.
414. Kulak CAM, Borba VZC, Bilezikian JP, Silvado CE, de Paola L, Boguszewski CL: Bone mineral density and serum levels of 25 OH Vitamin D in chronic users of antiseizure drugs. *Arq Neuropsiquiatr*, 62:940-948, 2004.
415. Mulder J, Bilezikian JP, Klibanski A: Bone density in survivors of childhood cancer. *J Clin Densitometry* 7:432-442, 2004.

416. Gennari L, Bilezikian JP: Aromatase activity and bone homeostasis in men. *J Clin Endocrinol Metab* 89:5898-5907, 2004.
417. Bilezikian JP, Rubin M, Silverberg SJ: Primary hyperparathyroidism: Diagnosis, evaluation and treatment. *Current Opinion in Endocrinology and Metabolism* 11:345-352, 2004.
418. Bilezikian JP, Dempster DW: Parathyroid hormone: a new development in the treatment of osteoporosis. *The Female Patient, Supplement*, 1-12, December, 2004.
419. Bilezikian JP: Editorial: Time for us to bid adieu. *J Clin Endocrinol Metab* 89:5887-5888, 2004.
420. Bondeson L, Grimelius L, DeLellis RA, Lloyd R, Akerstrom G, Larsson C, Arnold A, Eng C, Shane E, Bilezikian JP: Parathyroid carcinoma. In: *World Health Organization classification of tumors, pathology and genetics tumors of endocrine origin* (DeLillis RA, Lloyd RV, Heitz PU, Eng C, eds) Lyon, France, International Agency for Research on Cancer Press, 124-127, 2004.
421. Rubin MR, Thys-Jacobs S, Chan FKW, Koberle LMC, Bilezikian JP: Hypercalcemia due to vitamin D toxicity. IN: *Vitamin D, 2nd edition* (Feldman D, Pike JW, Glorieux F, eds) Elsevier Academic Press, San Diego, CA 1355-1378, 2005.
422. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM: Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab* 90:135-141, 2005.
423. Rubin MR, Bilezikian JP: The role of parathyroid hormone in the evolution of bone loss after organ transplantation. IN: *Bone Disease of Organ Transplantation* (Compston J, Shane E, eds) Elsevier Academic Press, San Diego, CA 173-192, 2005.
424. Rubin MR, Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: rheumatologic manifestations and bone disease. IN: *Bone Disease in Rheumatology* (Maricic M, Gluck OS, eds) Lippincott Williams & Wilkins, Philadelphia, PA 185-190, 2005.
425. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ: Primary hyperparathyroidism: new concepts in clinical, densitometric, and biochemical features. *J Int Med*, 257:6-17, 2005.

426. Bilezikian JP: Primary hyperparathyroidism. In: Bone and Mineral Manual, 2nd edition (Kleerekoper M, Siris E, McClung M, eds) Elsevier, San Diego, CA 157-159, 2005.
427. Rubin MR, Schussheim DH, Kulak CAM, Kurland ES, Rosen CJ, Bilezikian JP, Shane E: Idiopathic osteoporosis in premenopausal women. *Osteoporosis Int'l* 16:526-533, 2005.
428. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: Endocrinology, Fifth Edition (DeGroot LJ and Jameson JL, eds) Saunders, Philadelphia, PA 1533-1554, 2005.
429. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ: Arterial stiffness in mild primary hyperparathyroidism. *J Clin Endocrinol Metab* 90:3326-3330, 2005.
430. Bilezikian JP: Anabolic therapy for osteoporosis. *Int'l Journal of Fertility and Women's Medicine* 50:53-60, 2005.
431. Bilezikian JP, Dempster D, Luckey M, Rackoff P, Grisanti J, Tucci J, Lindsay R, Goldring S, Dawson-Hughes B: Discussions in Osteoporosis 4:1-8, 2005.
432. Rubin MR, Bilezikian JP: Parathyroid hormone as an anabolic therapy. *Drugs*, 65:2481-2498, 2005.
433. Burattin A, Bonadonna S, Bugari G, Manelli F, Valle D, Iori N, Villa S, Rosei EA, Bilezikian JP, Veldhuis JD, Giustina A: Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone (PTH) secretory dynamics in human subjects. *Eu J Endocrinol* 152(2):199-205, 2005.
434. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ: One year of alendronate after one year of parathyroid hormone (1-84). *N Eng J Med* 353:555-565, 2005.
435. Jacobs TP, Bilezikian JP: Rare causes of hypercalcemia. *J Clin Endo Metab* 90:6316-6322, 2005.
436. Bilezikian JP: PTH in clinical practice. *Menopause Management* 14 (Suppl 1) 22-24, 2005.

437. Bilezikian JP, Rubin MR, Finkelstein J: Parathyroid hormone as an anabolic therapy for women and men. *J Endocrinological Investigation*, 28 (Suppl 7):41-49, 2005.
438. Bilezikian JP, Rubin MR: Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. In: *Current Osteoporosis Reports* 4:5-13, 2006.
439. Gennari L, Nuti R, Bilezikian JP: Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. In: *Expert Review of Endocrinology and Metabolism* 1:281-296, 2006.
440. Bilezikian JP, Lindsay R, Goldring S, Tucci J, Luckey M, Gold D: *Discussions in Osteoporosis*, Adelphi, Inc., NY, 5:1-8, 2006.
441. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: *Dynamics of Bone and Cartilage Metabolism* (Seibel MJ, Robins SP, Bilezikian JP, eds) Elsevier Press, San Diego, CA, 767-778, 2006.
442. Fitzpatrick L, Bilezikian JP: PTH: Structure, Function and Dynamic Action. IN: *Dynamics of Bone and Cartilage Metabolism*, 2nd edition (Seibel MJ, Robins SP, Bilezikian JP, eds) Elsevier Press, San Diego, CA, 273-292, 2006.
443. Luckey MM, Bilezikian JP, Greenspan SL, Harris ST, McClung M, Watts NB: Osteoporosis – Management and Prevention in General Practice. *American Academy of Family Physicians*, 1-52, 2006.
444. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM: Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis: the PaTH Study. *J Clin Endocrinol Metab* 91:1370-1375, 2006. PMID: 16449339
445. Bilezikian JP, Rubin MR: Monitoring anabolic treatment. IN: *Dynamics of Bone and Cartilage Metabolism*, 2nd edition (Seibel MJ, Robins SP, Bilezikian JP, eds.) Elsevier Academic Press, San Diego, CA 629-647, 2006.
446. Bilezikian JP: Primary hyperparathyroidism and parathyroid cancer. *Princeton Biomedical Communications* , 1-28, 2006.

447. Walker MD, Babbar R, Opotowsky AR, Rohira A, Nabizadeh F, Della Badia M, Chung W, Chiang J, Mediratta A, McMahon D, Liu G, Bilezikian JP: A referent bone mineral density database for Chinese American women. *Osteoporosis Int* 17:878-887, 2006. PMID: 16538554
448. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In: *Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism, Sixth Edition* (Favus M, editor) Am Soc Bone Min Research 181-184, 2006.
449. Silverberg SJ, Bilezikian JP: The diagnosis and management of asymptomatic primary hyperparathyroidism. *Nature Clinical Practice Endocrinology and Metabolism* 2:494-503, 2006. PMID: 16957763
450. Bilezikian JP: What's good for the goose's skeleton is good for the gander's skeleton. *J Clin Endocrinol Metab* 91:1223-1225, 2006. PMID: 16601197
451. Mazziotti G, Angeli A, Bilezikian J, Canalis E, Giustina A: Glucocorticoid-induced osteoporosis: An update. *Trends in Endocrinology and Metabolism* 17:144-149, 2006. PMID: 16678739
452. Raisz LG, Bilezikian JP, Rosenblatt M, Martin TJ, Noda M, Towler D, Eisman J. In Memoriam: Gideon A. Rodan (1934-2006). *J Bone Min Res* 21:979-983, 2006.
453. Bilezikian JP: In Memoriam: Gideon A. Rodan 1934-2006. *J. Clin Densitometry* 9:2-3, 2006.
454. Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP, Hodsman AB, Josse RG, Kendler DL, Lewiecki EM, Miller PD, Olszynski WP, Petak SM, Syed ZA, Theriault D, Watts NB: Standards for performing DXA in individuals with secondary causes of osteoporosis. *J Clin Densitometry*, 9:47-57, 2006. PMID: 16731431
455. Agarwal C, Seigle R, Agarwal S, Bilezikian JP, Hyman JE, Oberfield SE: Pseudohypoparathyroidism: A rare cause of bilateral slipped capital femoral epiphysis. *J Pediatrics* 149:406-408, 2006. PMID: 16939757
456. Heaney RP, Bilezikian JP, Holick MF, Nieves JN, Weaver CM: The role of calcium in peri- and postmenopausal women: position statement of The North American Menopause Society. *Menopause* 13:859-879, 2006.

457. Girotra M, Rubin MR, Bilezikian JP: Anabolic agents for osteoporosis: What is their likely place in therapy? *Treatment in Endocrinology* 6:347-358, 2006. PMID: 17107220
458. Bilezikian JP, Silverberg SJ, Rubin M, Potts, Jr. JT: Asymptomatic primary hyperparathyroidism: present management and future options. *IN: Clinical Cases in Bone and Mineral Metabolism* 3:132-140, 2006.
459. Bilezikian JP, Rubin M, Silverberg SJ: Asymptomatic primary hyperparathyroidism. *Brazilian Archives of Endocrinology and Metabolism* 50:647-656, 2006. PMID: 17117290
460. Girotra M, Rubin MR, Bilezikian JP: Anabolic skeletal therapy for osteoporosis. *Brazilian Archives of Endocrinology and Metabolism* 50:745-754, 2006. PMID: 17117299
461. Borges JLC, Bilezikian JP: Update on osteoporosis therapy. *Brazilian Archives of Endocrinology and Metabolism* 50:755-763, 2006. PMID: 17117300
462. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM: Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. *J Clin Densitometry* 9:4-14, 2006. PMID: 16731426
463. Bilezikian JP: Osteonecrosis of the jaw: do bisphosphonates pose a risk? *N Eng J Med* 355:2278-2281, 2006. PMID: 17135582
464. Leib ES, Binkley N, Bilezikian JP, Kendler DL, Lewiecki EM, Petak SM: Position Development Conference of the International Society for Clinical Densitometry. *J Rheum* 33:11:2319-2321, 2006. PMID: 17086613
465. Girotra M, Rubin MR, Bilezikian JP: The use of parathyroid hormone in the treatment of osteoporosis. *Reviews in Endocrine and Metabolic Disorders* 7:113-121, 2006. PMID: 17043762
466. Bilezikian JP: Primary hyperparathyroidism and hypoparathyroidism. In: *Conn's Current Therapy 2007*, (Rakel RE & Bope ET, eds), Saunders-Elsevier Philadelphia, 751-756, 2007

467. Bilezikian JP: Primary hyperparathyroidism. In: www.ENDOTEXT.org (Version of January 01, 2007) DeGroot L, Editor; Arnold A, Section Editor; (MDTEXT.COM, Inc, S. Dartmouth, MA) 2007.
468. Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ: Heterogeneity in skeletal response to full-length parathyroid hormone (PTH) in the treatment of osteoporosis. *Osteoporosis Int* 18:973-980, 2007. PMID: 17333451
469. Kulak CAM, Borba VZC, Silvado CE, de Paola L, Seibel M, Bilezikian JP, Boguszewski CL: Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy. *Brazilian Archives of Endocrinology* 51:466-471, 2007. PMID: 17546247
470. Antonucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM: Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. *J Clin Endocrinol Metab* 92:942-947, 2007. PMID: PMC3746103
471. Bilezikian JP: Anabolic therapy for osteoporosis. *Women's Health*, (London, England), 3:243-254, 2007. PMID: 19803856
472. Roschger P, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, Bilezikian JP, Klaushofer K: New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. *J Bone Min Res* 22:717-723, 2007. PMID: 17266396
473. Gennari L, Bilezikian JP: Osteoporosis in men. *Endocrine and Metabolism Clinics of North America* 36:399-419, 2007. PMID: 17543726
474. Gennari L, Bilezikian JP: Osteoporosis in men: pathophysiology and treatment. *Current Rheumatology Reports* 9:71-77, 2007. PMID: 17437671
475. Walker MD, Babbar R, Opatowsky A, McMahon DJ, Liu G, Bilezikian JP: Determinants of bone mineral density in Chinese-American women. *Osteoporosis Int* 18:471-478, 2007. PMID: 17120181
476. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM: Summary of the International Society for Clinical Densitometry 2005 Position Development Conference. *J Bone Min Res* 22:643-645, 2007. PMID: 17280530

477. Rubin MR, Silverberg SJ, D'Amour P, Bilezikian JP: An aminoterminal molecular form of parathyroid hormone distinct from PTH (1-84) is overproduced in parathyroid carcinoma. *Clin Chem* 53:1470-1476, 2007. PMID: 17599957
478. Thys-Jacobs S, McMahon D, Bilezikian JP: Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder. *J Clin Endocrinol Metab* 92:2952-2959, 2007. PMID: 17488795
479. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge R, Schwanaer LE, Olson KA, Klassen P, Bilezikian JP: Cinacalcet HCl reduces the serum calcium concentration in inoperable parathyroid carcinoma. *J Clin Endocrinol Metab* 92:3803-3808, 2007. PMID: 17666472
480. Borba VZC, Paz-Filho GJ, Kulak CAM, Seibel MJ, Bilezikian JP: Bone turnover 18 months after a single intravenous dose of zoledronic acid. *Int J Clin Practice* 61:1058-1062, 2007. PMID: 17504370
481. Wüthrich RP, Martin D, Bilezikian JP: The role of calcimimetics in the treatment of hyperparathyroidism. *European J Clin Investigation* 37:915-922, 2007. PMID: 18036025
482. Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R: Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. *J Clin Endocrinol Metab* 92:3535-3541, 2007. PMID: 17609307
483. Canalis E, Giustina A, Bilezikian JP: Mechanisms of anabolic therapies for osteoporosis. *N Eng J Med* 357:905-916, 2007. PMID: 17761594
484. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JP: Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. *Bone* 41:19-24, 2007. PMID: 17490921; PMCID: PMC2721277
485. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C: Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. *J Clin Endocrinol Metab* 92:3114-3121, 2007. PMID: 17535997
486. Canalis E, Mazziotti G, Giustina A, Bilezikian JP: Glucocorticoid-induced osteoporosis. *Osteoporosis Int* 18:1319-1328, 2007. PMID: 17566815

487. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. *J Clin Endocrinol Metab* 92:3001-3005, 2007. PMID: 17536001
488. Bilezikian JP, Fitzpatrick LA, Silverberg SJ: The skeletal actions of parathyroid hormone in primary hyperparathyroidism and in osteoporosis. IN: *Osteoporosis, Third Edition* (Marcus R, Feldman D, Nelson D, Rosen C, eds) Elsevier, San Diego 1227-1246, 2007.
489. Mazziotti G, Giustina A, Canalis E, Bilezikian JP: Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. *Brazilian Archives of Endocrinology and Metabolism* 51:1404-1412, 2007. PMID: 18209880
490. Gennari L, Bilezikian JP: Osteoporosis in men. *J Musculoskeletal Medicine* 24:461-470, 2007.
491. Bilezikian JP, Rubin, MR: Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. *Current Primary Care Reports, Current Medicine, Philadelphia, PA* 2:100-108, 2007.
492. Rubin MR, Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: rheumatologic manifestations and bone disease. In: *Rheumatology, 4th edition*, (Hochberg, Silman, Smolen, Weinblatt, Weisman, eds) Elsevier, 1989-1993, 2007.
493. Reddy J, Bilezikian JP, Smith SJ, Mosca L: Low bone mineral density is associated with breast arterial calcification. *J Clin Endocrinol Metab* 93:208-211, 2008. PMID: 17971427; PMCID: PMC2190738
494. Thys-Jacobs S, McMahon D, Bilezikian JP: Differences in free estradiol and sex hormone binding globulin in women with and without premenstrual dysphoric disorder. *J Clin Endocrinol Metab* 93:96-102, 2008. PMID: 17956950; PMCID: PMC2190737
495. Bilezikian JP: Primary hyperparathyroidism and hypoparathyroidism. IN: *Conn's Current Therapy 2008*, (Rakel RE & Bope ET, eds) Saunders-Elsevier Philadelphia, 634-637, 2008.
496. Kousteni S, Bilezikian JP: Cellular actions of parathyroid hormone. IN: *Principles of Bone Biology* (Bilezikian JP, Martin TJ, Raisz LG, eds.), 3rd Edition, Elsevier/Academic Press, San Diego, 639-656, 2008.

497. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In: Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism, Seventh Edition (Rosen, C, editor) Am Soc Bone Min Research 66:302-306, 2008.
498. Bilezikian JP: Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Current Osteoporosis Reports 6:24-30, 2008. PMID: 18430397
499. Lewiecki EM, Bilezikian JP, Cooper C, Hochberg MC, Luckey MM, Maricic M, Miller PD: Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. J Clin Densitometry 11:313-324, 2008. PMID: 18280193
500. Gennari L, Khosla S, Bilezikian JP: Estrogen effects on bone in the male skeleton. IN: Principles of Bone Biology (Bilezikian JP, Martin TJ, Raisz LG, eds.), 3rd Edition, Elsevier/Academic Press, San Diego, 1801-1818, 2008.
501. Rubin MR, Bilezikian JP, Birken S, Silverberg SJ: Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol 159:469-474, 2008. PMID: 18625691; PMCID: PMC2970867
502. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane, E, Siris E, Udesky J, Silverberg SJ: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15-years. J Clin Endocrinol Metab 93:3462-3470, 2008. PMID: 18544625; PMCID: PMC2567863
503. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP: Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785-3793, 2008. PMID: 18682511
504. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM: Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 23:1974-1982, 2008. PMID: 18684084; PMCID: PMC2686921

505. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R: The effects of tibolone in older postmenopausal women. *N Eng J Med* 359:697-708, 2008. PMID: 18703472; PMCID: PMC3684062
506. Zoehrer R, Dempster DW, Bilezikian JP, Zhou H, Silverberg SJ, Shane E, Roschger P, Paschalis EP, Klaushofer K: Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism. *J Clin Endocrinol Metab* 93:3484-3489, 2008. PMID: 18593769; PMCID: PMC2567864
507. Cetani F, Ambrogini E, Banti C, Bilezikian JP, Pinchera A, Marcocci C: Utility of parafibrin and genetic studies to improve the pathological assessment of abnormal parathyroid tissue. *J Endocrinol Invest* 31:900-904, 2008. PMID: 19092296
508. Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan S, Rosen C, Black D: Effects of parathyroid hormone and alendronate on type 1 collagen isomerization in postmenopausal women with osteoporosis: The PaTH study. *J Bone Miner Res* 23:1442-1448, 2008. PMID: 18442311; PMCID: PMC2683159
509. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney Jr. J, Silverberg SJ, Bilezikian JP: Dynamic and structural properties of the skeleton in hypoparathyroidism. *J Bone Miner Res*. 23:2018-2024, 2008. PMID: 18684087; PMCID: PMC2686925
510. Walker MD, Novotny R, Bilezikian JP, Weaver CM: Race and diet interactions in the acquisition, maintenance, and loss of bone. *J Nutr*, 138:1256S-1260S, 2008. PMID: 18492866
511. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans D, Lewiecki EM, Silverman S: Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 Position Development Conference. *J Clin Densitometry* 11:75-91, 2008. PMID: 18442754
512. Fitzpatrick LA, Bilezikian JP, Silverberg SJ: Actions of parathyroid hormone on the vasculature and cardiovascular system. IN: *Principles of Bone Biology* (Bilezikian JP, Martin TJ, Raisz LG, eds), 3rd Edition, Elsevier/Academic Press, San Diego, 657-663, 2008.

513. Ogita M, Rached MT, Dworakowski E, Bilezikian JP, Kousteni S: Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent PTH administration, *Endocrinology* 149:5713-5723, 2008. PMID: 18617606; PMCID: PMC2584601
514. Lewiecki EM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S: Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. *South Med J.* 2008. PMID: 18580720
515. Fitzpatrick LA, Bilezikian JP, Silverberg SJ: Parathyroid hormone and the cardiovascular system. *Current Osteoporosis Reports* 6:77-83, 2008. PMID: 18778568
516. Kousteni S, Bilezikian JP: The cell biology of parathyroid hormone in osteoblasts. *Current Osteoporosis Reports* 6:72-76, 2008. PMID: 18778567
517. Raisz LG, Bilezikian JP, Martin TJ: Pathophysiology of osteoporosis. IN: *Principles of Bone Biology* (Bilezikian JP, Martin TJ, Raisz LG, eds.), 3rd Edition, Elsevier/Academic Press, San Diego, 1635-1647, 2008.
518. Gennari L, Khosla S, Bilezikian JP: Estrogen and fracture risk in men. *J Bone Min Res* 23:1548-1551, 2008. PMID: 18800918
519. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP: Parathyroid carcinoma. *J Bone Min Res* 23:1869-1880, 2008. PMID: 19016595; PMCID: PMC3276344
520. Cremers S, Bilezikian JP, Garnero P: Bone markers – new aspects. *Clinical Laboratory* 54:461-472, 2008. PMID: 19216252
521. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S: International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. *Bone* 43:1115-1121, 2008. PMID: 18793764.

522. Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S, Bishop NJ, Leonard MB, Bianchi M-L, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS: Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. *Osteoporos Int* 19:1369-1378, 2008. PMID: 18633664
523. Walker MD, Bilezikian JP: Racial differences in bone density and fracture risk in the United States. *Int'l J Rheumatic Diseases* 11:341-346, 2008.
524. Bilezikian JP: Combination anabolic and antiresorptive therapy for osteoporosis. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, Seventh Edition, 53:252-254, 2008.
525. Thys-Jacobs S, McMahon D, Bilezikian JP: Lower IGF-1 concentrations in women with premenstrual dysphoric disorder. *Am J Ob Gyn* 198:506.e1-506e8, 2008. PMID: 18199422
526. Doga M, Mazziotti G, Bonadonna S, Patelli I, Bilezikian JP, Canalis E, Giustina A: Prevention and treatment of glucocorticoid-induced osteoporosis. *J Endocrinol Investig*, 31:53-58, 2008. PMID: 18791353
527. Gennari L, Bilezikian JP: Osteoporosis in men. In: *Endocrinologia e Diabetes*, Second Edition (Bandeira F, Graf H, Griz L, Faria M, Lazaretti, Castro M, eds) MEDBOOK, Rio de Janeiro, Brazil, 467-476, 2009.
528. Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin TJ, Recker RR, Heaney RP, Seeman E, Papapoulos S, Goldring SR: Targeting bone remodeling for the treatment of osteoporosis: Summary of the Proceedings of an ASBMR Workshop. *J Bone Min Res* 24:373-385, 2009. PMID: 19260805
529. Khan A, Bilezikian JP, Potts Jr JT: The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. *J Clin Endocrinol Metab* 94:333-334, 2009. PMID: 19193907
530. Bilezikian JP, Khan A, Potts Jr JT: Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. *J Clin Endocrinol Metab* 94:335-339, 2009. PMID: 19193908 PMCID: PMC3214274

531. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, Banti C, Del Fiacco R, Bilezikian JP, Pinchera A, Marcocci C: Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab* 94:2306-2312, 2009. PMID: 19401378; PMCID: PMC3214277
532. Bilezikian JP: Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. *Am J Med* 122:514-521, 2009. PMID: 19187808
533. Marcocci C, Chanson P, Shoback D, Bilezikian JP, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Ren L, Lu J, Peacock M: Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. *J Clin Endocrinol Metab* 94:2766-2772, 2009. PMID: 19470620; PMCID: PMC3214593
534. Lewiecki EM, Baim S, Bilezikian JP, Eastell R, LeBoff MS, Miller PD: 2008 Santa Fe Bone Symposium: Update on Osteoporosis. *J Clin Densitometry* 12:135-137, 2009. PMID: 19426925
535. Gennari L, Bilezikian JP: Glucocorticoid-induced osteoporosis: hope on the HORIZON. *Lancet* 373:1225-1226, 2009. PMID: 19362657
536. Lewiecki EM, Baim S, Langman CB, Bilezikian JP: The Official Positions of the International Society for Clinical Densitometry: Perceptions and Commentary. *J Clin Densitometry* 12:267-271, 2009. PMID: 19546020
537. Walker MD, McMahon DJ, Udesky J, Liu G, Bilezikian JP: Application of high resolution skeletal imaging to measurements of volumetric bone density and skeletal microarchitecture in Chinese American and Caucasian women: explanation of a paradox. *J Bone Miner Res* 12:1953-1959, 2009. PMID: 20001598; PMCID: PMC2791512
538. Mazziotti G, Giustina A, Canalis E, Bilezikian JP: Treatment of glucocorticoid-induced osteoporosis. *Therapeutic Advances in Musculoskeletal Diseases*, 1:27-34, 2009. PMID: 22870425; PMCID: PMC3382670
539. Bilezikian JP: Primary hyperparathyroidism. In: www.ENDOTEXT.org (Version of April 01, 2009) DeGroot L, Editor; Singer F, Section Editor; (MDTEXT.COM, Inc, S. Dartmouth, MA), 2009.

540. Khan A, Bilezikian JP, Potts Jr JT: Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines. *Endocrine Practice* 15:494-498, 2009. PMID: 19546049; PMCID: PMC3115761
541. Khan AA, Bilezikian JP, Kung A, Syed ZA, Dubois SJ, Standish TI: Alendronate in men with primary hyperparathyroidism. *Endocrine Practice* 15:705-713, 2009. PMID: 19625240
542. Watts NB, Lewiecki M, Bonnicksen SL, Laster AJ, Binkley N, Blank RD, Guesens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP: The clinical value of monitoring bone density in patients treated with bisphosphonates for osteoporosis. *J Bone Min Res* 24:1643-1646, 2009. PMID: 19712042
543. Rubin MR, Dempster DW, Kohler T, Zhou H, Shane E, Nickolas T, Stein E, Sliney Jr J, Silverberg SJ, Bilezikian JP, Muller R: Three-dimensional cancellous bone structure in hypoparathyroidism. *Bone* 46:190-195, 2009. PMID: 19782782; PMCID: PMC2818211
544. Marcocci C, Cianferotti L, Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism in men. In: *Osteoporosis in Men* (Orwoll E, Bilezikian JP, Vanderscheuren D, eds.) Elsevier, San Diego 465-478, 2010.
545. Girotra M, Cosman F, Bilezikian JP: Treatment of male osteoporosis with parathyroid hormone. In: *Osteoporosis in Men* (Orwoll E, Bilezikian JP, Vanderscheuren D, eds.) Elsevier, San Diego 681-690, 2010.
546. Bilezikian JP: Clinical use of parathyroid hormone in osteoporosis. IN: *Osteoporosis – Pathophysiology and Clinical Management*, 2nd Edition (Adler RA, ed), Humana Press, 511-526, 2010.
547. Cohen A, Dempster DW, Muller R, Guo XE, Nickolas TL, Liu XS, Zhang XH, Wirth AJ, van Lenthe GH, Kohler T, McMahon DJ, Zhou H, Rubin MR, Bilezikian JP, Lappe JM, Recker RR, Shane E: Assessment of trabecular and cortical architecture and mechanical competence of bone by transilial bone biopsy: comparison with high-resolution peripheral computed tomography. *Osteoporosis Int'l* 21:263-273, 2010. PMID: 19455271; PMCID: PMC2908272
548. Rubin MR, Sliney Jr J, McMahon DJ, Silverberg SJ, Bilezikian JP: Therapy of hypoparathyroidism with intact parathyroid hormone. *Osteoporosis Int'l*, 21:1927-1934, 2010. PMID: 20094706; PMCID: PMC2947814

549. Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Cosman F: Fragility fractures of the hip and femur: incidence and patient characteristics. *Osteoporosis Int* 21:399-408, 2010. PMID: 19484169
550. Liu XS, Zhang XH, Sekhon KK, Adam MF, McMahon DJ, Shane E, Bilezikian JP, Guo XE: High-resolution peripheral quantitative computed tomography can accurately assess microstructural and mechanical properties of human distal tibial bone. *J Bone Min Res* 25:746-756, 2010. PMID: 19775199; PMCID: PMC3130204
551. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. In: *Endocrinology*, Sixth Edition, (DeGroot LJ, Jameson JL, eds) Potts JT, Section Editor, Saunders-Elsevier, Philadelphia, 1176-1197, 2010.
552. Lewiecki EM, Bilezikian JP, Laster AJ, Miller PD, Recker RR, Russell G, Whyte MP: 2009 Santa Fe Bone Symposium. *J Clin Densitometry* 13:1-9, 2010. PMID: 20171564
553. Rubin MR, Bilezikian JP: Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. *Brazilian Archives of Endocrinology and Metabolism* 54:220-226, 2010. PMID: 20485912; PMCID: PMC3702727
554. Bandeira F, Lazaretti-Castro M, Bilezikian JP: Hormones and Bone. *Brazilian Archives of Endocrinology and Metabolism* 54:85-86, 2010. PMID: 20485894
555. Cusano NE, Bilezikian JP: Teriparatide: variations on the theme of a 2-year therapeutic course. *BoneKey* 7:84-87, 2010.
556. Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism. *Brazilian Archives of Endocrinology and Metabolism* 54:106-109, 2010. PMID: 20485897; PMCID: PMC3127400
557. Kulak CAM, Borba VZC, Liu XS, Recker RR, Kimmel DB, Reis L, Jorgetti V, Kulak Jr J, Rabelo LM, Zhou H, Guo XE, Bilezikian JP, Boguszewski CL, Dempster DW: Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. *J Bone Miner Res* 25:1931-1940, 2010. PMID: 20564248

558. Blank RD, Bilezikian JP, Bonnick S, Laster AJ, Leib ES, Lewiecki EM, Miller PD, Watts NB, Binkley NC: "Evidence-Based" or "Logic-Based" Medicine? *Osteoporosis Int* 21:1681-1683, 2010. PMID: 20464543
559. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM: AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. *Endocr Pract*. Nov-Dec; 16 Suppl 3:1-37 and 16:1016-1019, 2010. PMID: 21224201
560. Kung AWC, Wu CH, Itabashi A, Lee JK, Park HM, Zhao Y, Chan WP, Kendler DL, Leib ES, Lewiecki EM, Bilezikian JP, Baim S, on behalf of the Asia Pacific Panel of ISCD: International Society for Clinical Densitometry Official Positions: Asia Pacific Region Consensus. *J Clin Densitometry* 13:346-351, 2010. PMID: 20663696
561. Carpinteri R, Porcelli T, Meia C, Patelli I, Bilezikian JP, Canalis E, Angeli A, Giustina A, Mazziotti G: Glucocorticoid-induced osteoporosis and parathyroid hormone. *J Endocrinol Invest* 33:16-21, 2010. PMID: 20938221
562. Clemens TL, Cao X, Bilezikian JP: JBMR's Big Tent. *J Bone Min Res* 25:1467, 2010.
563. Silva BC, Bilezikian JP: New approaches to the treatment of osteoporosis. *Ann Rev Med*, 62:307-322, 2011. PMID: 21054170
564. Caron P, Simonds WF, Maiza JC, Rubin M, Cantor T, Rousseau L, Bilezikian JP, Souberbielle JC, D'Amour P: Nontruncated amino terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma. *Clin Endocrinol* 74:694-698, 2011. PMID: 21521290; PMCID: PMC3089698
565. Lewiecki EM, Bilezikian JP, Khosla S, Marcus R, McClung MR, Miller PD, Watts NB, Maricic M: Osteoporosis Update from the 2010 Santa Fe Bone Symposium. *J Clin Densitometry*, 14:1-21, 2011. PMID: 21295739;
566. Stein EM, Dempster DW, Udesky J, Zhou H, Bilezikian JP, Shane E, Silverberg SJ: Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. *Bone* 1:48(3):557-61, 2011. PMID: 20950725; PMCID: PMC3039097

567. Bilezikian JP, Drezner M, Kream B, Stern P, Clemens T, Elderkin A, Siris E, Krane S, Eisman J, Arnold A, Feyen J, Hurley M, Kawaguchi H, Lorenzo J, Peck W, Pilbeam C, Rowe D, Martin TJ, Hock J, DeLuca H, Rodan S, Lukert B, Chen T, Klein-Nulend J, Lawrence G. Raisz: November 13, 1925-August 25, 2010 In Memoriam. *J Bone Miner Res* 26:903-911, 2011. PMID: 21541991
568. Bilezikian JP: Primary hyperparathyroidism. In: www.ENDOTEXT.org (Version of 2011) DeGroot L, Editor; Singer F, Section Editor; (MDTEXT.COM, Inc, S. Dartmouth, MA), 2011.
569. Bilezikian JP: Primary hyperparathyroidism and hypoparathyroidism. IN: *Conn's Current Therapy*, 2011 (Bope ET, Kellerman R, Rakel RE, eds) Elsevier, Philadelphia, 662-666, 2011.
570. Cusano NE, Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: rheumatological manifestations and bone disease. IN: *Rheumatology*, 5th Edition (Hochberg M, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds.) Elsevier, 2007-2011, 2011.
571. Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM: Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis. *J Clin Densitom* 14:68-73, 2011. PMID: 21095149
572. Rubin MR, Manavalan JS, Dempster DW, Shah J, Cremers S, Kousteni S, Zhou H, McMahan DJ, Sliney J, Shane E, Silverberg SJ, Bilezikian JP: Parathyroid hormone stimulates the number and maturation of circulating osteoblast lineage cells in hypoparathyroidism. *J Clin Endocrinol Metab* 96:176-186, 2011. PMID: 20881259; PMCID: PMC3038485
573. Lowe H, Cusano NE, Binkley N, Blamer WS, Bilezikian JP: Vitamin D toxicity due to a commonly available "over the counter" remedy from the Dominican Republic. *J Clin Endocrinol Metab* 96:291-295, 2011. PMID: 21123442
574. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D: Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. *J Clin Endocrinol Metab*, 96:E9-E18, 2011. PMID: 20943783; PMCID: PMC3203649

575. Walker MD, Liu XS, Stein E, Zhou B, Bezati E, McMahon DJ, Udesky J, Liu G, Shane E, Guo XE, Bilezikian JP: Differences in bone microarchitecture between postmenopausal Chinese-American and white women. *J Bone Miner Res* 26:1392-1398, 2011. PMID: 21305606; PMCID: PMC3558983
576. Bilezikian JP, Grbic JT: Bisphosphonates and osteonecrosis of the jaw: proceedings of an international conference. *Ann NY Acad Sci* 2011 Feb; 1218(1):1-2. PMID: 21291476
577. Liu XS, Walker MD, McMahon DJ, Udesky J, Liu G, Bilezikian JP, Guo XE: Better skeletal microstructure confers greater mechanical advantages in Chinese-American women versus Caucasian women. *J Bone Min Res* 26:1783-1792, 2011. PMID: 21351150; PMCID: PMC3551974
578. Kanis JA, Bianchi G, Bilezikian JP, Kaufman, JM, Khosla S, Orwoll E, Seeman E: Towards a diagnostic and therapeutic consensus in male osteoporosis. *Osteoporosis Int*, 22:2789-2798, 2011. PMID: 21509585; PMCID: PMC3555694
579. Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP: The effects of ronacaleret, a calcium-sensing receptor antagonist on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. *J Clin Endocrinol Metab* 96:2441-2449, 2011. PMID: 21593114
580. Rubin MR, Dempster DW, Sliney J, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP: PTH (1-84) administration reverses abnormal bone remodeling dynamics and structure in hypoparathyroidism. *J Bone Miner Res*, 26:2727-2736, 2011. PMID: 21735476; PMCID: PMC4019384
581. Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM: Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH Study). *J Clin Endocrinol Metab*, 96:E1982-E1989, 2011. PMID: 21994958; PMCID: PMC3232610

582. Borges JL, Bilezikian JP, Jones-Leone AR, Acosta AP, Amberly PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR: A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. *Diabetes Obes Metab*, 13:1036-1046, 2011. PMID: 21682834
583. Bilezikian JP: Treatment with parathyroid hormone (PTH) for osteoporosis: novel methods and benefits. *J Clin Rheum and Musculoskeletal Med* 2:6-13, 2011.
584. Cusano NE, Bilezikian JP: Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. *Curr Med Res Opin* 27:1705-1707, 2011. PMID: 21740288
585. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R: Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. *J Clin Densitom* 14:171-180, 2011. PMID: 21810521
586. Mazziotti G, Giustina A, Canalis E, Bilezikian JP: Glucocorticoid-induced osteoporosis. IN: *Oxford Textbook of Endocrinology and Diabetes*, 2nd Edition, (Wass JAH, Stewart PM, eds) Oxford University Press, Oxford, England, 754-762, 2011.
587. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: *Oxford Textbook of Endocrinology and Diabetes*, 2nd Edition, (Wass JAH, Stewart PM, eds) Oxford University Press, Oxford, England, 653-664, 2011.
588. Cusano NE, Thys-Jacobs S, Bilezikian JP: Hypercalcemia due to Vitamin D toxicity. IN: *Vitamin D*, 3rd edition (Feldman D, Pike JW, Glorieux F, eds) Elsevier Academic Press, San Diego, CA 1381-1402, 2011.
589. Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Juppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J: Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target organ involvement, treatment, and challenges for future research. *J Bone Miner Res* 26:2317-2337, 2011. PMID: 21812031; PMCID: PMC3405491.

590. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP: Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. *Nat Rev Rheumatol* 7:447-456, 2011. PMID: 21670768
591. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP: Circulating sclerostin in disorders of parathyroid gland function. *J Clin Endocrinol Metab*, 96:3804-3810, 2011. PMID: 21937621; PMCID: PMC3232608
592. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley J, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV; Task Force of the FRAX Initiative: Interpretation and use of FRAX in clinical practice. *Osteoporos Int* 22:2395-2411, 2011. PMID: 21779818
593. Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M: Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. *J Bone Miner Res*, 26:2823-2826, 2011. PMID: 21997141
594. Cusano NE, Costa AG, Silva BC, Bilezikian JP: Therapy of osteoporosis in men with teriparatide. *J Osteoporos* 2011:463675. PMID: 22132345; PMCID: PMC3205768
595. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP: Catabolic and anabolic actions of parathyroid hormone on the skeleton. *J Endocrinol Invest*, 34:801-810, 2011. PMID: 21946081; PMCID: PMC4315330
596. Costa AG, Cusano NE, Silva BC, Bilezikian JP: Osteoporosis in men. IN: *Temas de Osteoporosis y otras Enfermedades Oseas (Topics in Osteoporosis and Other Bone Diseases)*. (Arinovic R and Arriagada M, eds) Chilean Foundation of Osteoporosis, 163-177, 2012.
597. Bilezikian JP, Costa AG, Cusano NE, Silva BCC: Primary hyperparathyroidism. IN: *Temas de Osteoporosis y otras Enfermedades Oseas (Topics in Osteoporosis and Other Bone Diseases)*. (Arinovic R and Arriagada M, eds) Chilean Foundation of Osteoporosis, 403-424, 2012.
598. Holt EH, Bilezikian JP: Calcium disorders. IN: *Principles and Practice of Hospital Medicine* (McKean SC, Ross JJ, Dressler DD, Brotman DJ, Ginsberg JS, eds), McGraw Hill, New York 2067-2076, 2012.

599. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS: Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 97:1802-1822, 2012. PMID: 22675062
600. Lewiecki EM, Bilezikian JP: Denosumab for the treatment of osteoporosis and cancer-related conditions. *Clin Pharmacol Ther* 91:123-133, 2012. PMID: 22158568
601. Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, Zhang HB, Li F, Jing HL, Zhong DR, Jin J, Gao P, Zhou L, Qi F, Yu W, Bilezikian JP, Meng XW: Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of literature. *J Bone Miner Res*, 27:1967-1975, 2012. PMID: 22532501
602. Christen P, Ito K, Muller R, Rubin MR, Dempster DW, Bilezikian JP, van Rietbergen B: Patient-specific bone modeling and remodeling simulation of hypoparathyroidism based on human iliac crest biopsies. *J Biomech* 45:2411-2416, 2012. PMID: 22883080; PMCID: PMC3702730
603. Walker MD, Saeed I, McMahon DJ, Udesky J, Liu G, Lang T, Bilezikian JP: Volumetric bone mineral density at the spine and hip in Chinese American and white women. *Osteoporos Int* 23:2499-2506, 2012. PMID: 22147209; PMCID: PMC3552556
604. Walker MD, Dempster DW, McMahon DJ, Udesky J, Shane E, Bilezikian JP, Silverberg SJ: Effect of renal function on skeletal health in primary hyperparathyroidism. *J Clin Endocrinol Metab* 97:1501-1507, 2012. PMID: 22399521; PMCID: PMC3339888
605. Ascenzi MG, Liao VP, Lee BM, Billi F, Zhou H, Lindsay R, Cosman F, Nieves J, Bilezikian JP, Dempster DW: Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. *J Bone Miner Res* 27:702-712, 2012. PMID: 22161803; PMCID: PMC4156315
606. Costa AG, Bilezikian JP: Sclerostin: therapeutic horizons based upon its actions. *Curr Osteoporos Rep*, 10:64-72, 2012. PMID: 22234741
607. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT: Benefits and risks of bisphosphonate therapy for osteoporosis. *J Clin Endocrinol Metab* 97:2272-2282, 2012. PMID: 22523337

608. Compston JE, Bilezikian JP: Bisphosphonate therapy for osteoporosis: the long and short of it. *J Bone Miner Res*, 27:240-242, 2012. PMID: 22271395
609. Costa AG, Cusano NE, Silva BC, Bilezikian JP: Osteoporosis in men. In: *Endocrinologia Clinica 5th Edition* (Vilar, L, ed), Grupo Editorial Nacional, Rio de Janeiro, 951-957, 2012.
610. Siris ES, Boonen S, Mitchell PJ, Bilezikian J, Silverman S: What's in a name? What constitutes the clinical diagnosis of osteoporosis? *Osteoporosis Int* 23:2093-2097, 2012. PMID: 22543575
611. Cusano NE, Rubin MR, Sliney J Jr, Bilezikian JP: Mini-review: new therapeutic options in hypoparathyroidism. *Endocrine* 41:410-414, 2012 PMID: 22311174; PMCID: PMC3690471.
612. Lewiecki EM, Laster AJ, Miller PD, Bilezikian JP: More bone density testing is needed, not less. *J Bone Miner Res* 27:739-742, 2012. PMID: 22383457
613. Bilezikian JP: Primary hyperparathyroidism. In: www.ENDOTEXT.org (Version of 2012) DeGroot L, Editor; Singer F, Section Editor; (MDTEXT.COM, Inc, S. Dartmouth, MA), 2012. PMID 25905161
614. Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, Miller PD, Morgan SL, Orwoll ES, Potts JT Jr: Proceedings of the 2011 Santa Fe Bone Symposium. *J Clin Densitom* 15:1-20, 2012. PMID: 22284629
615. Bilezikian JP: Primary hyperparathyroidism and hypoparathyroidism. In *Conn's Current Therapy*, 2012 (Bope ET and Kellerman ED, eds) Elsevier-Saunders, Philadelphia 717-721, 2012.
616. Bilezikian JP, Zerbini C, Lewiecki EM, Borges JL, Miller PD, Hans D, Camargos BM, McClung M: In Memoriam: Sergio Ragi-Eis, MD. *J Clin Densitometry*, 15(3):257-259, 2012. PMID: 22919712
617. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C; IOF CSA Inadequate Responders Working Group: Treatment failure in osteoporosis. *Osteoporosis Int* 23:2769-2774, 2012. PMID: 22836278

618. Bilezikian JP: Primary hyperparathyroidism. *Endocrine Practice* 18:781-790, 2012. PMID: 22982802
619. Cipriani C, Irani D, Bilezikian JP: Safety of osteoanabolic therapy: a decade of experience. *J Bone Min Res* 27:2419-2428, 2012. PMID: 23165426
620. Cusano NE, Bilezikian JP: Combination anabolic and antiresorptive therapy for osteoporosis. *Endocrinol Metab Clin North Am* 41:643-654, 2012. PMID: 22877434
621. Walker MD, Cusano NE, Sliney Jr J, Romano M, Zhang C, McMahon DJ, Bilezikian JP: Combination therapy with risedronate and teriparatide in male osteoporosis. *Endocrine* 44:237-246, 2012. PMID: 23099796
622. Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer L, Kanis JA, Langdahl B, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE* for the Joint IOF-ECTS GIO Guidelines Working Group: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporosis Int* 23:2257-2276, 2012. PMID: 22434203
623. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). *J Clin Endocrinol Metab* 97:2990-3011, 2012. PMID: 22723327
624. Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, McMahon DJ, Zhang CA, Romano M, Dworakowski E, Costa A, Cusano N, Irani D, Sarquis M, Cremers S, Shane E, Guo XE, Bilezikian JP: Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and compromised bone stiffness in postmenopausal women. *J Bone Miner Res*, 28:1029-1040, 2013. PMID: 23225022; PMCID: PMC3631282
625. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: physiology and surgical indications. IN: *Surgery of the Thyroid and Parathyroid Glands*, 2nd Edition (Randolph GW, ed), Elsevier-Saunders, Philadelphia 531-538, 2013.
626. Bilezikian JP: Primary hyperparathyroidism and hypoparathyroidism. IN: *Conn's Current Therapy*, (Bope ET, Kellerman R, Rakel RE, eds) Elsevier, Philadelphia, PA 689-692, 2013.

627. Cusano NE, Silverberg SJ, Bilezikian JP: Normocalcemic primary hyperparathyroidism. *J Clin Densitometry* 16:33-39, 2013. PMID: 23374739; PMCID: PMC3564219
628. Silverberg SJ, Walker MD, Bilezikian JP: Asymptomatic primary hyperparathyroidism. *J Clin Densitometry* 16:14-21, 2013. PMID: 23374736; PMCID: PMC3987990
629. Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney Jr J, Cremers SC, Bilezikian JP: Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. *J Clin Endocrinol Metab* 98:137-144, 2013. PMID: 23162103; PMCID: PMC3537109
630. Costa AG, Bilezikian JP: Bone turnover markers in primary hyperparathyroidism. *J Clin Densitometry* 16:22-27, 2013. PMID: 23374737; PMCID: PMC3577420
631. Walker MD, Liu XS, Zhou B, Agarwal S, Liu G, McMahon DJ, Bilezikian JP, Guo XE: Pre- and postmenopausal differences in bone microstructure and mechanical competence in Chinese-American and white women. *J Bone Miner Res*, 28:1308-1318, 2013. PMID: 23299863; PMCID: PMC3644543
632. Payer J, Bilezikian JP, Holzer G, Lakatos P, Lesnyak O, Lorenc R, Zendeli A, Resch H: Congress Report: 5th Central and Eastern Europe (CEE) Summit on Osteoporosis in Bratislava, 2-3 December 2011. *Arch Osteoporos* 8:123, 2013. PMID: 23400563
633. Bilezikian JP, Cusano NE: Combination anabolic and antiresorptive therapy for osteoporosis. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 8th Edition (Rosen CJ, Ed.). Wiley-Blackwell, Ames, Iowa, 444-447, 2013.
634. Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Gitanjali PG, Cobitz AR, Nino AJ, Fitzpatrick LA: Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 98:1519-1528, 2013. PMID: 23450056
635. Bilezikian JP: Approach to parathyroid disorders. IN: *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 8th edition (Rosen CJ, Ed.). Wiley-Blackwell, Ames, Iowa, 537-542, 2013.

636. Borges JL, Freitas A, Bilezikian JP: Accelerated fracture healing with teriparatide. *Arq Bras Endocrinol Metabol* 57:153-156, 2013. PMID: 23525295
637. Costa A, Cusano NE, Silva BC, Bilezikian JP: New approaches to osteoporosis therapeutics. In: *Osteoporosis, 4th Edition*, (Marcus R, Feldman D, Dempster D, eds) Elsevier, San Diego, CA, 1963-1986, 2013.
638. Lewiecki EM, Adler R, Bilezikian JP, Luckey M, Marcus R, McClung M, Miller PD, Tanner B, et al. Proceedings of the 2012 Santa Fe Bone Symposium. *J Clin Densitometry*. 16:584-600, 2013. PMID: 23419827.
639. Cusano NE, Bilezikian JP: Diagnosis and management of primary hyperparathyroidism. *J Clinical Outcomes Management* 20:181-192, 2013.
640. Bilezikian JP, Fitzpatrick LA, Silverberg SJ: The skeletal actions of parathyroid hormone in primary hyperparathyroidism and in osteoporosis. In: *Osteoporosis, 4th Edition*, (Marcus R, Feldman D, Dempster D, eds) Elsevier, San Diego, CA 1249-1266, 2013.
641. Vu T, Wang XF, Wang Q, Cusano N, Irani D, Silva B, Ghasem-Zadeh A, Udesky J, Romano M, Zebaze R, Jerums G, Boutroy S, Bilezikian JP, Seeman E: New insights into the actions of PTH in primary hyperparathyroidism on cortical and trabecular compartments of bone. *Bone* 55:57-63, 2013 PMID: 23541782.
642. Arantes HP, Kulak C, Fernandes CE, Zerbini C, Bandeira F, Barbosa IC, Brenol JCT, Borba VC, Russo LA, Chiang AY, Bilezikian JP, Lazaretti-Castro M: Correlation between 25 hydroxyvitamin D levels and latitude in Brazilian postmenopausal women with low bone mass: from the Arzoxifene Generation Study. *Osteoporos Int* 24:2707-2712, 2013. PMID: 23632825
643. Poiana C, Radoi V, Carsote M, Bilezikian JP: New clues that may link osteoporosis to the circulating lipid profile. *Bone Research* 1:260-266, 2013.
644. Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J, Udesky J, Cremers S, Sarquis M, Guo XE, Hans D, Bilezikian JP: Trabecular bone score-TBS-a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab* 98:1963-1970, 2013. PMID: 23526463; PMCID: PMC3644593

645. Costa AG, Cusano NE, Silva BC, Bilezikian JP: Osteoporosis in men. In: Bandeira F, Gharib H, Golbert A, Griz L, and Faria M, eds). Springer, New York, 323-333, 2013.
646. Boutroy S, Walker MD, McMahon D, Liu G, Bilezikian JP: Lower cortical porosity and higher tissue mineral density in Chinese-American versus White women. *J Bone Miner Res* 29:551-561, 2014. PMID: 23913668
647. Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney Jr J, Bilezikian JP: The effect of PTH(1-84) on quality of life in hypoparathyroidism. *J Clin Endocrinol Metab*, 98:2356-2361, 2013. PMID: 23596139; PMCID: PMC3667253
648. Cusano NE, Maalouf N, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP: Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based non-referral populations. *J Clin Endocrinol Metab* 98:2734-2741, 2013. PMID: 23690312; PMCID: PMC3701271
649. Cusano NE, Lee JA, Kazam E, Bilezikian JP: Primary hyperparathyroidism associated with laser therapy to the larynx. *Endocr Prac* 19:888-890, 2013. PMID: 24014000
650. Costa A, Walker MD, Zhang AC, Cremers S, Dworakowski E, McMahon DJ, Liu G, Bilezikian JP: Circulating sclerostin levels and markers of bone turnover in Chinese-American and White women. *J Clin Endocrinol Metab* 98:4736-4743, 2013. PMID: 24037879; PMCID: PMC3849675
651. Greenspan SL, Bilezikian JP, Watts NB, Berry CA, Stowell SA, Karcher RB: A clinician performance initiative to improve quality of care for patients with osteoporosis. *J Womens Health* 22:853-860, 2013. PMID: 24011023; PMCID: PMC3837565
652. Chiavistelli S, Bilezikian JP: Commentary: does calcium intake influence the development of primary hyperparathyroidism? *BoneKEY* 10:314, 2013.
653. Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado C, Bilezikian JP, Seeman E: Differing effects of denosomab and alendronate on cortical and trabecular bone. *Bone*, 59:173-179, 2014. PMID: 24275677

654. Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP: β -adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender and site-specific effects. *Osteoporosis Int* 25:121-129, 2014. PMID: 24114396
655. Silva BC, Walker MD, Abraham A, Boutrouy S, Zhang C, McMahon DJ, Liu G, Hans D, Bilezikian JP: Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese-American and white women. *J Clin Densitometry* 16:554-561, 2013. PMID: 24080513; PMCID: PMC3818347
656. Gennari L and Bilezikian JP: Idiopathic osteoporosis in men. In: *Current Osteoporosis Reports* 11:286-298, 2013. PMID: 24052235.
657. Cusano NE, Costa AG, Silva BC, Bilezikian JP: Newer adult bone drugs. In: *Bone Drugs in Pediatrics: Efficacy and Challenges* (Klein GL, Ed.). Springer, New York, 199-222, 2014.
658. Cusano NE, Anderson L, Rubin MR, Silva BC, Costa AG, Irani D, Sliney JJ, Bilezikian JP: Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series. *J Clin Endocrinol Metab* 98(11):4285-4290, 2013. PMID: 24037886; PMCID: PMC3816261
659. Silva BC, Costa AG, Cusano NE, Bilezikian JP: Osteoporosis: what's new and on the horizon. *Clin Obstet and Gynecol* 56:730-738, 2013. PMID: 24036482
660. Cusano NE and Bilezikian JP: Comparative effectiveness of combination osteoanabolic and antiresorptive therapy for osteoporosis: an update. *J Comparative Effectiveness Research*. 2:511-513, 2013. PMID: 24236786.
661. Shepherd JA, Baim S, Bilezikian JP, Schousboe JT: Executive Summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Body Composition. *J Clin Densitom*, 16(4):489-495, 2013 PMID: 24183639.
662. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S: Executive Summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry. *J Clin Densitom* 16:455-466, 2013. PMID: 24183638

663. Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA: Improved adherence with PTH (1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. *Osteoporosis Int*, 24(4):1503-1511, 2013. PMID: 22930240.
664. Bilezikian JP: Hyperparathyroidism and hypoparathyroidism. In: *Conn's Current Therapy*, (Bope ET, Kellerman RD, eds) Elsevier, Philadelphia, PA 729-733, 2014.
665. Jacobs TP, Jones G, Kumar R, Schlingmann K, Shapses S, Bilezikian JP: A lifetime of hypercalcemia and hypercalciuria, finally explained. *J Clin Endocrinol Metab* 99:708-712, 2014. PMID: 24423361; PMCID: PMC3942238
666. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP: Trabecular bone score: a non-invasive analytical method based upon the DXA image. *J Bone Miner Res* 29(3):518-530, 2014. PMID: 24443324
667. Watts NB, Bilezikian JP: Advances in target-specific therapy for osteoporosis. *J Clin Endocrinol Metab* 99(4):1149-1151, 2014. PMID: 24446660
668. Lewiecki EM, Bilezikian JP, Bonewald L, Compston JE, Heaney RP, Kiel DP, Miller PD, Schousboe JT: Osteoporosis Update: Proceedings of the 2013 Santa Fe Bone Symposium. *J Clin Densitom* 17(3):330-343, 2014. PMID: 24613387
669. Marocci C, Cetani F, Bilezikian JP: Parathyroid carcinoma. IN: *Endocrine Surgery* (Hubbard JGH, Inabnet WB, Lo CY, eds.), (In Press), 2015.
670. Fitzpatrick LA, Bilezikian JP, Wooddell MJ, Paul G, Kolatkar NS, Nino AJ, Miller CG, Bogado CE, Arnaud CD, Cobitz AR: Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with Type 2 diabetes mellitus: study design and baseline characteristics. *J of Drug Assessment* (In Press), 2015.
671. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A: Skeletal Endocrinology Forum: Research in Osteoporosis Today and Tomorrow. *Endocrine* (In Press), 2015.
672. Bilezikian JP: Primary hyperparathyroidism. In: *Decision Support in Medicine*, LLC (In Press), 2015.

673. Cusano NE, Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: rheumatological manifestations and bone disease. In: Rheumatology, 6th Edition (Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH) Mosby-Elsevier, Philadelphia, PA 1688-1691, 2014.
674. Bandeira F, Griz L, Chaves N, Carvalho N, Borges LM, Lazaretti-Castro M, Borba V, de Castro LC, Borges JL, Bilezikian JP: Diagnosis and management of primary hyperparathyroidism. *Brazilian Archives of Endocrinology & Metabolism* 57(6):406-424, 2013. PMID: 24030180
675. Rubin MR, Manavalan J, Agarwal S, McMahon D, Nino A, Fitzpatrick L, Bilezikian J: Effects of Rosiglitazone vs Metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 99(10):E1933-1942, 2014. PMID: 24905061
676. Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP: Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, phase 3 study. *Lancet Diabetes Endocrinol* 1:275-283, 2013. PMID: 24622413
677. Liu J, Cusano NE, Silva BC, Zhao L, He X, Tao B, Sun L, Zhao H, Fan W, Romano ME, Ning G, Bilezikian JP: Primary hyperparathyroidism: a tale of two cities revisited – New York and Shanghai. *Bone Research* 2:162-169, 2013.
678. Siris ES, Adler R, Bilezikian JP, Bolognese M, Dawson-Huges B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB: The clinical diagnosis of osteoporosis: a consensus report from the national bone health alliance working group *Osteoporosis Int'l* 25:1439-1443, 2014.
679. Rothman MS, Miller PD, Lewiecki E, Bilezikian JP: Bone density testing: science, the media, and patient care. *Curr Osteopor Rep* 12(2):227-229, 2014. PMID 24659466
680. Costa AG, Bilezikian JP, Lewiecki EM: Update on romosozumab: a humanized monoclonal antibody to sclerostin. *Expert Opin Biol Ther* 14:697-707, 2014. PMID 24665957

681. de Almeida CBS, Machado VC, Bandiera F, Cusano NE, Silva BC, Bilezikian JP: Bone disease in primary hyperparathyroidism. In: Osteoporosis and Related Disorders. Brazilian Archives of Endocrinology and Metabolism (In Press), 2014. PMID: PMC4315357
682. Bandeira F, Costa AG, Soares Filho MA, Pimentel L, Lima L, Bilezikian JP: Bone markers and osteoporosis therapy. *Arq Bras Endocrinol Metabol* 58(5):504-513, 2014. PMID: 25166041
683. Silva BC, Bilezikian JP: Trabecular Bone Score: perspectives of an imaging technology coming of age. *Arq Bras Endocrinol Metabol*, 58(5):493-503, 2014. PMID: 25166040
684. Boeving A, Bilezikian JP, Rea RR, Almeida ACR, Deonizio JMD, Thom CC, Borba VZC, Kulak CAM: Evaluation of bone mineral density in patients with type 1 diabetes: association with metabolic control, chronic complications and risk factors for low bone mass. *Brazilian Archives of Endocrinology* (Submitted), 2015.
685. Misof BM, Dempster DW, Zhou H, Roschger P, Fratzi-Zelman N, Fratzi P, Silverberg SJ, Shane E, Cohen A, Stein E, Nickolas TL, Recker RR, Lappe J, Bilezikian JP, Klaushofer K: Relationship of bone mineralization density distribution (BMDD) in cortical and cancellous bone within the iliac crest of healthy premenopausal women. *Calcif Tissue Int* 95(4):332-339, 2014. PMID: 25134800
686. Paschalis EP, Roschger P, Rubin MR, Shane E, Zoehrer R, Misof BM, Dempster D, Sliney J, Compito C, Zhou H, Silverberg SJ, Bilezikian JP, Klaushofer K: Bone mineralization density and collagen cross-link ratios in hypoparathyroidism. *Bone* (Submitted), 2015.
687. Rubin MR, Sroga GE, Poundarik A, Zhou H, Dempster DW, Vashishth D, Bilezikian JP: Microindentation in human bone biopsy samples. *Bone* (Submitted), 2015.
688. Miller CG, Bogado CC, Nino AJ, Northcutt AR, Yu HJ, Lewiecki EM, Paul G, Cobitz AR, Wooddell MJ, Bilezikian JP, Fitzpatrick LA: Evaluation of quantitative computed tomography cortical hip quadrant in a clinical trial with rosiglitazone: a potential new study endpoint. *J Clin Densitom*, 19:485-491, 2016. PMID 27052635
689. Silva BC, Fleischer J, Lenane Z, Fan W, McMahon D, Bilezikian JP: Spontaneous remission of primary hyperparathyroidism related to an autoimmune disease – A case report. *Endocrine Practice* (In Press), 2015.

690. Cusano NE, Rubin MR, Irani D, Sliney J Jr, Bilezikian JP: Use of parathyroid hormone in hypoparathyroidism. *J Endocrinol Invest* 36(11):1121-1127, 2013. PMID: 24445125; PMCID: PMC4315334
691. Tanaka S, Adachi T, Kuroda T, Nakamura T, Shiraki M, Sugimoto T, Takeuchi Y, Saito M, Bilezikian JP: New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. *Bone Res* 2:252-258, 2014. PMID: 26273530
692. Cusano NE, Rubin MR, Zhang C, Anderson L, Levy E, Costa AG, Irani D, Bilezikian JP: Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism. *J Clin Endocrinol Metab*, 99:E2025-E2029, 2014. PMID: 25137422
693. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Consensus Statement: Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. *J Clin Endocrinol Metab* 99:3561-3569, 2014. PMID: 25162665
694. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Jian-Min L, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP: Consensus Statement: Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. *J Clin Endocrinol Metab*, 99:3580-3594, 2014. PMID: 25162667
695. Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Kravitz BG, Northcutt AA, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA: A randomized, double-blind, mechanism of action study to evaluate the skeletal effects of rosiglitazone in postmenopausal women with type 2 diabetes mellitus. (In preparation), 2015.
696. Costa AG, Cremers S, Dworakowski E, Lazaretti-Castro M, Bilezikian JP: Comparison of two commercially available ELISAs for circulating sclerostin. *Osteoporos Int* 25(5):1547-1554, 2014. PMID: 24562839
697. Khan A, Bilezikian JP, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Toth M: Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. *Eur J Endocrinol* 172(5):527-535, 2015. PMID: 25637076

698. Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JP, Caudarella R: Utility of the trabecular bone score (TBS) in secondary osteoporosis. *Endocrine* 47:435-448, 2014. PMID: 24853880
699. Cusano NE, Bilezikian JP: Parathyroid hormone in the evaluation of hypercalcemia. *JAMA* 312:2680-2681, 2014. PMID:25536261
700. Cusano NE, Rubin MR, McMahon DJ, Irani D, Anderson L, Levy E, Bilezikian JP: PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. *J Clin Endocrinol Metab*, 2014. 99:3694-3699, 2014. PMID: 24978675
701. Rubin MR, Cusano NE, Bilezikian JP: Replacement therapy with PTH(1-84). IN: *Hypoparathyroidism* (Brandi ML, Brown EM, eds) Springer, NY 333-344, 2015.
702. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: *Endocrinology*, 7th edition (Jameson JL, DeGroot LJ, eds) Saunders, Elsevier 1105-1124, 2015.
703. Bilezikian JP, Marcus R, Levine MA, Marcocci C, Potts JT, Silverberg SJ: Preface to the Third Edition. IN: *The Parathyroids* (Bilezikian JP, editor-in-chief) Elsevier, San Diego xix-xx, 2015.
704. Silva BC, Bilezikian JP: Anabolic and catabolic pathways of parathyroid hormone on the skeleton. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 15:233-244, 2015.
705. Cusano NE, Silverberg SJ, Bilezikian JP: Normocalcemic PHPT. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 22:331-339, 2015.
706. Costa AG, Marcocci C, Bilezikian JP: Bone turnover markers in primary hyperparathyroidism. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 28:423-428, 2015.
707. Dempster DW, Silverberg SJ, Shane E, Bilezikian JP: Bone histomorphometry and bone quality in primary hyperparathyroidism. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 29:429-445, 2015.

708. Silva BC, Cusano NE, Hans D, Lewiecki EM, Bilezikian JP: Skeletal imaging in primary hyperparathyroidism. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 30:447-454, 2015.
709. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 34:489-497, 2015.
710. Fink DA, Cusano NE, Costa AG, Bilezikian JP: Hypercalcemia associated with local and ectopic hormone production. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 39:577-585, 2015.
711. Rubin MR, Marcocci C, Bilezikian JP: Skeletal manifestations of hypoparathyroidism. IN: *The Parathyroids*, 3rd edition (Bilezikian JP, editor-in-chief) Elsevier, San Diego 54:771-779, 2015.
712. Cipriani C, Carnevale V, Biamonte F, Piemonte S, Pepe J, Nieddu L, Bilezikian JP, Minisola S: Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study. *Eur J Endocrinol*, 171(4):481-487, 2014. PMID: 25015979; PMCID: PMC4319661
713. Cusano NE, Rubin MR, Bilezikian JP: Parathyroid hormone therapy for hypoparathyroidism. *Best Pract Res Clin Endocrinol Metab* 29(1):47-55, 2015. PMID 25617172
714. Cipriani C, Bilezikian JP: Commentary on “Silent renal stones in primary hyperparathyroidism: prevalence and clinical features.” *Endocrine Practice* 11:1231-1233, 2014. PMCID:PMC4311518 PMID: 25297666
715. Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N: Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. *J Clin Endocrinol Metab* 101:44-51, 2016. PMID 26580234
716. Watts N, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G: Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 101:157-166, 2016. PMID 26580237

717. Walker MD, Shi S, Russo JJ, Liu XS, Zhou B, Zhang C, Liu G, McMahon DJ, Bilezikian JP, Guo XE: A trabecular plate-like phenotype is over-represented in Chinese-American versus Caucasian women. *Osteoporosis Int* 25(12):2787-2795, 2014. PMID: 25069706
718. Cusano NE, Rubin MR, Bilezikian JP: PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. *Expert Rev Endocrinol Metab* 5-13, 2015. PMCID: PMC4334142 PMID: 25705243
719. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP: Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. *Osteoporosis Int*, 28:1-19, 2017. PMID 27613721
720. Bilezikian JP: Hyperparathyroidism and hypoparathyroidism. IN: *Conn's Current Therapy* (Bope ET, Kellerman RD, eds), Elsevier 761-765, 2015.
721. Binkley N, Adler R, Bilezikian JP: Osteoporosis diagnosis in men: the T-score controversy revisited. *Curr Osteoporosis Rep* 12(4):403-409, 2014. PMID: 25255867
722. Masi L, Agnusdei D, Bilezikian J, Chappard D, Chapurlat R, Cianferotti L, Devogelaer JP, El Maghraoui A, Ferrari S, Javaid MK, Kaufman JM, Liberman UA, Lyritis G, Miller P, Napoli N, Roldan E, Papapoulos S, Watts NB, Brandi ML: Taxonomy of rare genetic metabolic bone disorders. *Osteoporosis Int* 26:2529-2558, 2015. PMID: 26070300 Erratum to: Taxonomy of rare genetic metabolic bone disorders. *Osteoporosis Int* 26:2717-2718. PMID: 26370825
723. Lewiecki EM, Bilezikian JP, Binkley N, Hans D, Krueger D, Miller PD, Oates M, Shane E.: Update on Osteoporosis from the 2014 Santa Fe Bone Symposium. *Endocr Res* 40(2):106-119, 2015. PMID: 25803304
724. Cipriani C, Biamonte F, Costa AG, Zhang C, Blondi P, Diacinti D, Pepe J, Piemonte S, Scillitani A, Minisola S, Bilezikian JP: Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. *J Clin Endocrinol Metab* 100:1309-1315, 2015. PMID: 25646791

725. Walker MD, Cong E, Lee JA, Kepley A, Zhang C, McMahon DJ, Bilezikian JP, Silverberg SJ: Low vitamin D levels have become less common in primary hyperparathyroidism. *Osteoporos Int*, 26:2837-2843, 2015. PMID: 26084258
726. Abraham A, Rubin M, Accili D, Bilezikian JP, Pajvani UB: Hypoglycemia secondary to sulfonyleurea ingestion in a patient with end stage renal disease: Results from a 72-hour fast. *Case Rep Endocrinol* 742-781, 2015. PMID 26664768
727. Misof BM, Roschger P, Dempster DW, Zhou H, Bilezikian JP, Klaushofer K, Rubin MR: PTH(1-84) administration in hypoparathyroidism transiently reduces bone matrix mineralization. *J Bone Miner Res*, 31:180-189, 2016 PMID: 26111772
728. Silva BC, Bilezikian JP: Parathyroid Hormone: anabolic and catabolic actions on the skeleton. IN: *Curr Opin Pharmacol*, 22:41-50, 2015 (Gallagher J, Russell G, eds) . PMID: 25854704
729. Costa AG, Bilezikian JP, Lewiecki EM: The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. IN: *Curr Opin Nephrol Hypertens* 24:324-329, 2015. PMID: 26050118
730. Arantes HP, Gimeno SG, Chiang AH, Bilezikian JP, Lazaretti-Castro M: Incidence of vertebral fractures in calcium and vitamin-D supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene generations trial. *Arch Endocrinol Metab* 60:54-59, 2016. PMID 26909483
731. Furst J, Bilezikian JP, Rubin MR: The effects of diabetes and obesity on the skeleton. IN: *Preventive Nutrition*, 5th edition, *The Comprehensive Guide for Health Professionals* (Bendich A and Deckelbaum RJ, eds) Springer, 425-438, 2015.
732. Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M: Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE Phase 3 Study. *Endocrine* 55:273-282, 2017. PMID 27734257
733. Cusano NE, Nishiyama KK, Zhang C, Rubin MR, Boutroy S, McMahon DJ, Guo XE, Bilezikian JP: Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. *J Bone Miner Res* 31:308-316, 2016. PMID: 26234545

734. Holt EH, Bilezikian JP: Calcium disorders. IN: Principles and Practice of Hospital Medicine, 2nd Edition, (McKean SC, Ross JJ, Dressler DD, Scheurer, DB, eds) McGraw Hill, IL, 1961-1971, 2017.
735. Zhou B, Zhang Z, Wang J, Yu YE, Liu XS, Nishiyama KK, Rubin MR, Shane E, Bilezikian JP, Guo XE: *In Vivo* Precision of digital topological skeletonization based individual trabecula segmentation (ITS) analysis of trabecular microstructure at the distal radius and tibia by HR-pQCT. *Pattern Recognit Lett*, 76:83-89, 2016. PMID 27175044
736. Pawlowska M, Cusano N, Bilezikian JP: Primary hyperparathyroidism: current management guidelines. IN: Medical and Surgical Treatment of Parathyroid Diseases: An Evidence-Based Approach (Stack BC and Bodenner DL, eds) Springer, NY, 331-342, 2017.
737. Cipriani C, Abraham A, Silva BC, Cusano NE, Rubin MR, McMahon DJ, Zhang C, Hans D, Silverberg SJ, Bilezikian JP: Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. *Endocrine*, 55:591-598, 2017. PMID 27757772.
738. Costa AG, Bilezikian JP: How long to treat with denosumab. *Curr Osteoporos Rep* 13:415-420, 2015. PMID 26474564
739. Pawlowska M, Bilezikian JP: Beyond DXA: Advances in clinical applications of new bone imaging technology. *Endocr Pract*, 22:990-998, 2016. PMID 27214295
740. Bandeira L, Bilezikian J: Primary hyperparathyroidism. *F1000Res*, pii:F1000 Faculty Rev-1, 2016. PMID 27508075
741. Lewiecki EM, Baron R, Bilezikian JP, Gagel RE, Leonard MB, Leslie WD, McClung MR, Miller P: Proceedings of the 2015 Santa Fe Bone Symposium: Clinical applications of scientific advances in osteoporosis and metabolic bone disease. *J Clin Densitom*, 19:102-116, 2016. PMID 26750746
742. Gennari L, Bandeira F, Bilezikian JP: Osteoporosis in men. IN: *Endocrinologica e Diabetes*, 3rd Edition (Medbook, Rio de Janeiro) 496-507, 2015.
743. Bandeira F, Cusano NE, Silva BC, Cassibba S, Almeida CB, Machado VC, Bilezikian JP: Bone disease in primary hyperparathyroidism. *Arq Bras Endocrinol Metabol* 58(5):553-561, 2014. PMID: 25166047

744. Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F: Primary hyperparathyroidism. *Nat Rev Dis Primers*, 2:1-16, 2016. PMID 27194212
745. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr: Management of hypoparathyroidism: summary statement and guidelines. *J Clin Endocrinol Metab* 101:2273-2283, 2016. PMID 26943719
746. Clarke BL, Brown EM, Collins MT, Juppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischn AF, Thakker RV: Epidemiology and diagnosis of hypoparathyroidism. *J Clin Endocrinol Metab* 101:2284-2299, 2016. PMID 26943720
747. Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes T, Bouillon R: Presentation of hypoparathyroidism: etiologies and clinical features. *J Clin Endocrinol Metab* 101:2300-2312, 2016. PMID 26943721
748. Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT, Jr: Management of hypoparathyroidism: present and future. *J Clin Endocrinol Metab* 101:2313-2324, 2016. PMID 26938200
749. Bandeira L, Lewiecki EM, Bilezikian JP: Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. In: *Expert Opin Drug Metabol Toxicol* 12:681-689, 2016. PMID 27070719
750. De Lellis, RA, Arnold, A, Bilezikian JP, Eng C, Larsson C, Lloyd RV, Mete O: Parathyroid Carcinoma. In: *WHO Classification of Tumours of Endocrine Organs*, 4th edition (Lloyd RV, Osamura RY, Kloppel G, Rosai J, eds), Int'l Agency for Research on Cancer, Lyon, France, 147-152, 2017.
751. Bilezikian JP: Bone loss in the Intensive Care Unit. Editorial, *Am J Respir Crit Care Med* 193:706-707, 2016. PMID 27035777
752. Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP: Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. *J Clin Endocrinol Metab* 101:2742-2750, 2016 PMID 27144931
753. Silva BC, Rubin MR, Cusano NE, Bilezikian JP: Bone imaging in hypoparathyroidism. *Osteoporos Int*, 28:463-471 2017. PMID 27577725.

754. Rubin MR, Zwahlen A, Dempster DW, Zhou H, Cusano NE, Zhang C, Muller R, Bilezikian JP: Effects of parathyroid hormone administration on bone strength in hypoparathyroidism. *J Bone Miner Res* 31:1082-1088, 2016. PMID: 26724790
755. Bilezikian JP: Hyperparathyroidism and hypoparathyroidism. In: *Conn's Current Therapy* (Bope ET, Kellerman RD, eds), Elsevier, Philadelphia, PA 767-770, 2016.
756. Bandeira L, Costa AG, Cusano NE, Silva BC, Bilezikian JP: Osteoporosis in men. In: *Endocrinologia Clinica 6th Edition* (Vilar L, ed), Grupo Editorial Nacional, Rio de Janeiro. (Submitted), 2016.
757. Bilezikian JP, Bandeira L, Khan A, Cusano NE: Hyperparathyroidism *Lancet*. 2017 Sep 15. pii: S0140-6736(17)31430-7. doi: 10.1016/S0140-6736(17)31430-7. [Epub ahead of print] Review. PMID 28923463.
758. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D: Eighteen months of treatment with subcutaneous Abaloparatide followed by six months of treatment with alendronate in postmenopausal women with osteoporosis: Results of the ACTIVEExtend Trial, *Mayo Clin Proc*, 92:200-210, 2017. PMID 28160873
759. Costa AG, Cremers S, Bilezikian JP: Sclerostin measurement in human disease: validity and current limitations. In: *Sclerostin: Bench to Bedside*. *Bone*, 96:24-28, 2017. PMID 27742501
760. Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A: Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/Vitamin D axes, treatment options and guidelines. *Endocrine*, 54:603-611, 2016. PMID 27766553
761. Cusano NE, Thys-Jacobs S, Bilezikian JP: Hypercalcemia due to vitamin D toxicity. In: *Vitamin D, Fourth Edition*, (Feldman D, ed) Elsevier, San Diego (In Press), 2016.
762. Moreira CA, Bilezikian JP: Stress fractures: concepts and therapeutics. *J Clin Endocrinol Metab* 102:525-534, 2017. PMID 27732325
763. Vokes T, Rubin MR, Mannstadt M, Juppner H, Cusano NE, Winer K, Bilezikian JP: Hypoparathyroidism. IN: *Primer on The Metabolic Bone Diseases and Disorders of Mineral Metabolism* (Bilezikian JP, Editor-in-Chief), (In Press), 2016.

764. Bandeira L, Lewiecki EM, Bilezikian JP: Romosozumab for the treatment of osteoporosis. *Expert Opin Biol Ther* 17:255-263, 2017. PMID 28064540.
765. Walker MD, Bilezikian JP: Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. *Endocrine*, 55:3-5, 2017. PMID 27858283
766. Lewiecki EM, Bilezikian JP, Bukata SV, Camacho P, Clarke BL, McClung MR, Miller PD, Shepherd J: Proceedings of the 2016 Santa Fe Bone Symposium: New concepts in the management of osteoporosis and metabolic bone diseases. *J Clin Densitom*, 1-19, 2017. PMID 28185765
767. Rubin MR, Cusano NE, Zhang C, Fan WW, Bilezikian JP: Increased osteocalcin levels by administration of PTH in hypoparathyroidism are associated with improved social functioning. *J Clin Endocrinol Metab* (To be submitted), 2016.
768. Bandeira L, Bilezikian JP: Novel therapies for postmenopausal osteoporosis. *Endocrinol Metab Clin North Am*, 46:207-219, 2017. PMID 28131134.
769. Lesnyak O, Sahakyan S, Zakroyeva A, Bilezikian JP, Hutchings N, Babalyan V, Galstyan R, Lebedev A, Johansson H, Harvey NC, McCloskey E, Kanis JA: Epidemiology of fractures in Armenia: development of a country-specific FRAX model as comparison to its surrogate. *Osteoporosis Int'l* (Submitted), 2017.
770. Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, Figueroa CA, Kir S, Zhou X, Mannstadt M, Baron R, Bronson RT, Horowitz MC, Wu JY, Bilezikian JP, Dempster DW, Rosen CJ, Lanske B: Parathyroid hormone directs bone marrow mesenchymal cell fate. *Cell Metab* 25:661-672, 2017. PMID 28162969
771. Stack Jr BC, Tolley NS, Bartel TB, Bilezikian JP, Bodenner D, Camacho P, Cox J, Jackson JE, Morris JC, Orloff LA, Palazzo F, Ridge D, Scott-Coombes, D, Steward D, Terris DJ, Thompson G, Randolph G: Re-operative parathyroid surgery: Joint Guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. (In Press), 2017.
772. Walker M, Sum M, Zhu T, Zhou B, Zhang Z, Bilezikian JP, Guo E, Qin L: Chinese women in both the United States and Hong Kong have cortical microstructural advantages and more trabecular plates compared to white women. *Bone Res* (In Press), 2017.

773. Costa AG, Lewiecki EM, Bilezikian JP: Denosumab. IN: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th Edition (Bilezikian JP, Editor-in-Chief), (In Press), 2017.
774. Bilezikian JP: Primary hyperparathyroidism. In: www.ENDOTEXT.org (Version of 2017) DeGroot L, Editor; Singer F, Section Editor; (MDTEXT.COM, Inc, S. Dartmouth, MA), (In Press) 2017.
775. Bilezikian JP: Hyperparathyroidism and hypoparathyroidism. IN: Conn's Current Therapy (Bope ET, Kellerman RD, eds), Elsevier, Philadelphia, PA, 286-290, 2017.
776. Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP: Osteoporosis in Crisis: It's Time to Focus on Fracture. J Bone Miner Res 32:1391-1394, 2017. PMID 28556236
777. Bilezikian JP: Approach to parathyroid disorders. IN: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th edition (Bilezikian JP, editor), (In Press), 2017.
778. Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Reijnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM: Hypoparathyroidism. Nat Rev Dis Primers 3:1-20, 2017. PMID 28857066
779. Bandeira LC, Rubin MR, Cusano NE, Bilezikian JP: Vitamin D and Hypoparathyroidism. Frontiers of Hormone Research Emerging Aspects of Vitamin D in Clinical Medicine (In Press), 2017.
780. Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris A, Shevroja E, Banks K, Leder B, Zanchetta JR, Hans D: Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporosis Int (Submitted), 2017.
781. Bilezikian JP, Clarke BL, Mannstadt M, Rothman J, Vokes T, Lee HM, Krasner A: Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25- μ g or 50- μ g daily doses. Clin Ther. 2017 [Epub ahead of print] PMID: 28942334

782. Bilezikian JP, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A: Denosumab restores cortical bone loss associated with aging and reduces upper extremity fracture risk: Analyses from the FREEDOM Extension Cross-over Group. (To Be Submitted), 2017.
783. Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP: Recombinant human parathyroid hormone on health-related quality of life in adults with chronic hypoparathyroidism. *J Clin Endo Metab* (In Revision), 2017.
784. Misiorowski W, Czajka-Oraniec I, Kochman M, Zgliczynski W, Bilezikian JP: Osteitis fibrosa cystica - a forgotten radiological feature of primary hyperparathyroidism. *Endocrine*, 2017 [Epub ahead of print] PMID 28900835
785. Toulis KA, Bilezikian JP, Thomas GN, Hanif W, Kotsa K, Tahrani A, Nirantharakumar K: Initiation of sodium-glucose co-transporter 2 inhibitors and treatment-emergent fractures. (Submitted), 2017.
786. Tay D, Cremers S, Bilezikian JP: Dose regimens and delivery systems of parathyroid hormone and analogues in osteoporosis and in hypoparathyroidism – translational pharmacology from the molecule to the patient. *Brit J Clin Pharm* (In Press), 2017.
787. Bilezikian JP, Markovac J: The Journal Editorial Team and Working with the Publisher. (In Press), 2017.
788. Gennari L, Bilezikian JP: New and developing pharmacotherapy for male osteoporosis. In: *Expert Opinion on Pharmacotherapy*, (In Press), 2017.
789. Tay YKD, Cusano NE, Rubin MR, Williams J, Omeragic B, Bilezikian JP: Trabecular bone score in obese and non-obese subjects with primary hyperparathyroidism before and after parathyroidectomy. *J Clin Endocrinol Metab* (Submitted), 2017.
790. Cusano NE, Rubin M, Silva BC, Tay YKD, Williams JM, Agarwal S, Omeragic B, Guo XE, Bilezikian JP: Skeletal microstructure and estimated bone strength improve following successful parathyroidectomy in primary hyperparathyroidism. *J Clin Endocrine Metab* (Submitted), 2017.

791. Paschalis EP, Gamsjaeger S, Glorieux FH, Rauch F, Dempster D, Zhou H, Shane E, Cohen A, Bilezikian JP, Rubin M, Lane JM, Brozek W, Moreira C, Skarantovos G, Lyritis G, Pavo I, Stepan J, Papapoulos S, Eriksen EF, Frantzl P, Klaushofer K: Organic matrix quality of forming bone is a major determinant of whether an individual sustains fragility fractures. *N Eng J Med* (Submitted), 2017.
792. Sum M, Bilezikian JP: Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production. (To Be Submitted), 2017.
793. Hutchings N, Aghajanova E, Baghdasaryan S, Qefoyan M, Sullivan C, He X, Manoukian M, Gerasimov G, Braverman L, Bilezikian J: Iodine nutrition in Armenia: a model of representative surveillance. (To Be Submitted), 2017.
794. Hutchings N, Tovmasyan I, Hovsepyan M, Qefoyan M, Baghdasaryan S, Bilezikian JP: Neonatal thyroid stimulating hormone screening as a tool for monitoring iodine nutrition in Armenia. (Submitted), 2017.

ABSTRACTS:

1. Bilezikian JP and Aurbach GD: Characterization and solubilization of the beta-adrenergic receptor of the turkey erythrocyte. *Fed Proc* 32:567A, 1973.
2. Bilezikian JP, Powell D, Doppman JL, Shimkin PM, Heath DA, Mallette LE, Wells SA and Aurbach GD: Primary hyperparathyroidism: Preoperative localization of abnormal glands by selective venous sampling and determination of parathyroid hormone. *Clin Res* 21:617A, 1973.
3. Gardner JD, Klaeveman HL, Bilezikian JP and Aurbach GD: Regulation of membrane cation transport by catecholamines: Role of adenylate cyclase-cyclic AMP system. *J Clin Invest* 52:ii, 1973.
4. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK and Aurbach GD: Hyperparathyroid neuromuscular disease. American College of Physicians, 54th Annual Meeting, 9A, April, 1973.
5. Heath DA, Bilezikian JP, Fedak SA, Mallette LE and Aurbach GD: The effect of posture and exercise on cyclic 3'5'-AMP in the extracellular fluid of man. The Endocrine Society, 55th Annual Meeting, 227A, 1973.
6. Bilezikian JP: Review of hyperparathyroidism by Paloyan, Lawrence, and Strauss. *Ann Int Med* 80:564, 1974.
7. Spiegel AM, Bilezikian JP and Aurbach GD: Increased adrenergic receptor concentration in membranes of stress-induced erythrocytes. *Clin Res* 23, 390A, 1975.
8. Derenoncourt FJ, Bilezikian JP, Feind CR, Weber CJ, Hardy MA and Reemtsma K: Beta-adrenergic control of cyclic AMP secretion in cultured human parathyroid adenomas. *Clin Res* 25:389A, 1977.
9. Bilezikian JP: Review of Handbook of Physiology, Section 7, Volume VII (RO Greep and EB Astwood, Eds.), *Ann Int Med* 87:137, 1977.
10. Schonberg M, Bilezikian JP, Apfelbaum M and Benn RC: Gain in beta-adrenergic receptor sites and catecholamine stimulation of adenylate cyclase associated with myoblast fusion. *Proc Intl Soc Neurochemistry*. 6:47, 1977.

11. Bilezikian JP and Loeb JN: Thyroid status and the beta-adrenergic responsiveness of the turkey erythrocyte. The Endocrine Society, 60th Annual Meeting, 94A, 1978.
12. Canfield RE, Bilezikian JP, Jacobs TP, Polay JS, D'Adamo AC, Eisman JA and DeLuca HF: The response of dihydroxycholecalciferol to hypocalcemia in human subjects. The Endocrine Society, 60th Annual Meeting, 260A, 1978.
13. Eisman JA, DeLuca HF, Canfield RE and Bilezikian JP: Application of radioreceptor assay for 1,25-dihydroxycholecalciferol to stress testing in man. Annual Meeting of the Australian Endocrine Society, 1978.
14. Ball WJ Jr, Tse-Eng D, Bilezikian JP, Wallick E, Schwartz A and Butler VP Jr: Studies of a quinidine-digoxin interaction. Fed Proc 38:4308A, 1979.
15. Bilezikian JP, Gammon DE, Rochester CL and Shand DG: A radio-receptor assay for propranolol. Clin Res 27:228A, 1979.
16. Omrani GR, Gammon DE and Bilezikian JP: A soluble endogenous regulator of catecholamine-responsive adenylate cyclase. The Endocrine Society, 61st Annual Meeting, 846A, 1979.
17. Lau YH, Robinson RB, Rosen MR and Bilezikian JP: Beta-adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. Circulation 60:781A, 1979.
18. Bilezikian JP, Canfield RE, Jacobs TP, Polay JS, D'Adamo AP, Eisman JA and DeLuca HF: The response of 1 alpha, 25-dihydroxyvitamin D₃ to hypocalcemia in human subjects. The Digests, 1979.
19. Schonberg M, Smith TJ, Krichevsky A and Bilezikian JP: Glucocorticoids enhance glucose uptake and affect beta-adrenergic responsiveness in muscle cell cultures. Fed Proc 39:2908A, 1980.
20. Smith TJ, Dana R, Krichevsky A, Bilezikian JP and Schonberg M: Dexamethasone inhibits fusion, cyclic AMP accumulation and beta-adrenergic receptors in muscle cells in vitro. The Endocrine Society, 62nd Annual Meeting, 813A, 1980.
21. Shane E and Bilezikian JP: The role of an endogenous regulator of catecholamine-responsive adenylate cyclase activity during rat reticulocyte maturation. The Endocrine Society, 62nd Annual Meeting, 756A, 1980.

22. Furukawa H, Bilezikian JP and Loeb JN: Altered catecholamine-dependent K influx in hypothyroid turkey erythrocytes. Clin Res 28:478A, 1980.
23. Shane E, Rochester CL, Gammon DE and Bilezikian JP: A radioreceptor assay for propranolol and 4-hydroxypropranolol in human plasma. Clin Res 28:243, 1980.
24. Shane E, Baquiran DC and Bilezikian JP: An oral therapy for the hypercalcemia of primary hyperparathyroidism. Clin Res 28:523A, 1980.
25. Jacobs TP, Siris ES, Bilezikian JP, Baquiran DC and Canfield RE: Malignant hypercalcemia: Treatment with dichloromethylene diphosphonate. Annual Meeting of the American Society for Bone and Mineral Research, 21A. 1980.
26. Schonberg M, Krichevsky A, Smith TJ and Bilezikian JP: Beta-adrenergic dependent stimulation of deoxyglucose uptake in muscle cell cultures. Advances in Cyclic Nucleotide Research 14:688, 1981.
27. Shane E and Bilezikian JP: Guanine nucleotide-induced shift in binding affinity for beta-adrenergic agonists in rat reticulocytes and turkey erythrocyte membranes. Advances in Cyclic Nucleotide Research 14:661, 1981.
28. Bilezikian JP: Review of magnesium deficiency in the pathogenesis of disease. MS Seelig, Plenum Medical Book Company, New York, 1980. Ann Int Med 94:552, 1981.
29. Shane E, Jacobs TP, Siris ES, Steinberg S, Stoddart K, Canfield RE and Bilezikian JP: Dichloromethylene diphosphonate reduces serum calcium in parathyroid carcinoma. Annual Meeting of the American Society for Bone and Mineral Research, 24A, 1981.
30. Canfield RE, Siris ES, Jacobs TP, Bilezikian JP, Shane E, Steinberg SF and Stoddart KE: Clinical experience with diphosphonate in multiple myeloma, metastatic bone disease and hyperparathyroidism. Presented at the Fourth Symposium CEMO, Nyon, Switzerland, Nov, 1981.
31. Morris SA, Schonberg M, Krichevsky A and Bilezikian JP: Desensitization of L6E9 muscle cells to isoproterenol: A function of cell density. Fed Proc 41:1306, 1982.

32. Kupfer LE, Robinson RB and Bilezikian JP: Identification of alpha-adrenergic receptors in primary cultures of rat heart cells with a new iodinated radioligand. *Fed Proc* 41:1305, 1982.
33. Morris SA and Bilezikian JP: Appearance of guanine nucleotide-dependent adenylate cyclase activity in turkey erythrocyte membranes. *Clin Res* 30:274A, 1982.
34. Steinberg SF and Bilezikian JP: Erythrocyte levels of propranolol accurately reflect the concentration of free drug in the plasma of patients. *Clin Res* 30:488A, 1982.
35. Merlini G, Fitzpatrick LA, Siris ES, Bilezikian JP and Osserman EF: Demonstration of a calcium binding IgG myeloma protein by two-dimensional electrophoresis. *Clin Res* 30:534A, 1982.
36. Shane E, Gammon DE, Goldstein J and Bilezikian JP: Further Purification and Characterization of the cytosol protein activator of catecholamine-sensitive adenylate cyclase activity. The Endocrine Society, 64th Annual Meeting, 710A, 1982.
37. Steinberg SF and Bilezikian JP: Identification of alpha-adrenergic receptors in rat heart membranes with a new iodinated radioligand. The Endocrine Society, 64th Annual Meeting, 270A, 1982.
38. Fitzpatrick LA, Merlini G, Siris ES, Osserman E and Bilezikian JP: Hypercalcemia associated with a unique calcium-binding IgG myeloma protein. American Society for Bone and Mineral Research, 4th Annual Meeting, 225, 1982.
39. Morris SA, Rowin KA, Tanowitz HB, Wittner M and Bilezikian JP: Desensitization in L6E9 myoblasts infected with *Trypanosoma Cruzi*. Annual Meeting of the American Society for Clinical Investigation, 472A, 1983.
40. Steinberg SF, Jaffe EA and Bilezikian JP: Identification of beta-adrenergic receptors in endothelial cells. The Endocrine Society, 65th Annual Meeting, 321A, 1983.
41. Shane E, Goldstein J, Gammon DE and Bilezikian JP: Cytosol activator protein inhibits ADP-ribosylation of rat reticulocyte membranes. The Endocrine Society, 65th Annual Meeting, 235A, 1983.

42. Cholst IN, Steinberg SF, Tropper P, Fox HE, Segre GV and Bilezikian JP: Hypermagnesemia is associated with inadequate parathyroid hormone reactivity to hypocalcemia. 5th Annual Meeting of the American Society for Bone and Mineral Research, 21A, 1983.
43. Avioli RC, Greene A, Shane E, Bilezikian JP, Turner RT and Bell NH: Enhancement of hormonal response of canine renal cortical adenylate cyclase by activator protein. 5th Annual Meeting of the American Society for Bone and Mineral Research, 43A, 1983.
44. Bilezikian JP: Medical management of primary hyperparathyroidism. Frances and Anthony D'Anna International Memorial Symposium of Clinical Disorders of Bone and Mineral Metabolism, Henry Ford Hospital, #78, 1983.
45. Steinberg SF, Chow Y and Bilezikian JP: Regulation of rat heart membrane adenylate cyclase by divalent cations, forskolin and GTP. Fed Proc 43:968A, 1984.
46. Bilezikian JP, Chow Y and Steinberg SF: Altered responsiveness of solubilized adenylate cyclase from rat heart membranes to divalent cations, forskolin and GTP. Fed Proc 43:969A, 1984.
47. Buchtal SD, Kupfer LE, Bilezikian JP and Danilo P Jr: Identification of alpha adrenergic receptors in adult and neonatal canine ventricles. Fed Proc 43:236A, 1984.
48. Kupfer LE, Robinson RB and Bilezikian JP: The regulation by L-triiodothyronine of alpha and beta-adrenergic receptors in cultured rat heart cells. Fed Proc 43:342A, 1984.
49. Morris SA and Bilezikian JP: Regulation of particulate and solubilized turkey erythrocyte adenylate cyclase by manganese, forskolin and guanine nucleotides. Fed Proc 43:967A, 1984.
50. Siris E, Clemens T, Dempster D, Shane E, Segre G, Lindsay R and Bilezikian JP: Tumor induced osteomalacia: Kinetics of mineral metabolism and bone histomorphometry. Clinical Res 32:523A, 1984.
51. Brown RP, Halper JH, Sweeney J, McBride PA, Bilezikian JP, Weksler ME and Stokes PE: Beta and serotonin receptor function in depression (Presented at the American Psychiatric Assoc Meeting, Los Angeles, CA, 1984).

52. Siris E, Clemens T, Dempster DW, Shane E, Segre G, Lindsay R and Bilezikian JP: Tumor induced osteomalacia: Kinetics of mineral metabolism and bone histomorphometry. Sixth Annual Meeting of the American Society for Bone and Mineral Research, 49A, 1984.
53. Shane E, Yeh M, Owens J, Feigin AS and Bilezikian JP: Reticulocyte cytosol activator protein enhances adenylate cyclase activity by augmenting ADP-ribosylation of the inhibitory guanine nucleotide regulatory proteins. *Clinical Res* 32:703A, 1984.
54. Morris SM and Bilezikian JP: Developmental aspects of adenylate cyclase activation in L6E9 myoblast cultures. *Fed Proc* 44:1806A, 1985.
55. Morris SM and Bilezikian JP: Forskolin activation and binding in rat heart membranes. *Fed Proc* 44:1807A, 1985.
56. Clemens TL, Silverberg S, Dempster D, Shane E, Williams S, Segre GV, Bilezikian JP and Lindsay R: Oral phosphate depresses serum 1,25-dihydroxyvitamin D concentrations in osteoporotic patients. (Presented at the International Vitamin D Workshop, Milano, Italy, March 1985.)
57. Shane E, Owens J, Yeh M and Bilezikian JP: The regulatory proteins of adenylate cyclase, Ns and Ni, are altered by rat reticulocyte cytosol activator protein. *The Endocrine Society, 67th Annual Meeting*, 897A, 1985.
58. Steinberg SF, Stern DM, Nawroth PP and Bilezikian JP: Factor Xa elevates cytosolic calcium in cultured endothelial cells. (Presented at the ISTH Xth Congress, July, 1985.)
59. Shane E, Avioli RC, Yeh M, Greene VS, Bell NH and Bilezikian JP: Cytosol activator protein augments adenylate cyclase activity in canine renal cortical membranes and inactivates the inhibitory guanine nucleotide regulatory protein. *Seventh Annual Meeting of the American Society for Bone and Mineral Research*, 306A, 1985.
60. Silverberg SJ, Shane E, Clemens TL, Dempster DW, Segre GV, Lindsay R and Bilezikian JP: Oral phosphate affects major indices of skeletal metabolism in normal human subjects. *Seventh Annual Meeting of the American Society for Bone and Mineral Research* 119A, 1985.

61. Buchtal SD, Bilezikian JP and Danilo P Jr: Developmental changes in beta and alpha1-adrenergic receptors in cardiac Purkinje fibers. Presented at the 58th Annual Meeting of the American Heart Association, Washington DC, November, 1985.
62. Morris SA and Bilezikian JP: Influence of EDTA on adenylate cyclase activity in mouse and rat heart membranes. *Fed Proceedings*, 4:214A, 1986.
63. Steinberg SF, Chow YK, Robinson RB and Bilezikian JP: Alpha1-adrenergic stimulation of inositol 1-phosphate formation in myocardial cells is regulated by a pertussis toxin substrate. *The Endocrine Society, 68th Annual Meeting*, 58A, 1986.
64. Weinstock RS, Goland RS, Shane E, Tohme JF, Lindsay R and Bilezikian JP: Bone mass in women with non-insulin dependent Diabetes mellitus. *J Diabetes* 35:470, 120A, 1986.
65. Silverberg SJ, de la Cruz L, Shane E, Dempster DW, Jacobs TP, Clemens TL, McMahon D, Siris E, Lindsay R and Bilezikian JP: Symptomatic and asymptomatic primary hyperparathyroidism. *J of Bone and Mineral Research, Supp I*, 177A, 1986.
66. Silverberg SJ, Shane E, Clemens TL, Dempster DW, de la Cruz L, Segre G, Lindsay R and Bilezikian JP: Altered 1,25-dihydroxyvitamin D3 metabolism in osteoporotic subjects following phosphate administration. *J of Bone and Mineral Research, Supp I*, 171A, 1986.
67. Weinstock RS, Goland RS, Shane E, Clemens TL, Tohme JF, Lindsay R and Bilezikian JP: Increased bone mineral density in women with non-insulin dependent Diabetes mellitus. *J of Bone and Mineral Research, Supp I*, 227A, 1986.
68. Horn EM, Chow YK, Neuberger GW, Corwin SJ, Powers ER, Bilezikian JP, Cannon PJ, Steinberg SF: The guanine nucleotide regulatory protein Ns is reduced in congestive heart failure. *Circulation, Supp II*, 789A, 1986.
69. Rosen MR, Steinberg SF, Chow YK, Bilezikian JP and Danilo P: Pertussis toxin modifies alpha1-adrenergic effects of Purkinje fiber automaticity via an N1-like regulatory protein. *Circulation, Supp II*, 794A, 1986.
70. Corwin SJ, Horn EM, Steinberg SF, Neuberger GW, Chow YK, Bilezikian JP and Powers ER: The effects of angiotensin converting enzyme inhibition on components of the beta receptor system in congestive heart failure. *Circulation, Supp II*, 1237A, 1986.

71. Tohme JF, Clemens TL, Silverberg SJ, Shane E, Bilezikian JP and Lindsay R: A simple test of parathyroid hormone suppressibility in humans using an oral calcium load. (Presented at the IXth International Conference on Calcium Regulating Hormones and Bone Metabolism, Nice, France, November, 1986).
72. Horn EM, Steinberg SF, Chow YK, Neuberger GW, Corwin SC, Powers ER and Bilezikian JP: Altered beta-adrenergic receptors and guanine nucleotide binding regulatory proteins in congestive heart failure. *Clin Res* 34:857A, 1986.
73. Morris SA and Bilezikian JP: Cardiac beta-adrenergic adenylate cyclase activity during the course of *T. cruzi* infection in mice. *Clin Res* 34:860A, 1986.
74. Tohme JF, Clemens TL, Silverberg SJ, Shane E, Bilezikian JP and Lindsay R: A Simple test of parathyroid hormone suppressibility in humans using an oral calcium load. *Clin Res* 34:880A, 1986.
75. Morris S, Bilezikian JP, Wittner M and Tanowitz HB: Effect of *T. cruzi* infection on adenylate cyclase complex in muscle cells. 35th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, Colorado, December, 1986.
76. Morris SA, Tanowitz HB, Bilezikian JP and Wittner M: Cardiac beta-adrenergic adenylate cyclase activity during the course of murine Chagas' disease. 35th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, Colorado, December, 1986.
77. Morris SA, Hatcher V, Bilezikian JP, Tanowitz H and Wittner M: Infection of human endothelial cells with *T. cruzi* alters cellular calcium metabolism. *Fed Proc* 46:53332A, 1987.
78. Silverberg SJ, Shane E, de la Cruz L, Clemens TL, Siris ES, Jacobs TP, Dempster DW, Tohme J, Lindsay R and Bilezikian JP: Dietary calcium intake and 1,25(OH)₂ vitamin D levels in primary hyperparathyroidism. *Clinical Research* 35:517A, 1987.
79. Silverberg SJ, Shane E, de la Cruz LS, Jacobs TP, Siris ES, Clemens TL, Dempster DW, Tohme JF, Lindsay R and Bilezikian JP: Primary hyperparathyroidism in the 1980's. *Clinical Research* 35:518A, 1987.
80. Horn EM, Barr ML, Steinberg SF, Morrow BS, Reemtsma K, Cannon PJ and Bilezikian JP: Guanine nucleotide binding proteins are reduced in the failing human myocardium. *Clinical Research* 35:287A, 1987.

81. Dempster DW, Shane E, Silverberg SJ, Clemens TL, de la Cruz L, Jacobs TP, Siris E, Tohme J, Parisien M, Feind CR, LoGerfo P, Lindsay R and Bilezikian JP: Iliac crest bone biopsy in primary hyperparathyroidism (PHPT): Relationship to clinical presentation and biochemical indices. *J Bone and Min Res* 2:Suppl I;105A, 1987.
82. Silverberg SJ, Shane E, Clemens TL, Dempster DW, de la Cruz L, Kim LY, Segre G, Lindsay R and Bilezikian JP: Evidence for abnormal 1,25(OH)D₂ metabolism in postmenopausal women with osteoporosis by dynamic testing. *J Bone and Min Res* 2: Suppl I;107A, 1987.
83. Silverberg SJ, Shane E, de la Cruz L, Jacobs TP, Siris E, Clemens TL, Feldman F, Cafferty M, Dempster DW, Tohme J, Lindsay R and Bilezikian JP: A current view of primary hyperparathyroidism. *J Bone and Min Res* 2:Suppl I;231A, 1987.
84. Shane E, Silverberg SJ, de la Cruz L, Clemens TL, Jacobs TP, Dixon A, Dempster DW, Tohme J, Lindsay R and Bilezikian JP: Dietary calcium and phosphate intake are positively correlated with 1,25(OH)₂ vitamin D levels in primary hyperparathyroidism. *J Bone and Min Res* 2:Suppl I;385A, 1987.
85. Bilezikian JP, Steinberg SF, Chow YK, Robinson RB, Horn EM and Rosen MR: The role of N protein-adrenergic interactions in the heart. (Presented at the First Conference of the Membrane Biophysics Group of the Biophysical Society, September, 1987).
86. Vulliamoz Y, Verosky M, Horn EM and Bilezikian JP: A pertussis toxin substrate regulates the cGMP response to alpha-adrenergic agonists in mouse heart. *Circulation* 76: Suppl IV, 245A, 1987.
87. Horn EM, Barr ML, Morrow BS, Reemtsma K, Cannon PJ and Bilezikian JP: N proteins from human myocardium and lymphocytes are coordinately reduced in congestive heart failure. *Circulation* 76: Suppl IV. 1229A, 1987.
88. Horn EM, Gottlieb SS, Morrow BS, Bilezikian JP and Packer M: Hemodynamic and prognostic significance of altered lymphocyte guanine nucleotide binding proteins in congestive heart failure. *Circulation* 76: Suppl IV, 349A, 1987.
89. Horn EM, Johnson N, Morrow BS, Rosen MR and Bilezikian JP: Developmental changes in delayed after depolarizations and N proteins in the canine coronary sinus. *Circulation* 76: Suppl IV, 1724A, 1987.

90. Han HM, Steinberg SF, Robinson RB and Bilezikian JP: Developmental changes in coupling of alpha1-adrenergic receptor to GTP binding proteins in the rat heart. *FASEB Journal* 2:1879A, 1988.
91. Turken S, Cafferty M, Silverberg SJ, de la Cruz L and Bilezikian JP: Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. *J Bone and Min Res* 3:Suppl I;88A, 1988.
92. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Jacobs TP, Siris ES, Parisien MV, Seldin D and Bilezikian JP: Skeletal disease in primary hyperparathyroidism. *J Bone and Min Res* 3:Suppl1;89A, 1988.
93. Cosman F, Morrow BS, Kopal MA and Bilezikian JP: Control of phospholipase C activity in ROS cell homogenates by GTP and calcium. *J Bone and Min Res* 3:Suppl I;164A, 1988.
94. Silverberg SJ, Shane E, Clemens T and Bilezikian JP: Abnormal PTH-1,25(OH)₂D axis in postmenopausal osteoporosis. *J Bone and Min Res* 3:Suppl 1;543A, 1988.
95. Coleman DT and Bilezikian JP: Parathyroid hormone stimulates formation of inositol phosphates from canine renal cortical tubular membranes. *J Bone and Min Res* 3:Suppl I;605A, 1988.
96. Parisien M, Dempster DW, Shane E, Silverberg SJ, Lindsay R and Bilezikian JP: Structural parameters of iliac bone biopsies in primary hyperparathyroidism. (Presented at the 5th International Congress on Bone Morphometry, Nigata, Japan), 1988.
97. Seldin DW, Silverberg SJ, Bilezikian JP and Alderson PO: Bone mineral content of the spine, hip and forearm in patients with primary hyperparathyroidism. *J of Nuclear Medicine* 29:427A, 1988.
98. Apfelbaum MA, Horn EM, Chaekal W, Morrow BS, Fishman G, Powers ER and Bilezikian JP: Loss of concordance between lymphocyte and myocardial beta-adrenergic receptor complex following cardiac transplantation. *Circulation* 78: Suppl II, 645A, 1988.
99. Horn EM, Neuberg GW, Morrow B, Chaekal W, Pajaro RE, deCholnoky PA, Weiss MB and Bilezikian JP: Exercise alters guanine nucleotide binding proteins. *J Am Coll Card* 13:40a, 1989.

100. Coleman DT, Morrow BS and Bilezikian JP: Nucleotide-associated inhibition of inositol-1,4,5-trisphosphate metabolism in canine renal cortical tubular membranes. *J Bone Min Res* 4:907A, 1989.
101. Silverberg SJ, Shane E, Jacobs TP, Siris E, Seldin D, Clemens TL and Bilezikian JP: "Bones and stones" in primary hyperparathyroidism. *J Bone Min Res* 4:545A, 1989.
102. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP and Dempster DW: Preservation of trabecular plates in primary hyperparathyroidism. *J Bone Min Res* 4:757A, 1989.
103. Epstein S, Movsowitz C, Silverberg SJ, Clemens TL, Singer F and Bilezikian JP: Osteonectin and calciotropic hormones in primary hyperparathyroidism. *J Bone Min Res* 4:2A, 1989.
104. Horn EM, Kukin ML, Neuberg GW, McCarty M, Gratch M, Bilezikian JP and Packer M: The inhibitory guanine nucleotide binding protein increases in heart failure patients who fail to respond to direct-acting vasodilators. *Circulation* 80: 466A (Suppl), 1989
105. Horn EM, Danilo P, Barr ML, Morrow BS, Gratch M, McCarty M, Smith CR, Rose EA, Pepino P and Bilezikian JP: Biochemical and electrophysiological evidence of increased Gi following cardiac denervation. *Circulation* 80: 1170A (Suppl), 1989.
106. Mellish RWE, Parisien M, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP and Dempster DW: Two-dimensional cancellous bone structure in patients with primary hyperparathyroidism. *J Bone Min Res* 5:375a, 1990.
107. Parisien M, Dempster DW, Silverberg SJ, Shane E, Seldin D, Lindsay R and Bilezikian JP: Relationship between bone mass as assessed by densitometry and by histomorphometry in primary hyperparathyroidism. *J Bone Min Res* 5:137a, 1990.
108. Glusman J, Morrow B and Bilezikian JP: Dexamethasone suppresses phospholipase C activation in ROS 17/2.8 cells. *J Bone Min Res* 5:463a, 1990.
109. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP and Bilezikian JP: Urinary hydroxy-pyridinium crosslinks of collagen as indices of bone resorption in primary hyperparathyroidism. *J Bone Min Res* 5:666a, 1990.

110. Silverberg SJ, Burtis WJ, Gartenberg F and Bilezikian JP: PTHRP levels in primary hyperparathyroidism. *J Bone Min Res* 5:667a, 1990.
111. Seibel MJ, Ratcliffe A, Siris ES, Tohme J, Shane E, Silverberg SJ, Robins SP and Bilezikian JP: New markers of cartilage and bone metabolism in skeletal and connective tissue related disorders. (Presented at the International Meeting of Diagnostic and Therapy of Rheumatic Disease, Germany and Switzerland, June 1990).
112. Sun LS, Camacho JA, Steinberg SF, Ursell P, Bilezikian JP and Robinson RB: Neuropeptide Y mimics the effect of sympathetic innervation on alpha1-adrenergic response in cultured ventricular myocytes. *Circulation* 82:187a (Supp III), 1990.
113. Horn EM, Rouleau JL, Sollano J, Coglianese ME, Kukin ML, Steingart R, Gottlieb SS, DeChamplain J, Bichet D, Ahern D, Taylor M, Hawley T, Bilezikian JP and Packer M: Effect of sympathetic activation on the components of the beta-adrenergic pathway in patients with an acute myocardial infarction and left ventricular dysfunction. *Circulation* 82:316a (Supp III), 1990.
114. Camacho JA, Morris SA, Manning DR and Bilezikian JP: Developmental expression of rat myocardial G proteins: Correlation of mRNA and immunochemistry. *Circulation* 82:760a (Supp III), 1990.
115. Morris SA, Tanowitz HB, Bilezikian JP, Factor S, Barr S and Wittner M: Biochemical characteristics of Chagas' cardiomyopathy. (Presented at the Annual Parasitology Meetings, New Orleans, November, 1990).
116. Bilezikian JP, Silverberg SJ, Shane E, Parisien M and Dempster DW: Characterization and evaluation of primary hyperparathyroidism. (Presented at the Consensus Development Conference on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism, National Institutes of Health, October 29-31, 1990).
117. Huber F, Vulliemoz Y, Sun LS, Robinson RB, Bilezikian JP: Characterization of the muscarinic receptor coupled to inositol phosphate formation in cultured myocytes from newborn rat hearts. *FASEB J.* 5:2826A, 1991.
118. Vulliemoz Y, Huber F, Bilezikian JP: Guanine nucleotide regulation of inositol 1,4,5-trisphosphate metabolism in membranes of cultured newborn rat heart myocytes. *FASEB J.* 5:642A, 1991.

119. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Bilezikian JP: Development of abnormal biochemical values in primary hyperparathyroidism. *J Bone Min Res* 6:655a (Suppl I), 1991.
120. Silverberg SJ, Deftos LJ, Kim T, Hill CS, Bilezikian JP: Bone alkaline phosphatase in primary hyperparathyroidism. *J Bone Min Res* 6:624a (Suppl I), 1991.
121. Glusman JE, Morris SA, Rohde SE, Camacho JA, Cosman F, Bilezikian JP: Opposing influence of dexamethasone and retinoic acid on ROS 17/2.8 cells. *J Bone Min Res* 6:118a (Suppl I), 1991.
122. Parisien M, Recker R, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster D: Does primary hyperparathyroidism protect against post-menopausal cancellous bone loss? *J Bone Min Res* 6:852a (Suppl I), 1991.
123. Camacho JA, Robinson RB, Bilezikian JP: Regulation of the mRNA for the alpha1-adrenergic receptor subtype B in the developing myocardium. *Circulation* 84: Suppl II; 261a, 1991.
124. Morris SA, Florant G, Saxon M, Manning D and Bilezikian JP: Adaptations of the marmot myocardial beta-adrenergic receptor cyclase complex during hibernation. *Circulation* 84: Suppl II; 393, 1991.
125. Nussbaum S, Warrell R, Rude R, Bilezikian JP, Glusman J, Stewart A, Sacco J, Stepanavage B, Gertz B, Averbuch S. Treatment of cancer-associated hypercalcemia with alendronate (aminohydroxybutylidene bisphosphonate). *Proceedings, American Soc of Clin Oncology* II:1306a, 1992.
126. Shane E, Silverberg SJ, Kim T, del C Rivas M, Staron RB, Bilezikian JP: Osteoporosis and fractures after cardiac transplantation. *Bone and Mineral* 17 (Suppl) 323a, 1992.
127. Parisien M, Cosman F, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster DW: Relationship between bone mass by densitometry and by histomorphometry in primary hyperparathyroidism and in osteoporosis. *Bone and Mineral* 17 (Suppl) 554a, 1992.
128. Sun LS, Steinberg SF, Vulliamoz Y, Bilezikian JP, Alter A, Robinson RB: Neonatal rat ventricular myocytes in culture have functional M3 cholinergic receptors linked to positive chronotropy and phosphoinositide hydrolysis *Circulation* 86, 1207a, 1992.

129. Glusman JE, Morris SA, Rohde SE, Bilezikian JP: Qualitative G-protein changes mediate dexamethasone and retinoic acid effects on ROS 17/2.8 adenylate cyclase activity. *J Bone Min Res* 7 (Suppl), 541a, 1992.
130. Silverberg SJ, Gartenberg F, Bilezikian JP: Primary hyperparathyroidism protects cancellous bone density in postmenopausal women. *J Bone Min Res* 7 (Suppl), 813a, 1992.
131. Silverberg SJ, Deftos LJ, Kim TS, Bilezikian JP: Calcitonin in primary hyperparathyroidism. *J Bone Min Res* 7 (Suppl), 812a, 1992.
132. Rohde SE, Bex FJ, Bilezikian JP: Opposing influence of WY-47,766 on adenylate cyclase and phosphoinositide signalling in ROS 17/2.8 cells. *J Bone Min Res* 7 (Suppl), 489a, 1992.
133. Del C Rivas M, Silverberg SJ, Kim T, Bilezikian JP, Shane E: Bone loss and fractures occur within six months after heart transplantation. *J Bone Min Res* 7 (Suppl), 358a, 1992.
134. Parisien M, Mellish RW, Schnitzer M, Nieves J, Cosman F, Recker RR, Kimmel D, Silverberg SJ, Shane E, Bilezikian JP, Lindsay R, Dempster DW: Cancellous bone structure in postmenopausal women: comparison among osteoporosis or primary hyperparathyroidism and normals. *J Bone Min Res* 7 (Suppl), 87a, 1992.
135. Parisien M, Mellish RW, Schnitzer M, Nieves J, Cosman F, Recker RR, Kimmel D, Silverberg SJ, Shane E, Bilezikian JP, Lindsay R, Dempster DW: Structural variables in postmenopausal women: comparison among normal women and patients with osteoporosis or primary hyperparathyroidism. (Proceedings of Morphometry Meeting, 6th International Congress, Lexington, Kentucky, 1992).
136. Vulliamoz Y, Shen H, Bilezikian JP: Muscarinic regulation of cAMP in cardiomyocytes from newborn rats. *FASEB J* 7:135A, 1993.
137. Warrell R, Mullane M, Bilezikian JP, Edelstein M, Mallette L, Stepanavage M, Averbuch S, and the Alendronate Hypercalcemia Group: Treatment of cancer-associated hypercalcemia with alendronate: a randomized double-blind comparison with etidronate. *Proc Amer Soc Clin Oncol* 12:438(A1514), 1993.

138. Parisien M, Schnitzer M, Nieves J, Mellish RWE, Silverberg SJ, Shane E, Recker R, Kimmel D, Cosman F, Bilezikian JP, Lindsay R, Dempster RW: Trabecular connectivity and bone turnover in three post menopausal states: osteoporosis, primary hyperparathyroidism and normal. In: Proc. Fourth International Symposium on Osteoporosis (FISO), (Christiansen C, Riis B, eds.), FISO, Rodovre, Denmark, 162-163, 1993.
139. Bilezikian JP, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Seibel MJ: Assessment and follow-up of bone turnover in asymptomatic primary hyperparathyroidism. *Calcified Tissue Int'l* 52:Suppl 1, 56, 1993.
140. Bilezikian JP: Management of asymptomatic primary hyperparathyroidism. 75th Annual Meeting of the Endocrine Society, S4, 1993.
141. Rohde SE, Bex FJ, Bilezikian JP: Differential actions of parathyroid hormone and parathyroid hormone-related peptide fragments on the adenylate cyclase and phosphoinositide signalling pathways in ROS 17/2.8 cells. *J Bone Min Res* 8:(Suppl I) 356a, 1993.
142. Silverberg SJ, Gartenberg F, McMahon D, Bilezikian JP: Parathyroidectomy improves bone density at cancellous sites in asymptomatic primary hyperparathyroidism. *J Bone Min Res* 8:(Suppl I) 212a, 1993.
143. Bilezikian JP: Primary Hyperparathyroidism in the 1990's. (Presented at the College of Physicians & Surgeons Alumni Day Scientific Session, May 14, 1994).
144. Rosen CJ, Hodsmann AM, Bilezikian JP: Effects of parathyroid hormone (PTH) on serum insulin-like growth factor-1 and insulin-like growth factor binding proteins. 76th Annual Meeting of the Endocrine Society, S1572, 1994.
145. Rosen CJ, Bing-you R, Silverberg SJ, Bilezikian JP: Enhancement of cancellous bone mass after parathyroidectomy is associated with changes in circulating insulin-like growth factor binding proteins. *J Bone Min Res* 9 (Suppl I): C424, 1994.
146. Silverberg SJ, Gartenberg F, Bilezikian JP: Usefulness of parathyroid hormone assays to reflect other features of primary hyperparathyroidism. *J Bone Min Res* 9 (Suppl I): A494, 1994.

147. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris ES, Bilezikian JP: Medical management of primary hyperparathyroidism in patients who do or do not fulfill criteria for parathyroid surgery. *J Bone Min Res* 9 (Suppl I): A492, 1994.
148. Morris SA, Chen H, Rohde S, Bex FJ, Bilezikian JP: Opposing influence of an antiresorbing agent OST-766 on adenylyl cyclase and phosphoinositide signalling is revealed by exposure to living cells. *J Bone Min Res* 9 (Suppl I): B41, 1994.
149. Ogino K, Burkhoff D, Bilezikian JP: Hemodynamic basis for cardiac effects of parathyroid hormone and parathyroid hormone-related protein. The Endocrine Society; 77th Annual Meeting, 102A, 1995.
150. Kleerekoper M, Bilezikian JP: Mortality of untreated primary hyperparathyroidism. *Am J Med (Letter)*, 99:577-578, 1995.
151. Staron RB, Greenspan R, Bilezikian JP, Miller TT, Shane E, Haramati N: Errors in computerized bone densitometric analysis: 40 months' experience. *American J Roentgenology* 164:286A, 1995.
152. Bilezikian JP: The use of estrogens as hormone replacement therapy in the U.S.A. (Presented at the E₂ International Workshop. Baden Bei Wien, Austria, 1995).
153. Hara M, Ogino K, Burkhoff D, Rosen MR, Bilezikian JP: Cardiac actions of parathyroid hormone-related protein: electrophysiological properties. *J Bone Min Res* 10 (Suppl I): T543, 1995.
154. Kurland ES, Bilezikian JP, Silverberg SJ, Vereault D, Rosen CJ: Serum IGF-1 levels are reduced in men with idiopathic osteoporosis. *J Bone Min Res* 10 (Suppl I): P256, 1995.
155. Ortiz O, Silverberg SJ, Katrandjian I, Savoia MT, Homma S, Bilezikian JP: Myocardial calcifications in asymptomatic primary hyperparathyroidism. *J Bone Min Res* 10 (Suppl I): T592, 1995.
156. Corbett JW, Morris SA, Kerr JS, Harlow PP, Wong PC, Bilezikian JP: Novel in vitro anti-absorptive agents, activity in signal transduction pathways associated with parathyroid hormone. *J Bone Min Res* 10 (Suppl I): T429, 1995.

157. Locker FG, Silverberg SJ, Bilezikian JP: Levels of 1,25-dihydroxyvitamin D in primary hyperparathyroidism may help to guide recommendations for dietary calcium intake. *J Bone Min Res* 10 (Suppl I): S599, 1995.
158. Dempster DW, Parisien M, Schnitzer M, Silverberg SJ, Shane E, Liang XG, Shen V, Lindsay R, Bilezikian JP: A longitudinal study of bone structure and turnover in patients with mild primary hyperparathyroidism who undergo parathyroidectomy or are managed medically. *J Bone Min Res* 10 (Suppl I): T604, 1995.
159. Silverberg SJ, Gartenberg F, Bilezikian JP: Reversal of lumbar spine osteopenia after parathyroidectomy in primary hyperparathyroidism. *J Bone Min Res* 10 (Suppl I): 59A, 1995.
160. Hara M, Liu YM, Cohen IS, Yu H, Danilo P, Ogino K, Bilezikian JP, Rosen MR: Parathyroid hormone and related peptide modulate impulse initiation and pacemaker current in heart. *Circulation* 92:8:I-639, 1995.
161. Bilezikian JP: New approaches to diseases of calcium metabolism. Presented at the 1st Annual Clinical Conference of the World Foundation for Medical Studies in Female Health, LaCosta, California, October 26-29, 1995.
162. Bilezikian JP: Optimal calcium intake. *J Amer Med Assoc* 274:1012-1013 (Letter), 1995.
163. Ortiz O, Silverberg SJ, Katrandjian I, Savoia MT, Homma S, Bilezikian JP: Myocardial calcifications in asymptomatic primary hyperparathyroidism. Presented at the Asian Federation of Endocrine Societies, Manila, December 8, 1995.
164. Bilezikian JP: Meeting Highlights. Asymptomatic Primary Hyperparathyroidism. *Endocrine News* 21:4-5, 1996.
165. Collins MT, Skarulis MC, Silverberg SJ, Bilezikian JP, Spiegel AM, Marx SJ: Successful treatment of refractory, parathyroid hormone-mediated hypercalcemia with the calcium-sensing receptor agonist NPS R-568. 10th International Congress of Endocrinology, 725A, 1996.
166. Bilezikian JP: Role of bone densitometry in the evaluation of asymptomatic primary hyperparathyroidism. *Calc. Tis. Int'l.* 226A, 1996.

167. Silverberg SJ, Thys-Jacobs S, Locker FG, Sanguinetti EL, Marriott TB, Bilezikian JP: The effect of the calcimimetic drug NPS R-568 on parathyroid hormone secretion in primary hyperparathyroidism. *J Bone Min Res* 11:(Supp I) 87A, 1996.
168. Thys-Jacobs S, Coromilas J, Shane E, Bilezikian JP: Profound vitamin D deficiency in a premenopausal woman with recurrent ventricular tachycardia of right bundle branch block-left axis deviation morphology. *J Bone Min Res* 11:(Supp I) S497A, 1996.
169. Locker FG, Silverberg SJ, Bilezikian JP: Influence of dietary calcium intake on bone mineral density & biochemical parameters in primary hyperparathyroidism. *J Bone Min Res* 11:(Supp I) T747A, 1996.
170. Dempster DW, Parisien M, Liang X-G, Schnitzer M, Shen V, Silverberg S, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP: Bone histomorphometry in postmenopausal women with primary hyperparathyroidism. *J Bone Min Res* 11:(Supp I) 16A, 1996.
171. Kurland ES, Chan F, Vereault D, Rosen CJ, Bilezikian JP: Growth hormone axis in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-1 (IGF-1). *J Bone Min Res* 11:(Supp I) M582A, 1996.
172. Dempster DW, Kurland ES, Cosman F, Schnitzer M, Parisien M, Chan F, Shane E, Rosen CJ, Lindsay R, Bilezikian JP: Bone histomorphometry in osteoporotic men with low circulating levels of insulin-like growth factor-1 (IGF-1). *J Bone Min Res* 11:(Supp I) M583A, 1996.
173. Bilezikian JP: Osteoporosis. *J Women's Health* 5:269, 1996.
174. Hara M, Danilo P, Ogino K, Bilezikian JP, Rosen MR: The effects of parathyroid hormone and parathyroid hormone-related peptide on sinoatrial node impulse initiation are attributable to an action on the pacemaker current, I_f . *Circulation* 94:2771A, 1996.
175. Bilezikian JP: Osteoporosis: New hope for the future. Presented at the Annual Conference of the World Foundation for Medical Studies in Female Health, San Antonio, Texas, October 25, 1996.

176. Bilezikian JP: Parathyroid hormone and renal osteodystrophy Presented at a symposium: Parathyroid Hormone and Osteoporosis, Buenos Aires, Argentina, August 7, 1996.
177. Bilezikian JP: Skeletal status in primary hyperparathyroidism Presented at a symposium: Parathyroid Hormone and Osteoporosis, Buenos Aires, Argentina, August, 7, 1996.
178. Silverberg SJ, Locker FG, Shane E, Jacobs TP, Siris ES, Bilezikian JP: The effect of the menopause on lumbar spine bone density in primary hyperparathyroidism. *J Bone Min Res* 11:(Supp I) T746A, 1996.
179. Silverberg SJ, Bilezikian JP: Evaluation and management of primary hyperparathyroidism. *J Clin Endocrinol Metab (Letter)* 82:983, 1997.
180. Thys-Jacobs S, Papadopoulos A, Rodino M, Donovan D, Bilezikian JP: Calcium regulating hormones in polycystic ovarian syndrome - evidence of calcium dysregulation and profound vitamin D deficiency. The Endocrine Society, 79th Annual Meeting, P1-343, 1997.
181. Thys-Jacobs S, Papadopoulos A, Morris S, Shane E, Bilezikian JP: Vitamin D deficiency in shock. The Endocrine Society, 79th Annual Meeting, P3-208, 1997.
182. Bilezikian JP: Medical therapy of primary hyperparathyroidism. The Endocrine Society, 79th Annual Meeting, S44-3, 1997.
183. Bilezikian JP: Primary hyperparathyroidism: modern views on an old disease *Folia Endocrinologica Japonica* 73:79, 1997.
184. Morishima A, Grumbach MM, Bilezikian JP: Estrogen markedly increases bone mass in an estrogen deficient young man with aromatase deficiency. *J Bone Min Res* 12:(Suppl I) 96A, 1997.
185. Thys-Jacobs S, Papadopoulos A, Donovan D, Bilezikian JP: Calcium regulating hormones in polycystic ovarian syndrome - evidence of calcium dysregulation and vitamin D deficiency. *J Bone Min Res* 12:(Suppl I) T467, 1997.

186. Silverberg SJ, Shane E, Locker FG, Parisien M, Dempster D, Bilezikian JP: Vitamin D deficiency may alter the clinical course of primary hyperparathyroidism. *J Bone Min Res* 12: (Suppl I) S679, 1997.
187. Silverberg SJ, Lowenfeld A, Perzin K, Jacobs TP, LoGerfo P, Bilezikian JP: Parathyroid cancer presents with a new phenotype in the 1990's. *J Bone Min Res* 12:(Suppl I), S678, 1997.
188. Silverberg SJ, Locker FG, Lane NC, Jacobs TP, Shane E, Siris ES, Bilezikian JP: Primary hyperparathyroidism: A ten year prospective experience in over 100 patients. *J Bone Min Res* 12:(Suppl I) P315A, 1997.
189. Boncimino K, Shane E, Addesso V, Bilezikian JP, Mancini D: Bone loss after cardiac transplantation: Relation to magnesium homeostasis. *J Bone Min Res* 12:(Suppl I) T497A, 1997.
190. Bilezikian JP, Silverberg SJ: Asymptomatic primary hyperparathyroidism: modern views on an old disease. (Presented at: Parathyroid Diseases: From the Gene to the Cure, Florence, Italy, September 1997).
191. Silverberg SJ, Bilezikian JP: The course of asymptomatic primary hyperparathyroidism. *J Bone Min Res* (Letter to the Editor) In Press, 1997.
192. Kurland ES, Rodino MA, Whyte MP, Reinus WR, Bilezikian JP: Axial osteomalacia versus fluorosis. *J Bone Min Res* 12:(Suppl I)S531A, 1997.
193. Bilezikian JP: Osteoporosis: Preventive strategies. World Foundation for Medical Studies in Female Health, 3rd Annual Conference (Key Biscayne, FL) October 23-26, 1997.
194. Bilezikian JP: Importance of estrogens in skeleton health of men and women. Presented at the 27th Annual Meeting of the Endocrine Society of India, Lucknow, India (December 17, 1997).
195. Bilezikian JP, Kulak CAM, Silverberg SJ: Evolution of primary hyperparathyroidism: a global perspective. Presented at the Meeting of the Indian Society for Bone and Mineral Research, Lucknow, India (December 16, 1997).

196. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism: to lose bone or not to lose. *J Bone Min Res* 2:2127-2128, 1997.
197. Rosen CJ, Beamer WG, Donahue LR, Baylink DJ, Rogers J, Turner CH, Bilezikian JP: IGF-I, muscle mass and bone density. Presented to the Committee on Body Composition, Nutrition and Health of Military Women, Food and Nutrition Board, National Academy of Sciences, Washington, D.C. (December 10, 1997).
198. Kurland E, Rackoff PJ, Adler RA, Bilezikian JP, Rogers J, Rosen CJ: Heritability of serum IGF-I and its relationship to bone density. The Endocrine Society, 80th Annual Meeting, OR36-1, 1998.
199. Thys-Jacobs S, Papadopoulos A, Donovan D, Bilezikian JP: Calcium regulating hormones in polycystic ovarian syndrome - evidence of calcium dysregulation and vitamin D deficiency. The Endocrine Society, 80th Annual Meeting, P1-357, 1998.
200. Shimoyama M, Ogino K, Taniguchi S, Yoshida A, Burkhoff D, Bilezikian JP, Shigemasa C, Hisatome I: Fragment-specific actions of parathyroid hormone in isolated, perfused rat hearts. The Endocrine Society, 80th Annual Meeting, P1-591, 1998.
201. Shimoyama M, Ogino K, Burkhoff D, Bilezikian JP, Hisatome I: Signal transduction pathways and the chronotropic actions of PTH in isolated rat hearts. The Endocrine Society, 80th Annual Meeting, P-592, 1998.
202. Kulak CAM, Schussheim DH, McMahon D, Silverberg SJ, Bilezikian JP, Shane E: Low bone mass in premenopausal women. The Endocrine Society, 80th Annual Meeting, P3-87, 1998.
203. Schussheim DH, Kulak CAM, McMahon D, Silverberg SJ, Bilezikian JP, Shane E: Etiology of low bone mass in young women. *Bone (Suppl 5)* 23:T282, 1998.
204. Silverberg SJ, Bilezikian JP: Youthfulness as a criterion for surgery in primary hyperparathyroidism. *Bone (Suppl 5)* 23:T354, 1998.
205. Silverberg SJ, Bilezikian JP: Non-intervention in patients who meet guidelines for surgery in primary hyperparathyroidism. *Bone (Suppl 5)* 23:T348, 1998.

206. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP: Parathyroid hormone (PTH 1-34) increases cancellous bone mass markedly in men with idiopathic osteoporosis. *Bone (Suppl 5)* 23:1039A, 1998.
207. Kurland ES, Cosman F, McMahon DJ, Shen V, Lindsay R, Rosen CJ, Bilezikian JP: Changes in bone markers predict bone accrual in osteoporotic men treated with parathyroid hormone. *Bone (Suppl 5)* 23:1040A, 1998.
208. Shimoyama M, Ogino K, Taniguchi S, Yoshida A, Hisatome I, Bilezikian JP, Shigemasa C: Signal transduction pathways and chronotropic actions of PTH and its fragments in isolated, perfused rat hearts. *Bone (Suppl 5)* 23: T197, 1998.
209. Kulak CAM, Bandeira C, Voss D, Sobieszczyk SM, Silverberg SJ, Bandeira F, Bilezikian JP: Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. (Letter to the Editor), *J Clin Endocrinol & Metab* 83:3761, 1998.
210. Gao H, Morris SA, Bilezikian JP: Cell passage specific properties of the PTH-sensitive adenylyl cyclase complex in SaOS.2 cells. *Bone (Suppl 5)* 23:T029, 1998.
211. Bilezikian JP: Low bone mass in men. 5th Annual Meeting of the International Society of Clinical Densitometry, New Orleans, p. 51, 1999.
212. Bilezikian JP: The role of estrogens in the skeletal health of men and women. 3rd Int'l Congress on Osteoporosis, Xi'an, China, p.27, 1999.
213. Schussheim DH, Kulak CAM, Rosen CJ, Kurland ES, McMahon D, Silverberg SJ, Bilezikian JP, Shane E: Serum insulin-like growth factor-1 is decreased in young women with idiopathic low bone mass or osteoporosis. Endocrine Society, 81st Annual Meeting, 93A (OR23-3), 1999.
214. Bilezikian JP: Management of hypercalcemia. 8th Annual National Kidney Foundation Clinical Nephrology Meetings, Washington, D.C., 123-125, 1999.
215. Bilezikian JP: Management of hypercalcemia. 8th Annual Meeting of the American Association of Clinical Endocrinologists, San Diego, CA, 133-135, 1999.
216. Bilezikian JP: Calcimimetics in the treatment of hyperparathyroidism. Endocrine Society, 81st Annual Meeting, 57A (S60-3), 1999.

217. Bilezikian JP: New advances in anabolic therapies for osteoporosis. Presented at the Endocrine Society 81st Annual Meeting, San Diego, CA, 1999.
218. Bilezikian JP: Primary hyperparathyroidism: new insights into its natural history and management. International Symposium on Thyroid and Parathyroid Tumors, March 24-27, 1999, 19A.
219. Gilsanz V, Rogers J, Bilezikian JP, Friez JK, Rosen CJ: A simple sequence repeat in the IGF-I gene and its relationship to serum IGF-I and peak bone mass in pubertal boys and girls. Endocrine Society, 81st Annual Meeting 93A (OR23-2), 1999.
220. Kurland E, Rackoff PJ, Pochenkova M, Spotila LD, Naylor J, Rogers J, Witte S, Adler RA, Bilezikian JP, Rosen CJ: IGF-I and bone mass in osteoporotic and healthy families: evidence for heritable determinants of the IGF-I phenotype and their relationship to bone. *J Bone Min Res* 14 (Suppl I) S331, 1999.
221. Bone H, Zizic T, Bilezikian JP, Sampson A, Bell N, Mulloy A, Applegate W, Lane N, Weinstein R, Maragoto A, Kaur A, Santora A: Effect of alendronate sodium on bone mineral density in postmenopausal osteoporotic black women of African-American descent. Endocrine Society, 81st Annual Meeting, 444A (P3-27), 1999.
222. Schussheim DH, Kulak CAM, Kurland E, Rosen CJ, Silverberg SJ, McMahon DJ, Siris ES, Bilezikian JP, Shane E: Decreased serum insulin-like growth factor-1 levels are associated with low bone mass in young women. *J Bone Min Res* 14 (Suppl I) S390, 1999.
223. Gao H, Bilezikian JP, Murrills R, Bodine PVN, Bex FJ, Morris SA: Mechanism of cell passage specific effects of pertussis toxin on PTH-sensitive adenylyl cyclase complex in SaOS-2 cells. *J Bone Min Res* 14 (Suppl I) S544, 1999.
224. Silverberg SJ, Bilezikian JP: Utility of NIH Consensus Conference Guidelines for surgery in asymptomatic primary hyperparathyroidism. *J Bone Min Res* 14 (Suppl I) S143, 1999.
225. Silverberg SJ, Brown I, Bilezikian JP: Seasonal variation in 25-hydroxyvitamin D in primary hyperparathyroidism. *J Bone Min Res* (Suppl I) S221, 1999.
226. Bilezikian JP: Gender and bone metabolism. (Presented at the Annual Conference on Gender-Specific Medicine, Orlando, Florida, September, 1999).

227. Bilezikian JP, Zapalowski C, Kulak CAM, Rosen C, Miller PD: Recent concepts in bone densitometry. *Osteologia* 2:79, 1999.
228. Kulak CAM, Bilezikian JP: Bisphosphonates: characteristics and use in osteoporosis. *Osteologia* 2:81-82, 1999.
229. Bilezikian JP: Osteoporosis in men. *Osteologia* 2:80, 1999.
230. Bilezikian JP: The use of anabolic agents in the treatment of osteoporosis. *Osteologia* 2:80-81, 1999.
231. Bilezikian JP: Primary hyperparathyroidism: new insights into its natural history and management. *Osteologia* 2:78, 1999.
232. Bilezikian JP, Meng X, Shi Y, Silverberg SJ: Primary hyperparathyroidism in women: New York and Beijing (A Tale of Two Cities). (Presented at the World Foundation for Medical Studies in Female Health, 5th Annual Clinical Conference, San Francisco, CA, October, 1999).
233. Bilezikian JP: The role of estrogens in the skeletal health of men and women. (Presented at the 10th Annual Meeting, North American Menopause Society, New York, September, 1999).
234. Dempster DW, Cosman F, Kurland ES, Nieves J, Woelfert L, Shane E, Lindsay R, Bilezikian JP: Histomorphometric analysis of paired biopsies from osteoporotic subjects before and after treatment with parathyroid hormone. *J Bone Miner Res* 15:825, 2000.
235. Tohme JF, Bilezikian JP, Sutherland B, Rodino MA: Treatment of osteoporosis with cyclic intravenous pamidronate. *J Bone Min Res* 14 (Suppl I) S278, 1999.
236. Bone H, Zizic T, Bilezikian JP, Sampson A, Bell N, Mulloy A, Applegate W, Lane N, Weinstein R, Maragoto A: Effect of alendronate sodium on bone mineral density in postmenopausal osteoporotic black women of African-American descent. *J Bone Min Res* 14 (Suppl I) S278, 1999.
237. Bilezikian JP: The use of antiresorptive and anabolic agents in the therapy of osteoporosis. (Winter Symposium of the Texas Academy of Family Physicians, Aspen, Colorado, January, 2000).

238. Bilezikian JP: Osteoporosis. Partnership in Women's Health Programs in Medicine, 1/00.
239. Bilezikian JP: Secondary osteoporosis. Third Conference on Osteoporosis, Southern Medical Association, Amelia Island, Florida, 2/20/00.
240. Bilezikian JP: Osteoporosis in men. Third Conference on Osteoporosis, Southern Medical Association, Amelia island, Florida, 2/20/00.
241. Bilezikian JP: Primary hyperparathyroidism: new insights into its natural history and management. Critical Issues in Endocrinology and Metabolism for the New Millennium, Methodist Healthcare and Baptist Hospital, Nashville, TN (Presented in Kauai, HI 3/00).
242. Bilezikian JP: Epidemiology and treatment of osteoporosis. Critical Issues in Endocrinology and Metabolism for the New Millennium, Methodist Healthcare and Baptist Hospital, Nashville, TN (Presented in Kauai, HI, 3/00).
243. Bilezikian JP: Hormone replacement therapy: a workshop. Critical Issues in Endocrinology and Metabolism for the New Millennium, Methodist Healthcare and Baptist Hospital, Nashville, TN (Presented in Kauai, HI, 3/00).
244. Bilezikian JP: Osteoporosis Treatment: Overview. NIH Consensus Development Conference, Osteoporosis Prevention, Diagnosis and Therapy, 3/00.
245. Bilezikian JP: Primary hyperparathyroidism: new insights into its natural history and management. In: Endocrinology and Metabolism: An Update for the Primary Physician, Johns Hopkins University (Presented at the Renaissance Harborplace Hotel, 3/00).
246. Bilezikian JP: Long-term follow-up of primary hyperparathyroidism: implications for clinical management. (Presented at the 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, 6/00).
247. Shoback D, Bilezikian JP, Binder TA, Graves T, Turner SA, Peacock M: Calcimimetic AMG073 normalizes total serum calcium in patients with primary hyperparathyroidism. J Bone Min Res 15 (Suppl I) S210, 2000.

248. Dempster DW, Cosman F, Kurland ES, Miller R, Nieves J, Woelfert L, Shane E, Plavetic K, Bilezikian JP, Lindsay R: Two and three-dimensional structural analysis of paired biopsies from osteoporotic patients before and after treatment with parathyroid hormone. *J Bone Min Res* 15 (Suppl I) S194, 2000.
249. Kurland ES, Cosman F, Rosen CJ, Lindsay R, Bilezikian JP: Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoporosis in men: Changes in bone mineral density, bone markers, and optimal duration of therapy. *J Bone Min Res* 15 (Suppl I) S230, 2000.
250. Gao H, Ho AY, Bilezikian JP, Morris SA: The effects of pertussis toxin (PT) on PTH[1-34] and forskolin-dependent adenylyl cyclase activity (ACA) in SaOS-2 cells: a role for protein kinase C (PKC). *J Bone Min Res* 15 (Suppl I) S505, 2000.
251. Silverberg SJ, Brown IN, Bilezikian JP, Deftos LJ: A new highly sensitive assay for parathyroid hormone in primary hyperparathyroidism. *J Bone Min Res* 15 (Suppl I) S167, 2000.
252. Kurland ES, Seltzer B, Kulak CAM, Schussheim D, Shane E, Rogers J, Bilezikian JP, Rosen CJ: Gender specific effects of an IGF-1 gene polymorphism on bone density and serum IGF-1 in relatives of men with idiopathic osteoporosis. *J Bone Min Res* 15 (Suppl I) S361, 2000.
253. Bilezikian JP: The role of androgens and estrogens in male skeletal health. Presented at the 10th Annual Scientific Meeting of the Australian and New Zealand Bone and Mineral Society, Hamilton Island, Australia, November 5, 2000.
254. Bilezikian JP: The role of estrogens in male and female skeletal health. *Osteologica* 3:243, 2000.
255. Bilezikian JP: Primary hyperparathyroidism: new insights into its natural history and management. *Osteologica* 3:261, 2000.
256. Bilezikian JP: Medical management of primary hyperparathyroidism. Presented at the V Congreso SIBOMM, Buenos Aires, Argentina, November 29 – December 1, 2000.
257. Bilezikian JP: Bone densitometry in men. Presented at the V Congreso SIBOMM, Buenos Aires, Argentina, November 29 – December 1, 2000.

258. Bilezikian JP: Rationale and adjunctive use of bone markers with bone mass measurements in evaluating and monitoring osteoporosis. Presented at the 11th Annual Meeting of the North American Menopause Society, September 7, 2000.
259. Bilezikian JP: Therapies for postmenopausal osteoporosis: what's new; what's next? Presented at the 11th Annual Meeting of the North American Menopause Society, September 7, 2000.
260. Bilezikian JP, Kurland ES: Parathyroid hormone as a therapy for osteoporosis in men. Presented at the 1st International Conference on Osteoporosis in Men. Siena, Italy, 2/22-2/24/01.
261. Bilezikian JP: Glucocorticoid-induced osteoporosis in the male. 2nd International Congress on Glucocorticoid-induced Osteoporosis, Mantova, Italy, 4/19-4/21/01. Abs. p. 10.
262. Bilezikian JP: New horizons for osteoporosis therapy: the potential of parathyroid hormone. Endocrine Society 83rd Annual Meeting, Denver, Colorado, 6/22/01, p. 20, 2001.
263. Bilezikian JP: Well into the new millennium. J Clin Endocrinol Metab 86:1-2, 2001.
264. Bilezikian JP: Parathyroid hormone: an anabolic therapy for osteoporosis. Presented at the Osteoporosis Society of Canada Meeting, Niagara Falls, 5/11/01.
265. Bilezikian JP: Osteoporosis in men. Presented at the Osteoporosis Society of Canada Meeting, Niagara Falls, 5/11/01.
266. Bilezikian JP: Alendronate: update on clinical use and efficacy. Presented at the Osteoporosis Society of Canada Meeting, Niagara Falls, 5/11/01.
267. Roschger P, Grabner BM, Messer P, Dempster DW, Cosman F, Nieves J, Lindsay R, Bilezikian JP, Kurland ES, Shane E, Fratzl P, Klaushofer K: Influence of intermittent PTH treatment on mineral distribution in the human ilium: a paired biopsy study before and after treatment. J Bone Min Res 16 (Suppl I) S179, 2001.

268. Cohen A, LoGerfo P, Gao P, Brown IB, Trokan S, Cantor T, Bilezikian JP, Silverberg SJ: PTH(1-84) and N-truncated PTH fragment in the serum and parathyroid glands of patients with primary hyperparathyroidism. *J Bone Min Res* 16 (Suppl I) S156, 2001.
269. Morris SA, Sun Q, Dworakowski E, Bilezikian JP: PTH-mediated receptor desensitization: kinetics and properties are influenced by peptide size. *J Bone Min Res* 16 (Suppl I) S308, 2001.
270. Kahn AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Motagally Z, Rubin M, Silverberg SJ, Standish TIM, Syed ZA: A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism. *J Bone Min Res* 16 (Suppl I) S226, 2001.
271. Black D, Rosen C, Greenspan S, Ensrud KE, Bilezikian JP, McGowan JA: PTH and bisphosphonates in the treatment of osteoporosis: design of the PTH and alendronate (PATH) Trial. *J Bone Min Res* 16(Suppl I) S287, 2001.
272. Schussheim DH, Rubin MR, Kulak CAM, Kurland ES, Rosen CJ, Silverberg SJ, Bilezikian JP, Shane E: Low bone mineral density is associated with low serum insulin-like growth factor-1 in perimenopausal but not in premenopausal women. *J Bone Min Res* 16 (Suppl I) S276, 2001.
273. Kurland ES, Heller SL, Cosman F, Diamond B, Lindsay R, Bilezikian JP: The post-PTH experience in men with idiopathic osteoporosis: bisphosphonates vs. non-pharmacologic therapy. *J Bone Min Res* 16 (Suppl I) S219, 2001.
274. Black DM, Rosen C, Greenspan S, Ensrud K, Bilezikian JP, McGowan J: Alendronate (PaTH) Trial. (Submitted for Presentation at the American College of Rheumatology Meeting, San Francisco, CA, 11/01/01).
275. Bilezikian JP: Hypercalcemia associated with cancer and other etiologies. *J Bone Min Metab* 19(Suppl) p. 84, 2001.
276. Bilezikian JP: New approaches to the therapy of osteoporosis: the potential of anabolic agents. (Annual Global Investigator and Study Coordinator Meeting, Seattle, WA, 9/14/01).

277. Bilezikian JP: An anabolic therapy for osteoporosis: the newest “hot topic”. (Presented at the Mid-Atlantic Osteoporosis Conference, Jefferson Medical College, 9/22/01).
278. Bilezikian JP: Osteoporosis horizons: what’s new; what’s next? (Presented at the New Concepts in Post-Menopausal Health Conference, New York, 10/20/01).
279. Bilezikian JP: The role of parathyroid hormone in the pathogenesis and treatment of osteoporosis. *Hong Kong Med J* 7(Suppl 2); 8: 2001.
280. Bilezikian JP: The potential of parathyroid hormone as a therapy for osteoporosis. (Presented at the World Foundation for Medical Studies in Female Health 2001 Annual Clinical Conference, New York, 12/19/01).
281. Bilezikian JP: Osteoporosis and osteopenia in premenopausal women. (Presented at the ASBMR, 23rd Annual Meeting, Phoenix, AZ, Meet the Professor Session, 10/13/01).
282. Bilezikian JP: Parathyroid hormone: a new option for the treatment of osteoporosis. (Presented at the ASBMR, 23rd Annual Meeting, Phoenix, AZ, Satellite Symposium, 10/14/01).
283. Bilezikian JP: PTH(1-34) in the treatment of osteoporosis: a review of the evidence. (Presented at the Annual Meeting of the American College of Rheumatology, 11/13/01).
284. Bilezikian JP: Osteoporosis Update. (Presented at the Annual Meeting of the American Association of Clinical Endocrinologists, Chicago, IL, 5/4/02).
285. Bilezikian JP, Potts JT, Jr.: Asymptomatic primary hyperparathyroidism: A perspective for the 21st century. (Presented at the NIH Workshop on Primary Hyperparathyroidism, Bethesda, MD, April 8-9, 2002).
286. Bilezikian JP: Primary hyperparathyroidism: a new time for new views. *Endocrine Society’s 84th Annual Meeting*, San Francisco, CA, S17.2, p 31, 2002.
287. Bilezikian JP: Primary hyperparathyroidism: new views for the new millennium. (Presented at the Endocrine Society’s 84th Annual Meeting, San Francisco, CA, Meet the Professor, June 21, 2002).

288. Dempster DW, Caldwell NJ, Goldstein SA, Parisien M, Silverberg SJ, Shane E, Fitzpatrick LA, Lindsay R, Bilezikian JP: Three dimensional assessment of trabecular architecture in mild primary hyperparathyroidism (PHPT). *J Bone Min Res* 17 (Suppl I) S166, 2002.
289. Mulder JE, Sklar CA, Klibanski A, Bilezikian JP: Estrogen in the establishment of peak bone mass. *J Bone Min Res* 17 (Suppl I) S481, 2002.
290. Opotowsky AR, Bilezikian JP: Racial differences in the effect of early milk consumption on postmenopausal bone mineral density. *J Bone Min Res* 17 (Suppl I) S354, 2002.
291. Katz RW, Sun Q, Dworakowski E, Morris S, Bilezikian JP: PTH analogues can be defined by their properties of signal transduction and desensitization. *J Bone Min Res* 17 (Suppl I) S391, 2002.
292. Sun Q, Katz RW, Bilezikian JP: Modulation of parathyroid hormone dependent activation of phospholipase C. *J Bone Min Res* 17 (Suppl I) S285, 2002.
293. Silverberg SJ, Bilezikian JP: "Incipient" of primary hyperparathyroidism: A "Forme Fruste" of an old disease. *J Bone Min Res* 17 (Suppl I) S165, 2002.
294. Rubin MR, Silverberg SJ, LiVolsi VL, Bennett B, Jacobs TP, Bilezikian JP: Atypical adenoma: a new form of parathyroid neoplasia. *J Bone Min Res* 17 (Suppl I) S381, 2002.
295. Black DM, Rosen CM, Greenspan S, Ensrud K, Bilezikian JP, Hue T, McGowan J: Parathyroid hormone (PTH) and alendronate in the treatment of osteoporosis: PTH and Alendronate (PaTH) Trial Update. *J Bone Min Res* 17 (Suppl I) S379, 2002.
296. Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Motagally Z, Rubin M, Silverberg SJ, Standish TIM, Syed ZA: A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism. *J Bone Min Res* 17 (Suppl I) S165, 2002.
297. Rubin MR, Maurer MS, Diamond BE, Coffin LEK, Bilezikian JP, Silverberg SJ: Vascular stiffness is increased in patients with primary hyperparathyroidism. *J Bone Min Res* 17 (Suppl I) S381, 2002.

298. Bilezikian JP: Male osteoporosis. (Presented at Loyola University Medical Center, Stritch School of Medicine Osteoporosis Symposium, June, 2002).
299. Bilezikian JP: Anabolic agents for osteoporosis. (Presented at Loyola University Medical Center, Stritch School of Medicine Osteoporosis Symposium, June, 2002).
300. Bilezikian JP: Historia natural del hiperparatiroidismo primario primary hyperparathyroidism: The natural history of primary hyperparathyroidism. (Presented at the X Chilean Osteology and Mineral Society Annual Meeting, Santiago, Chile, August, 2002).
301. Bilezikian JP: Nuevos horizontes en el tratamiento de la osteoporosis: hormona paratiroidea: New horizons in osteoporosis treatment: parathyroid hormone. (Presented at the X Chilean Osteology and Mineral Society Annual Meeting, Santiago, Chile, August, 2002).
302. Bilezikian JP: What's new in 2002 for the therapy of osteoporosis. (Presented at the Professional Education Symposium: New York Chapter of the Arthritis Foundation, June, 2002).
303. Peacock M, Bilezikian JP, Turner SA, Guo MD, McCary LC, Koenig KG, Shoback DM: Long-term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism (PHPT). Endocrine Society, 84th Annual Meeting, OR21-2 p. 92 (abs), 2002.
304. Bilezikian JP: Opportunities for the future: rebuilding bone, not just stopping the rot. Australia and New Zealand Bone and Mineral Society 12th Annual Scientific Meeting, October, 2002, 36A.
305. Bilezikian JP: Parathyroid hormone: a new horizon in the therapy of osteoporosis. Australia and New Zealand Bone and Mineral Society 12th Annual Scientific Meeting, October, 2002, 29A.
306. Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, Kinugawa T, Osaki S, Kato M, Tomikura Y, Bilezikian JP: Parathyroid hormone-related protein, a new mechano-sensitive regulatory molecule is produced in the myocardium and increased in patients with congestive heart failure. (To be Presented at the AHA Scientific Sessions, Chicago, IL, November, 2002).

307. Bilezikian JP: Guidelines of the International Society of Clinical Densitometry for measurements of bone mineral density. (Presented at the 25th Brazilian Congress of Endocrinology and Metabolism, Brasilia, Brazil, September, 2002).
308. Bilezikian JP: Primary hyperparathyroidism: New guidelines. (Presented at the 25th Brazilian Congress of Endocrinology and Metabolism, Brasilia, Brazil, September, 2002).
309. Bilezikian JP: Male osteoporosis: The role of estrogen. (Presented at the 25th Brazilian Congress of Endocrinology and Metabolism, Brasilia, Brazil, September, 2002).
310. Bilezikian JP: Parathyroid hormone: An anabolic therapy for osteoporosis. (Presented at the 25th Brazilian Congress of Endocrinology and Metabolism, Brasilia, Brazil, September, 2002).
311. Fleischer J, Becker C, Bilezikian JP: Bone density in severe primary hyperparathyroidism in a premenopausal woman. (Presented at the Annual Meeting of the International Society for Clinical Densitometry, Los Angeles, CA, 2/12-2/15/03).
312. Bilezikian JP, Silverberg SJ: Bone density in “incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. (Presented at the Annual Meeting of the International Society for Clinical Densitometry, Los Angeles, CA, 2/12-2/15/03).
313. Bilezikian JP: When should an OB/GYN refer for specialty care? (Presented at Symposium: Diagnosis and Management post WHI, New York, 11/24/02).
314. Bilezikian JP: New guidelines for the management of asymptomatic primary hyperparathyroidism. (6th European Congress of Endocrinology, Lyon, France, April, 2003).
315. Bilezikian JP, Rubin MR: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis. (Presented at the 3rd International Congress, Glucocorticoid–induced Osteoporosis, Turin, Italy, 3/6-3/8/03).
316. Bilezikian JP: Therapy of osteoporosis: new horizons. (Presented at the New Insights and Controversies in Post-Menopausal Health Seminar, Columbia University, New York, 1/25/03).

317. Silverberg SJ, Shane E, De La Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezikian JP: Skeletal disease in primary hyperparathyroidism. *J Bone Min Res* 1989;4:283-291. Commentary on occasion of its designation as a seminal paper, 2003.
318. Opotowsky AR, Bilezikian JP: Serum vitamin A and hip fractures: increased risk at both ends of the concentration curve. *Endocrine Society 85th Annual Meeting*, OR 21-3, p.83 (abs), 2003.
319. Bilezikian JP: Parathyroid hormone and male osteoporosis. *Osteoporosis Int.* 14(Suppl 1), 515, 2003.
320. Bilezikian JP: Male osteoporosis. (Presented at the International Conference on Osteoporosis and Bone Research, Beijing, China, 5/23-5/27/03).
321. Bilezikian JP, Potts Jr. JT: Bisphosphonate therapy in primary hyperparathyroidism. Letter to the Editor. *J Bone Min Res* 18:1890, 2003.
322. Black DM, Ensrud K, Greenspan S, Bilezikian JP, McGowan J, Lang T, Garnero P, Rosen C: The effects of PTH, alendronate alone or in combination on bone mass and turnover: 12 month results of the PaTH study trial. *J Bone Min Res* 18 (Suppl 2) S3, 2003.
323. Rubin M, Sliney J, McCary LC, Silverberg SJ, Bilezikian JP: Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCl in patients with parathyroid carcinoma. *J Bone Min Res* 18 (Suppl 2) S392, 2003.
324. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, McGowan JA, Palermo L, Black DM: Effect of PTH, alendronate or PTH plus alendronate on biochemical markers of bone turnover: one year results of the PaTH study. *J Bone Min Res* 18 (Suppl 2) S31, 2003.
325. Sun Q, Katz RW, Bilezikian JP: The role of calcium channels and a competent IP3 receptor complex for the expression of PTH-dependent phospholipase C activity. *J Bone Min Res* 18 (Suppl 2) S290, 2003.
326. Sun Q, Katz RW, Bilezikian JP: Down-regulation of parathyroid hormone in EW29 cells requires PKC but not PKA function. *J Bone Min Res* 18 (Suppl 2) S291, 2003.

327. Bilezikian JP: Primary Hyperparathyroidism. (Presented at the Endocrine Society Annual Meeting, Meet the Professor, Philadelphia, PA, 6/03).
328. Sun Q, Katz RW, Morris SA, Bilezikian JP: Bisphosphonates affect signaling pathways utilized by teriparatide [rhPTH(1-34)]. *J Bone Min Res* 18 (Suppl 2) S230, 2003.
329. Donovan MA, Opotowsky AR, Babbar RB, Rohira AL, Della Badia M, Liu G, Bilezikian JP: Osteoporosis in Chinese-American women: risk factors for fracture and development of a database for bone densitometry. *J Bone Min Res* 18 (Suppl 2) S116, 2003.
330. Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, McCary LC, Olson KA, Turner SA, Peacock M: The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. *J Bone Min Res* 18 (Suppl 2) S171, 2003.
331. Bilezikian JP: Osteoporosis (Preface). *Endocrinol Metab Clin N Am* 32:6-7, 2003.
332. Opotowsky AR, Bilezikian JP: Hip fracture risk is increased in men at both high and low levels of serum vitamin A. *J Bone Min Res* 18 (Suppl 2) S51, 2003.
333. Rubin M, Gao P, Cantor T, Bilezikian JP, Silverberg SJ: Parathyroid hormone is modified in parathyroid carcinoma: a novel N-terminally intact hormone with different immunoreactivity from PTH (1-84). *J Bone Min Res* 18 (Suppl 2) S393, 2003.
334. Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Shaikh A, Rubin M, Silverberg SJ, Standish TI, Syed ZA: A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism. *J Bone Min Res* 18 (Suppl 2) S98, 2003.
335. Kurland ES, Khosla S, Colvin TL, Heller SL, Powell J, Seltzer B, McMahon D, Bilezikian JP: The relative roles of the sex steroids in idiopathic osteoporosis in men. *J Bone Min Res* 18 (Suppl 2) S88, 2003.
336. Bilezikian JP: Diseases of bone. Surgeon General's Report on Osteoporosis and Bone Health (Submitted), Primary Hyperparathyroidism, 2003.

337. Bilezikian JP: Primary hyperparathyroidism. *Endocrinologia & Metabologia* 47 (Suppl I) S247-250, 2003.
338. Bilezikian JP: Male osteoporosis. *Endocrinologia & Metabologia* 47 (Suppl I) S245-246, 2003.
339. Bilezikian JP: Anabolic therapy for osteoporosis. *Endocrinologia & Metabologia* 47 (Suppl I) S241-244, 2003.
340. Bilezikian JP, Potts JT, Jr: Alendronate in primary hyperparathyroidism. *JBMR (Letter)*, 2003.
341. Bilezikian JP: Anabolic therapy for osteoporosis. (Presented at "The-State-of-the-Art in the Management of Osteoporosis". Office of Women's Health of US DHHS, July 27-29, 2003).
342. Cantor T, Rubin MR, Bilezikian JP, Gao P, Silverberg SJ: A novel form of parathyroid hormone found in parathyroid carcinoma with a preserved N terminus. *Am Soc Nephrol*, 2003.
343. Bilezikian JP: Clinical importance of bone quality. (Presented at the ASBMR 25th Annual Meeting, Minneapolis, MN, 9/20/03).
344. Bilezikian JP: The importance of bone quality in the overall assessment of bone strength. (International Conference on Osteoporosis and Bone Research, Symposium, Beijing, China, October 12, 2003).
345. Bilezikian JP: Primary Hyperparathyroidism. (Presented at the ASBMR 25th Annual Meeting, Meet the Professor, Minneapolis, MN, 9/21/03).
346. Bilezikian JP: Introduction to Calcium Section of Gender-Specific Medicine (M. Legato, Editor; J.P. Bilezikian, Section Editor) Elsevier, 2003.
347. Bilezikian JP: How therapy for osteoporosis reduces fracture incidence: the clinical importance of bone quality. (For Presentation: New Insights and Controversies in Post-Menopausal Health. College of Physicians & Surgeons, New York, 11/1/03).

348. Donovan M, Opotowsky A, Babbar R, Rohira A, Nabizadeh F, Della Badia M, Liu G, Bilezikian JP: Osteoporosis in Chinese-American women: risk factors for fracture and development of a bone densitometry database. (Presented at the ISCD 10th Annual Meeting, Miami, FL, 1/04, B-7 Abs #31).
349. Black DM, Bilezikian JP, Rosen CJ: PTH and alendronate in osteoporosis. *N Eng J Med (Letter)* 350:2, p191, January, 2004.
350. Bilezikian JP: Recombinant human PTH and bisphosphonate: which comes first? (Presented at Clinical Diabetes and Endocrinology in 2004, Aspen/Snowmass, CO, 1/04).
351. Bilezikian JP: Primary hyperparathyroidism: New concepts; new insights; new guidelines. (Presented at Clinical Diabetes and Endocrinology in 2004, Aspen/Snowmass, CO, 1/04).
352. Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Shaikh A, Rubin M, Silverberg SJ, Standish TI, Syed ZA: A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism. (Presented at the ISCD Annual Meeting, Miami, 2/04.)
353. Bilezikian JP: Treatment of osteoporosis: new concepts in defining therapeutic effects. (Presented at Mayo Clinic Conference: Hormone Therapy in Menopause; Uses and Conflicts, Cancun, Mexico 2/04).
354. Bilezikian JP, Geusens P, Rizzoli R, Santora AC, Thompson DE, Ross PD: Larger reductions in bone turnover and lower fracture risk – is there a plateau? *Endocrine Society 86th Annual Meeting, New Orleans, LA, June 2004 p.436 (Ab#521).*
355. Donovan M, Opotowsky S, Babbar R, Rohira A, Nabizadeh F, Della Badia M, McMahon D, Liu G, Bilezikian JP: Osteoporosis in Chinese American women: risk factors for fracture and development of a bone densitometry database. *Endocrine Society 86th Annual Meeting, New Orleans, LA, June 2004 p. 438 (Ab#528).*
356. Bilezikian JP: Beyond BMD: Understanding the link between bone quality and fracture risk. (AACE Symposium, Boston, MA, 4/30/04).
357. Bilezikian JP: Vexing problems in patients with metabolic bone disorders. (AACE Workshop, Boston, MA, 5/01/04).

358. Bilezikian JP: Primary hyperparathyroidism: Current guidelines for treatment and natural history of treated and untreated disease. (Presented at the Head and Neck Reconstruction and the Contemporary Management of Thyroid and Parathyroid Disease Course, New York, 3/20/04).
359. Bilezikian JP: Therapy of osteoporosis: How fracture incidence is reduced. (Presented at the 5th Cincinnati Bone Day, 4/02/04).
360. Bilezikian JP: Osteoporosis in Men: Androgens and other anabolic agents. (Presented at the American Society of Andrology 29th Annual Meeting, Baltimore, MD, 4/17/04).
361. Bilezikian JP: Primary hyperparathyroidism: New insights, new concepts. (Meet-the-Professor, 86th Annual Meeting of the Endocrine Society, New Orleans, LA, 6/17/04).
362. Rubin MR, Birken S, Bilezikian JP, Silverberg SJ: Human chorionic gonadotropin: a potential tumor marker for parathyroid carcinoma. *J Bone Min Res* 19 (Suppl 1) S326, 2004).
363. Rubin MR, D'Amour P, Brossard JH, Cantor T, Bilezikian JP, Silverberg SJ: A molecular form of PTH distinct from PTH(1-84) is produced in parathyroid carcinoma. *J Bone Min Res* 19 (Suppl 1) S327, 2004).
364. Rubin MR, Sliney J, Silverberg SJ, Bilezikian JP: Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCl. *J Bone Min Res* 19 (Suppl 1) S103, 2004).
365. Peacock M, Bilezikian JP, Scumpia S, Bolognese MA, Borofsky MA, Turner SA, Guo MD, McCary LC, Shoback DM: Cinacalcet HCl is an effective therapy for the hypercalcemia of primary hyperparathyroidism across a broad range of patients. *J Bone Min Res* 19 (Suppl 1) S52, 2004).
366. Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, Smallridge R, Schwanauer LE, Olson KA, Turner SA, Peacock M: Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma. *J Bone Min Res* 19 (Suppl 1) S103, 2004).
367. Mulder JE, Sklar CA, Mertens AC, Robison LL, Diller L, Klibanski A, Bilezikian JP: Estrogen in the establishment of peak bone mass among childhood cancer survivors. *J Bone Min Res* 19 (Suppl 1) S225, 2004.

368. Black DM, Rosen CJ, Palermo L, Hue T, Ensrud KE, Greenspan SL, Lang TF, McGowan JA, Bilezikian JP: The effect of 1 year of alendronate following 1 year of PTH 1-84: second year results from the PTH and alendronate (PaTH) trial. *J Bone Min Res* 19 (Suppl 1) S26, 2004.
369. Sellmeyer DE, Palermo L, Bouxsein ML, Bilezikian JP, Greenspan S, Ensrud K, Black DM, Rosen CJ: Heterogeneity in skeletal response to full-length parathyroid hormone (PTH). *J Bone Min Res* 19 (Suppl 1) S96, 2004).
370. Donovan MA, Opotowsky A, Babbar R, Nabizadeh F, Della Badia M, McMahon D, Liu G, Bilezikian JP: Osteoporosis in Chinese American women: development of a bone densitometry database. *J Bone Min Res* 19 (Suppl 1) S230, 2004).
371. Katz RW, Sun Q, Bilezikian JP: Bisphosphonates differentially affect osteoblast survival in-vitro. *J Bone Min Res* 19 (Suppl 1) S405, 2004.
372. Sun Q, Katz RW, Morris SA, Fan X, Bilezikian JP: Bisphosphonates affect osteoblast (UMR-106) GTPase activity. *J Bone Min Res* 19 (Suppl 1) S275, 2004.
373. Sun Q, Katz RW, Fan X, Bilezikian JP: Mechanism of concanavalin A on PTH receptor down-regulation on cell membrane. *J Bone Min Res* 19 (Suppl 1) S477, 2004).
374. Zhou H, Dempster DW, Lindsay R, Silverberg SJ, Bilezikian JP: Apoptosis of osteoblasts is increased in patients with mild primary hyperparathyroidism and preserved cancellous bone. *J Bone Min Res* 19 (Suppl 1) 186, 2004).
375. Paz-Filho GJ, Kulak CAM, Kaminski J, Radominski SC, Bilezikian JP, Borba VZC: One-year follow up of 27 patients with osteoporosis treated with a single intravenous dose of Zoledronate. *J Bone Min Res* 19 (Suppl 1) 443, 2004).
376. Bilezikian JP, Brandi ML, Rubin MR, Silverberg SJ: New concepts in clinical densitometric and biochemical features of primary hyperparathyroidism. *J Int Med* 255:700 (Abs), 2004.
377. Kulak CAM, Borba VZC, Bilezikian JP, Silvado CE, de Paola L, Boguszewski CL: Bone mineral density and serum levels of 25-OH vitamin D in chronic users of antiepileptic drugs. *Osteoporosis Int* 15 (Suppl 1) S279, 2004.

378. Reddy J, Mosca L, Smith SJ, Paultre F, Bilezikian JP: Is low bone mineral density associated with breast arterial calcifications, a potential marker of subclinical CHD? (Submitted for Presentation, Am Heart Assoc, 2004).
379. Bilezikian JP: Teriparatide: A bone formation therapy that reverses the progression of osteoporosis. (Presented at Osteoporosis Symposium: The New Horizon, Hong Kong, 5/22-5/23/04).
380. Bilezikian JP: Primary hyperparathyroidism: New insights, new concepts (Presented at Osteoporosis Symposium: The New Horizon, Hong Kong, 5/22-5/23/04).
381. Bilezikian JP: Is there a role for anabolic agents in prevention and treatment of osteoporosis? (Presented at the Annual Meeting of the World Foundation for Studies in Female Health, Chicago, IL, 12/10/04).
382. Bilezikian JP: Parathyroid hormone: paradoxes and possibilities. (Presented at the New England Bone Club, Prout's Neck, Maine, October 28, 2004).
383. Bilezikian JP: Clinical utility of bone markers. (Presented at the 26th Endocrinology and Metabolism Brazilian Congress, Florianopolis, Brazil, 11/8/04).
384. Bilezikian JP: Bone stimulating factors and osteoporosis. (Presented at the ISCD Annual Meeting, New Orleans, February, 2005).
385. Bilezikian JP: Not just for women: the challenge of bone density in men. (Presented at the ISCD Annual Meeting, New Orleans, February, 2005).
386. Bilezikian JP: Parathyroid hormone and male osteoporosis. (Presented at the III International Conference on Osteoporosis in Men, Genova Palazzo Ducale, 5/12-5/14/05).
387. Bilezikian JP: Natural history and medical aspects of primary hyperparathyroidism. (Presented at the AACE Annual Meeting, May, 2005).
388. Bilezikian JP: Bisphosphonates for primary hyperparathyroidism. (Presented at the 87th Annual Meeting of the Endocrine Society, San Diego, CA, June 2005).

389. Bilezikian JP: Medical approaches to primary hyperparathyroidism. (Annual Meeting of the Bone and Tooth Society, Birmingham, England, July 2005).
390. Lewiecki EM, Miller PD, Leib ES, Bilezikian JP: Letter to the Editor, *J Clin Densitometry*, *Osteoporosis Int*, 16:579, 2005.
391. Bilezikian JP: Primary hyperparathyroidism 2005. *Clinical Endocrinology Update*, 2005, Boston, MA, April 2005.
392. Bilezikian JP: Parathyroid hormone therapy: tailoring use to the individual patient. A new direction for the treatment of osteoporosis. *Nat'l Osteoporosis Foundation Symposium*, April 2005.
393. Bilezikian JP: Hyperparathyroidism: surgery vs medical therapy. (Presented at the 87th Endocrine Society Meeting, San Diego, CA, June 2005).
394. Bilezikian JP: Primary hyperparathyroidism: differential diagnosis, natural history, and management. (Presented at the Northeast Ohio University College of Medicine 16th Annual Update in Internal Medicine, May 2005).
395. Donovan M, Babbar R, Opotowsky A, Nabizadeh F, Rohira A, Chung W, Mediratta A, McMahan D, Liu G, Bilezikian JP: Osteoporosis in Chinese American women: Determinants of bone mass. *J Bone Min Res* 20 (Suppl 1) S219, 2005.
396. Black DM, Crawford RP, Palermo L, Bilezikian JP, Greenspan S, Keaveny TM: Finite element analysis of the PaTH (PTH and Alendronate) study: PTH increases vertebral strength by altering distribution of bone density. *J Bone Min Res* 20 (Suppl 1) S15, 2005.
397. Bouxsein ML, Black DM, Bilezikian JP, Muller J, Palermo L, Crawford PM, Keaveny TM: Combining biomechanical measures of bone strength with estimates of skeletal loading to assess the effects of osteoporosis therapies on vertebral fracture: the PaTH Study. *J Bone Min Res* 20 (Suppl 1) S340, 2005.
398. Bilezikian JP, Hendrix SL, Davidson M, Liu L, Louie M: Co-morbidity of decreased bone mineral density (BMD) and increased cholesterol levels among women aged 65 years and older: results from NHANES III. *J Bone Min Res* 20 (Suppl 1) S219, 2005.

399. Paz-Filho GJ, Kulak CAM, Bilezikian JP, Seibel MJ, Borba VZC: Bone turnover is reduced at 18 months after a single intravenous dose of zoledronic acid. *J Bone Min Res* 20 (Suppl 1) S228, 2005.
400. Rubin MR, Dempster DW, Silverberg SJ, Shane E, Muller R, Zhou H, Boskey AL, Bilezikian JP: Bone quality is markedly abnormal in hypoparathyroidism. *J Bone Min Res* 20 (Suppl 1) S297, 2005.
401. Rubin MR, Dempster DW, Silverberg SJ, Shane E, Roschger P, Klaushofer K, Bilezikian JP: Normal bone mineralization density distribution (BMDD) in hypoparathyroidism. *J Bone Min Res* 20 (Suppl 1) S298, 2005.
402. Rubin MR, Fleischer J, Seibel MJ, de Winter J, Dempster DW, Shane E, Silverberg SJ, Bilezikian JP: Low bone turnover in hypoparathyroidism can be restored to normal by PTH administration. *J Bone Min Res* 20 (Suppl 1) S298, 2005.
403. Kurland ES, McMahon DJ, Powell JS, Colvin TL, Greenberg DA, Bilezikian JP: Idiopathic osteoporosis in men is familial and sex-specific. *J Bone Min Res* 20 (Suppl 1) S340, 2005.
404. Kurland ES, Peck A, McMahon DJ, Bilezikian JP: A novel relationship between estrogen and leptin levels in men with idiopathic osteoporosis. *J Bone Min Res* 20 (Suppl 1) S166, 2005.
405. Sun Q, Katz R, Bilezikian JP: Bisphosphonates regulate mediators of cell transduction in osteoblasts. *J Bone Min Res* 20 (Suppl 1) S365, 2005.
406. Katz RW, Sun Q, Bilezikian JP: Effects of bisphosphonates on UMR-106 cells depend upon their cultural milieu. *J Bone Min Res* 20 (Suppl 1) S294, 2005.
407. Bilezikian JP: Management of severe osteoporosis. *Endocrinologia e Metabologia* 49 (Supp I) S169, 2005.
408. Bilezikian JP: Estrogen replacement therapy: the endocrinologist view. *Endocrinologia e Metabologia* 49 (Supp I) S166, 2005.
409. Bilezikian JP: Bone disease in primary hyperparathyroidism. *Endocrinologia e Metabologia* 49 (Supp I) S167-168, 2005.

410. Paz-Filho GJ, Kulak CAM, Bilezikian JP, Seibel MJ, Borba VZC: Bone turnover is reduced at 18 months after a single intravenous dose of zoledronic acid. (Presented at the Annual Meeting of ANZBM Society, Perth, Australia, September 2005).
411. Donovan MA, Opatowsky AR, Babbar R, Nabizadeh F, Rohira A, DellaBadia M, Chung W, Mediratta A, McMahon DJ, Liu G, Bilezikian JP: Osteoporosis in Chinese-American women: determinants of bone mass. (87th Annual Meeting of the Endocrine Society, San Diego, CA, 631A, 2005).
412. Bilezikian JP: Fracture Forum: The impact of osteoporosis in the hospital – protocols to treat a silent disease: osteoporosis. (In Press)
413. Black DM, Rosen CJ, Palermo L, Hue T, Ensrud KE, Greenspan SL, Lang TF, McGowan JA, Bilezikian JP: The effect of 1 year of alendronate following 1 year of PTH (PTH 1-84): Second year results from the PTH and alendronate (PaTH) Trial. (Presented at the European Calcified Tissue Society, Geneva, June 2005).
414. Bilezikian JP: Primary hyperparathyroidism. (Presented at the Hellenic Endocrine Society/AACE Meeting, Greece, September 2005).
415. Bilezikian JP: Menopause management. Q and A (In Press), 2005.
416. Hendrix SL, Davidson M, Bilezikian JP, Liu L, Louis M: Co-morbidity of decreased bone mineral density (BMD) and increased cholesterol levels among women aged 50 years and older: results from NHANES III. (Presented at NAMS Annual Meeting, 2005).
417. Bilezikian JP: Parathyroid hormone therapy for osteoporosis: New concepts in tailoring use to the individual patient. GIO, Trieste, Italy, Abstract Book pp19-21, 2005.
418. Bilezikian JP: Primary hyperparathyroidism and parathyroid cancer: A disease state review. Princeton Institute for CME, September 2005.
419. Bilezikian JP: Hyperparathyroidism: surgery vs medical therapy. Meet the Professor, ASBMR, September 2005.
420. Bilezikian JP: Primary hyperparathyroidism: Surgical vs. medical therapy. (Presented at the Annual Meeting of the Puerto Rican Endocrine Society, 12/05).

421. Bilezikian JP, Watts NB, Delmas P, Miller P: Impact of prior bisphosphonate therapy on the anabolic effects of teriparatide: rationale and design of the OPTAMISE study. (Presented at the ECTS 2006, Prague, May, 2006).
422. Watts NB, Bilezikian JP, Bringham FR, Lane NE: A New Direction for the Treatment of Osteoporosis. Presented at the NOF's 6th International Symposium on Osteoporosis, Washington DC, April 2005.
423. Walker MD, Babbar R, Opatowsky AR, McMahon DJ, Liu G, Bilezikian JP: Determinants of bone mass in Chinese American women. (To be presented at the Endocrine Society Meeting, June 2006).
424. Hendrix SL, Davidson M, Bilezikian JP, Liu L, Louis M: Bone mineral density (BMD) reduction and increased cholesterol levels are co-morbid conditions among women aged 65 years and older: Results from NHANES III. Sixth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis – ECCEO 6, Vienna, March, 2006.
425. Lowe H, Kurland ES, Bilezikian JP: Hypercalcemia due to PTHrP and vitamin D toxicity in a patient with cervical cancer. Presented at the Endocrine Fellows Foundation Research Forum, Atlanta, March, 2006.
426. Bilezikian JP: Parathyroid hormone: paradoxes and possibilities. Presented at the South African Menopause Society Congress, Sun City, South Africa, March, 2006.
427. Bilezikian JP: The diagnosis of osteoporosis: Can we trust bone densitometry? Presented at the South African Menopause Society Congress, Sun City, South Africa, March, 2006.
428. Bilezikian JP: New concepts in metabolic bone diseases: Case-based discussions. (To be presented at the AACE Annual Meeting, Chicago, April, 2006.)
429. Bilezikian JP: Primary hyperparathyroidism: new concepts, new guidelines, new management options. Presented at the Endocrine Fellows Foundation Research Forum, Atlanta, March, 2006.
430. Bilezikian JP, Christiansen C, Cummings SR, Delmas P, Eastell R, Ettinger B, Grobbee DE, Johnson S, Kenemans P, Mosca L: LIFT Study Discontinued. *Brit Med J*, Letter to the Editor (In Press), 2006.

431. Bilezikian JP, Black DM, Watts NB: Osteoporosis Opportunities: Steps along the path of treatment. *Medical Crossfire* 7:1-7, 2006.
432. Lewiecki EM, Binkley N, Bilezikian JP, Kendler DL, Leib ES, Petak SM: Official Positions of the International Society for Clinical Densitometry. 17:1700-1701 (Ltr), 2006.
433. Bilezikian JP: Osteoporosis in men: how is it different from osteoporosis in women? (Presented at the AACE Annual Meeting, Chicago, 2006).
434. Bilezikian JP: Anabolic therapy for osteoporosis: New concepts in tailoring use to the individual patient. (Presented at Women's Health 2006: Translating Research into Practice Conference, Norfolk, VA, April, 2006).
435. Cummings SR, Delmas P, Bilezikian JP, Christiansen C, Eastell R, Ettinger B, Grobbee DE, Johnson S, Kenemans P, Mosca L, Amari N: The effects of tibolone in older women with osteoporosis: preliminary results from the LIFT trial. (Presented at the Annual Meeting, IOF, Toronto, June, 2006).
436. Bilezikian JP: Primary hyperparathyroidism: (Bone loss is not always osteoporosis) new concepts, new guidelines, new management options in another common metabolic bone disease. (Presented at the Endocrine Nurses Society Meeting, The Endocrine Society Annual Meeting, Boston, June, 2006).
437. Miller P, Bilezikian J, Chen P, Marin F, Krege J, Wong M, Marcus R: Teriparatide therapy and risk of hypercalciuria in postmenopausal women with osteoporosis. *J Bone Min Res* 21 (Suppl 1) S299, 2006.
438. Luckey M, Bilezikian JP, Lindsay R, Saag K, Recknor C, Cahall D, Addachi R, Hodsman A, Miller P: Impact of prior bisphosphonate therapy on the anabolic effects of teriparatide: baseline data for subjects enrolled in the OPTAMISE study. *J Bone Min Res* 21 (Suppl 1) S416, 2006.
439. Han L, Almeida M, Chen XD, Manolagas SC, Bilezikian JP, Kousteni S: Hormonal control of periosteal expansion: estrogens and PTH control the fate of early periosteal osteoblast progenitors by opposite actions on the BMP-2 and Wnt signaling cascades. *J Bone Min Res* 21 (Suppl 1) S204, 2006.

440. Walker MD, Babbar R, Opotowsky S, McMahon D, Liu G, Bilezikian JP: Determinants of bone mass in Chinese American women. *J Bone Min Res* 21 (Suppl 1) S270, 2006.
441. Bilezikian JP, Borisov NN, Klemes AB, Steinbuch M: Fragility fracture outcomes among men and women: an observational study. *J Bone Min Res* 21 (Suppl 1) S161, 2006.
442. Keaveny TM, Hoffmann P, Singh M, Palermo L, Bilezikian JP: Femoral bone strength after two years of treatment of PTH, alendronate, or PTH + alendronate: Finite element analysis of the PaTH study. *J Bone Min Res* 21 (Suppl 1) S43, 2006.
443. Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan S, Rosen CJ, Black DM: The degree of type 1 collagen isomerization in postmenopausal women with osteoporosis after alendronate (ALN) or parathyroid hormone (PTH) administration: the PaTH study. *J Bone Min Res* 21(Suppl 1) S233, 2006.
444. Rubin MR, Dempster D, Sliney J, Compito C, Muller R, Paschalis E, Roschger P, Zoehrer R, Klaushofer K, Zhou H, Kohler T, Silverberg SJ, Bilezikian JP: Indices of bone quality are markedly abnormal in hypoparathyroidism. *J Bone Min Res* 21 (Suppl 1) S37, 2006.
445. Rubin MR, Suva LJ, Silverberg SJ, Sliney J, McMahon DJ, Bilezikian JP: Increased levels of IL-8 are associated with bone loss in primary hyperparathyroidism. *J Bone Min Res* 21 (Suppl 1) S439, 2006.
446. Roschger P, Dempster DM, Zhou H, Paschalis EP, Silverberg SJ, Bilezikian JP, Klaushofer K: Bone quality, as determined by quantitative backscattered electron imaging, in mild primary hyperparathyroidism. *J Bone Min Res* 21 (Suppl 1) S315, 2006.
447. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: further characterization and short term natural history. *J Bone Min Res* 21 (Suppl 1) S37, 2006.
448. Silverberg SJ, McMahon D, Udesky J, Fleischer J, Shane E, Jacobs T, Siris E, Bilezikian JP: Natural history of untreated primary hyperparathyroidism: bone density after 15 years. *J Bone Min Res* 21 (Suppl 1) S118, 2006.

449. Dempster DW, Muller R, Zhou H, Kohler T, Lim J, Shane E, Parisien M, Silverberg SJ, Bilezikian JP: Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. *J Bone Min Res* 21 (Suppl 1) S116, 2006.
450. Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, Smallridge R, Schwanauer LE, Olson KA, Klassen PS, Peacock M: Cinacalcet reduces hypercalcemia in patients with parathyroid carcinoma. *J Bone Min Res (Suppl 1)* S440, 2006.
451. Bilezikian JP: Clinical perspectives: use of anabolic therapy in the management of osteoporosis: Clinical considerations and optimization of anabolic therapy. (Presented at the IOF Scientific Meeting, Toronto, Canada, June, 2006).
452. Bilezikian JP: Bone anabolic therapy. *Revista Argentina de Osteologia* 5:19-20, 2006.
453. Bilezikian JP: Osteoporosis in men. *Revista Argentina de Osteologia* 5:22-23, 2006.
454. Bilezikian JP, Bone HG, Epstein S, Lewiecki EM: Osteoporosis Management: assessing fracture risk and identifying patients for intervention with anabolics. (Highlights from satellite symposium presented at ISCD, San Diego, CA, 2/06) 1-15, 2006.
455. Zoehrer R, Paschalis EP, Roschger P, Rubin MR, Dempster D, Sliney J, Compito C, Muller R, Zhou H, Kohler T, Silverberg SJ, Bilezikian JP, Klaushofer K: Hypoparathyroidism affects architectural and material quality of bone. (Submitted for presentation at the International Conference on Progress in Bone and Mineral Research, Vienna, Austria, November, 2006).
456. Reeve J, Bilezikian JP, Lindsay R: Osteoporosis challenges of the everyday practice: insights from gender differences and rare bone disease. *AACE Symposia Highlights, Medical Association Communications (MAC)*, April, 2006.
457. Bilezikian JP: Parathyroid hormone: paradoxes and possibilities. (Presented at the Japan Osteoporosis Society, October, 2006).
458. Bilezikian JP: Parathyroid hormone: current concepts with a view to the future. (Presented at the Japan Osteoporosis Society, October, 2006).

459. Bilezikian JP: Osteopenia: how to decide who to treat. (Presented at the Clinical Endocrinology Update, The Endocrine Society, October, 2006).
460. Bilezikian JP: Anabolic and combination therapy for osteoporosis. (Presented at the Clinical Endocrinology Update, The Endocrine Society, October, 2006).
461. Watts NB, et al. Osteonecrosis of the jaw (Letter to the Editor). *Annals Int Medicine*, 2006.
462. Bilezikian JP: Biology and clinical applications of parathyroid hormone. (Presented at the Endocrine Society Annual Meeting, Boston, June, 2006).
463. Bilezikian JP, Dawson-Hughes B, Grisanti JM, LeBoff M, Lindsay R, Luckey M, McClung M, Miller PD, Rackoff P, Tucci J: Discussions in Osteoporosis. Issue 6, Adelphi, Inc. pp 1-8, September, 2006.
464. Bandeira F, Borges JLC, Bilezikian JP: Hormones, the Endocrinologist and Osteoporosis. *Brazilian Archives of Endocrinology and Metabolism*, 2006.
465. Bilezikian JP: New osteoporosis drugs are a promising treatment option. *Endocrine News*, April, 2007.
466. Bilezikian JP: Primary hyperparathyroidism. (Presented at the The Endocrine Society Annual Meeting, Toronto, June, 2007).
467. Cummings SR, Bilezikian JP, Christiansen C, Eastell R, Ettinger B, Delmas P, Grobbee DE, Johnson S, Kenamas P, Mosca L, Amari N, Seifert W, Stathopoulos V, Verweij P, Mol-Arts M: The effects of tibolone in older women: Results of the LIFT Trial. (Presented at the ECTS Meeting, Copenhagen, May, 2007).
468. Cohen A, Dempster DW, Mueller R, Guo XE, Zhang XH, Wirth AJ, van Lenthe GH, McMahon DJ, Zhou H, Rubin MR, Bilezikian JP, Recker RR, Shane E: High resolution peripheral quantitative CT (HRpQCT) of the radius reflects iliac crest biopsy measures of microstructure and mechanical competence. *J Bone Miner Res* 22 (Suppl 1) S47, 2007.
469. Vargas-Jerez J, Walker MD, Gagel C, McMahon DJ, Lantigua RA, Bilezikian JP: Skeletal health between two different groups of Hispanic American women. *J Bone Miner Res* 22 (Suppl 1) S301, 2007.

470. Walker MD, Babbar R, Vargas-Jerez J, Udesky J, Gagel C, McMahon DJ, Lantigua R, Liu G, Bilezikian JP: Racial differences in skeletal health. *J Bone Miner Res* 22 (Suppl 1) S427, 2007.
471. Misra B, Silverberg SJ, Bilezikian JP: Screening for asymptomatic normocalcemic hyperparathyroidism in the United States. *J Bone Miner Res* 22 (Suppl 1) S352, 2007.
472. Zoehrer R, Dempster DW, Bilezikian JP, Zhou H, Silverberg SJ, Shane E, Fratzl P, Paschalis E, Roschger P, Klaushofer K: Bone quality in mild primary hyperparathyroidism. *J Bone Miner Res* 22 (Suppl 1) S354, 2007.
473. Rubin MR, Silverberg SJ, Sliney J, Bilezikian JP: Use of parathyroid hormone in hypoparathyroidism. *J Bone Miner Res* 22 (Suppl 1) S353, 2007.
474. Ogita M, Dworakowski E, Bilezikian JP, Kousteni S: Proliferation and differentiation of periosteal osteoblast progenitors are differentially regulated by sex steroids and intermittent PTH administration. *J Bone Miner Res* 22 (Suppl 1) S95, 2007.
475. Ogita M, Dworakowski E, Bilezikian JP, Kousteni S: Liganded versus unliganded estrogen receptor: a potential explanation for paradoxical regulation of periosteal expansion by estrogens. *J Bone Miner Res* 22 (Suppl 1) S242, 2007.
476. Bilezikian JP, Zhou X, Klemes AB, Boonen S: Risedronate efficacy for non-vertebral fractures is consistent across age groups. *J Bone Miner Res* 22 (Suppl 1) S450, 2007.
477. Miller P, Lindsay R, Watts N, Meeves S, Lang T, Delmas P, Bilezikian J: Patients previously treated with risedronate demonstrate greater responsiveness to teriparatide than those previously treated with alendronate: The OPTAMISE Study. *J Bone Miner Res* 22 (Suppl 1) S26, 2007.
478. Delmas P, Watts N, Miller P, Cahall D, Bilezikian J, Lindsay R: Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: The OPTAMISE Study. *J Bone Miner Res* 22 (Suppl 1) S27, 2007.
479. Hue TF, Bilezikian JP, Ensrud KE, Greenspan SL, Rosen CJ, Palermo L, Lang TF, Black DM: Year 3 effects on bone mass in women using bisphosphonates after PTH therapy: follow-up results from the PaTH II study. *J Bone Miner Res* 22 (Suppl 1) S28, 2007.

480. Black DM, Bauer DC, Palermo L, Rosen CJ, Greenspan SL, Bilezikian JP: Prediction of 24 month change in BMD on PTH followed by alendronate: the PaTH study. *J Bone Miner Res* 22 (Suppl 1) S26, 2007.
481. Bone HA, Greenspan S, Morris S, Bilezikian J: Characteristics of postmenopausal women treated with PTH(1-84) in the TOP study: relationship of baseline serum and urine Ca values to hypercalcemia and hypercalciuria. *J Bone Miner Res* 22 (Suppl 1) S209, 2007.
482. Bilezikian JP, Luckey M, Saag K, Adachi J, Greenspan S, Boonen S, Seeman E, Stewart J, Cosman F, Miller P: Teriparatide stimulates greater increases in bone turnover markers and in bone mineral density after risedronate than after alendronate: The OPTAMISE Study. (Submitted for Presentation at the American College of Rheumatology, Fall, 2007).
483. Bilezikian JP: Primary hyperparathyroidism. (Presented at the EFF-ASBMR Fellows Research Forum, Sante Fe, August 2, 2007.)
484. Bilezikian JP: Osteonecrosis of the jaw: The facts without the fictions. (Presented at the Sante Fe Bone Symposium, August 3-4, 2007).
485. Bilezikian JP: Osteoporosis: therapeutic concepts for the present and the future. (Presented at the Sante Fe Bone Symposium, August 3-4, 2007.)
486. Bilezikian JP: Osteoporosis in men. (Presented at the VII Congreso Sociedad Iberoamericana de Osteologia y Metabolismo Mineral; XV Congreso Chileno de Osteologia y Metabolismo Mineral, Chile, August 29-September 1, 2007.)
487. Bilezikian JP: Primary hyperparathyroidism. (Presented at the VII Congreso Sociedad Iberoamericana de Osteologia y Metabolismo Mineral; XV Congreso Chileno de Osteologia y Metabolismo Mineral, Chile, August 29-September 1, 2007.)
488. Bilezikian JP: Therapy of glucocorticoids-induced osteoporosis with teriparatide. (Presented at GIO 2007, Naples, Italy, October 11-13, 2007.)
489. Bilezikian JP: Primary hyperparathyroidism: new concepts and new approaches for 2007. (Presented at the EFF-ASBMR Fellows Forum at the ASBMR Annual Meeting, Hawaii, September, 2007.)

490. Bilezikian JP, Pittsley R: All fractures are not created equal: treatment of nonvertebral fractures. Chatham, July 2007.
491. Bilezikian JP: When osteoporosis is the wrong diagnosis: new insights linking vitamin D, parathyroid hormone, and bone to cardiovascular health. Millenium CME Institute, November, 1-4, 2007.
492. Bilezikian JP: Rationale and data for combination antiresorptive and anabolic therapy. Presented at the ASBMR-NIH Bone Remodeling Workshop, Washington, DC, December, 2007.
493. Chanson P, Shoback D, Lu J, Cheng S, Ren L, Bilezikian JP: Impact of cinacalcet treatment on health related quality of life (HRQOL) in patients with primary hyperparathyroidism (PHPT) who have failed or are contraindicated to parathyroidectomy (PTX). (Submitted for Presentation), European Congress of Endocrinology, Berlin, May, 2008.
494. Boonen S, Delmas PD, Watts NB, Lindsay R, Miller P, Stewart J, Bilezikian JP: Responsiveness of bone turnover markers to teriparatide is greater and earlier following treatment with risedronate compared with alendronate: The OPTAMISE Study. *Osteoporosis Int* 19 (Suppl 1): S95, 2008.
495. Delmas PD, Bilezikian JP, Lindsay R, Watts NB, Boonen S, Cahall DL, Miller P: Responsiveness to teriparatide is greater in patients previously treated with alendronate: The OPTAMISE Study. *Osteoporosis Int* 19 (Suppl 1): S21, 2008.
496. Zoehrer R, Paschalis EP, Roschger P, Fratzl P, Rubin MR, Dempster D, Bilezikian JP, Klaushofer K: Osteoporosis: more than bone turnover? (Submitted for Presentation), European Calcified Tissue Society Annual Meeting, 2008.
497. Bilezikian JP: PTH and the treatment of osteoporosis: past, present and future. Translating research into good clinical practice. (to be presented), Lisbon, Portugal, 2/15/08.
498. Thys-Jacobs S, McMahon D, Bilezikian JP: JCEM response to PMDD and its elusive causes. *J Clin Endocrinol Metab*, Letter to the Editor (Submitted), 2008.
499. Bilezikian JP: Primary Hyperparathyroidism. Presented at the 18th Annual Course: Controversies in the Management of Thyroid and Parathyroid Diseases (M. Urken, Chair), Tarrytown, NY, 4/4/08.

500. Bilezikian JP: Parathyroid Cancer. Presented at the 18th Annual Course: Controversies in the Management of Thyroid and Parathyroid Diseases (M. Urken, Chair), Tarrytown, NY, 4/4/08.
501. Bilezikian JP: Osteonecrosis of the Jaw. (Presented at the 3rd International Conference on Osteoporosis and Bone Research, Shanghai, China, October, 2007).
502. Bilezikian JP: Anabolic Therapy for Osteoporosis. (Presented at the 3rd International Conference on Osteoporosis and Bone Research, Shanghai, China, October, 2007).
503. van Londen GJ, Palermo L, Beck TJ, Lang TF, Bouxsein M, Wagner J, Black D, Bilezikian JP, Ensrud KE, Greenspan SL: Hip structural analysis and volumetric QCT in postmenopausal women from the PaTH Study: Mono- or combination therapy with alendronate and parathyroid hormone. *J Bone Min Res* 23(Suppl 1), S449, 2008.
504. Rubin MR, Cremers S, Dempster DW, Sliney Jr J, McMahon DJ, Zhou H, Nickolas T, Stein EM, Bilezikian JP: PTH increases bone turnover in hypoparathyroidism. *J Bone Min Res* 23 (Suppl 1), S128, 2008.
505. Rubin MR, Dempster DW, Sliney Jr J, McMahon DJ, Zhou H, Nickolas T, Stein EM, Bilezikian JP: PTH reverses abnormal bone remodeling and structure in hypoparathyroidism. *J Bone Min Res* 23 (Suppl 1), S12, 2008.
506. Lowe H, Binkley N, Blarer WS, Plum LA, Bilezikian JP: Vitamin D toxicity due to a commonly available remedy from the Dominican Republic. *J Bone Min Res* 23 (Suppl 1), S288, 2008.
507. Lowe H, McMahon DJ, Walker MD, Rubin M, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: update on a new clinical phenotype. *J Bone Min Res* 23 (Suppl 1), S225, 2008.
508. Rached MT, Ogita M, DePinho RA, Bilezikian JP, Kousteni S: FOXO1 signaling in the control of bone mass. *J Bone Min Res* 23 (Suppl 1), S32, 2008.
509. Misra B, McMahon DJ, Silverberg SJ, Bilezikian JP: New data on the impact of renal function on the relationship between 25-hydroxyvitamin D and parathyroid hormone. *J Bone Min Res* 23 (Suppl 1), S10, 2008.

510. Misra B, Silverberg SJ, Bilezikian JP: Prevalence and demographics of asymptomatic normocalcemic hyperparathyroidism in the United States. *J Bone Min Res* 23 (Suppl 1), S483, 2008.
511. Li W, Keyak J, Miller P, Bilezikian J, Stewart J, Lang T: Imaging the spatial distribution of proximal femoral response to one year of teriparatide therapy: The OPTAMISE Study. *J Bone Min Res* 23 (Suppl 1), S461, 2008.
512. Keyak J, Quek E, Miller P, Bilezikian J, Stewart J, Lang T: One year of teriparatide treatment increases proximal femoral strength in subjects with recent history of anti-resorptive treatment: The OPTAMISE Study. *J Bone Min Res* 23 (Suppl 1), S121, 2008.
513. Zhang XH, Liu XS, Rajapakse CS, Magland J, Wehrli FW, Shane E, Bilezikian JP, Guo XE: Morphological and mechanical analyses of registered HR-pQCT, μ MR and μ CT images of human tibiae. (Submitted for presentation at the Biomechanical Engineering Society, 2008).
514. Bilezikian JP: Primary hyperparathyroidism: Epidemiology and natural history. Presented at the 3rd International Workshop on Asymptomatic Primary Hyperparathyroidism. Orlando, FL, 2008.
515. Bilezikian JP: Primary hyperparathyroidism: a disorder with several different presentations. *Endocrinologia & Metabologia* 52 (Suppl 4) 5420-5421, 2008.
516. Bilezikian JP: Bone quality: What is it? How can it be measured? *Endocrinologia & Metabologia* 52 (Suppl 4) 5418-5419, 2008.
517. Bilezikian JP: Osteoporosis in men. *Endocrinologia & Metabologia* 52 (Suppl 4) 5419-5420, 2008.
518. Bilezikian JP, Delmas PD, Watts NB, Lindsay R, Stewart J, Miller P: Responsiveness of bone turnover markers to teriparatide is greater and earlier following treatment with risedronate compared with alendronate: The OPTAMISE Study. *Osteoporosis Int* 19(Suppl 2), S303, 2008.
519. Bilezikian JP, Delmas PD, Lindsay R, Watts NB, Cahall DL, Miller P: Responsiveness to teriparatide is greater in patients previously treated with risedronate than in those previously treated with alendronate: The OPTAMISE Study. *Osteoporosis Int* 19(Suppl 2), S385, 2008.

520. Bilezikian JP: PTH as a treatment for male osteoporosis. *Osteoporos Int* 19:1670, 2008.
521. Bilezikian JP: Clinical utility of anabolic therapy for osteoporosis. *Bone* 43:S16, 2008.
522. Bilezikian JP: Primary hyperparathyroidism: a disorder with several different presentations. *Bone* 43:S23, 2008.
523. Bilezikian JP: Novel mechanisms of bone formation. *Osteoporosis Int* 19 (Suppl 2) S226, 2008.
524. Bilezikian JP: Primary hyperparathyroidism: new concepts and new approaches for 2008. (Presented at the Third Annual EFF/ASBMR Fellows Forum, Montreal Canada 9/11/08).
525. Liu XS, Yin PT, Zhang XH, Cohen A, Shane E, Lappe JM, Recker RR, Bilezikian JP, Guo XE: HR-pQCT and individual trabeculae segmentation based morphological analyses can detect abnormal trabecular microstructure in premenopausal women with idiopathic osteoporosis. Orthopaedic Research Society, 2008.
526. Liu XS, Zhang XH, Sekhon KK, Adams MF, Rajapakse CS, Wald MJ, Magland J, Wehrli FW, Shane E, Bilezikian JP, Guo XE: Morphological and mechanical analyses of registered HR-pQCT, μ MR and μ CT images of human tibial bone segments. Orthopaedic Research Society, 2008.
527. Liu XS, Yin PT, Cohen A, Shane E, Lappe JM, Recker RR, Bilezikian JP, Guo XE: Relationships between stiffness of peripheral and central skeletal sites assessed by HR-pQCT and cQCT based finite element analyses. Orthopaedic Research Society, 2008.
528. Liu XS, Sekhon KK, Zhang XH, Shane E, Bilezikian JP, Guo XE: Individual trabeculae segmentation based morphological analyses of registered HR-pQCT and μ CT images of human tibial bone. Orthopaedic Research Society, 2008.
529. Walker MD, Go C, Udesky J, McMahon DJ, Liu G, Bilezikian JP: Bone quality in Chinese American and Caucasian women. *J Bone Min Res* 23 (Suppl 1) S361, 2008.

530. Paschalis EP, Roschger P, Zoehrer R, Misof BM, Rubin MR, Dempster D, Sliney J, Compito C, Zhou H, Silverberg SJ, Bilezikian JP, Klaushofer K: Differential effects on bone quality indices in hypoparathyroidism. *Bone* 44(Suppl): S357, 2009.
531. Bilezikian JP: Interpreting clinical trial data: how important are the differences between bisphosphonates? *Osteoporos Int* 19(Suppl 2):S507, 2008.
532. Bilezikian JP: Clinical aspects of anabolic therapy for osteoporosis. (Presented at the 3rd Skeletal Endocrinology Meeting, Brescia, Italy 3/27/09, Abstract Book, p.19).
533. Siris ES, Oster MW, Bilezikian JP: Reports of esophageal cancer and alendronate. *N Eng J Med* 360:1791, 2009.
534. Black D, Bilezikian J, Greenspan S, Palermo L, Wuster C, Munoz-Torres M, Hanley D, Bone H, Greisen H, Rosen C: Gains in lumbar spine BMD in highly compliant patients treated with PTH(1-84). *Bone* 44(Suppl): S428-S429, 2009.
535. Stein E, et al. Vitamin D insufficiency influences histomorphometric features of bone in primary hyperparathyroidism. (Presented at The Endocrine Society Meeting, Washington DC, 6/09).
536. Bilezikian JP: From hyperparathyroidism to hypoparathyroidism: what bone densitometry and other imaging modalities have taught us. (Meet the Professor, ISCD, Orlando, Florida, 3/12/09).
537. Fratzl-Zelman N, Misof BM, Rauch F, Glorieux F, Shane E, Bilezikian JP, Dempster DW, Fratzl P, Klaushofer K, Roschger P: Age and bone turnover associated changes in the cortical bone mineralization density distribution of the iliac crest. (Presented at IBMS, 2009).
538. Bilezikian JP: Diabetes and its treatment: outcomes for bone. (Presented at the National Osteoporosis Foundation Scientific Meeting, Washington DC, 4/09).
539. Bilezikian JP: 2009 Guidelines in Asymptomatic Primary Hyperparathyroidism. (Presented at the Annual Meeting of AACE, May 2009).
540. Bilezikian JP: Primary hyperparathyroidism: new concepts and new guidelines for 2009. (Presented at Carolinas' Chapter of AACE: 2009 Annual Meeting, Asheville, NC, 8/09).

541. Bilezikian JP: Vitamin D deficiency. (Presented at the Current Clinical Issues in Primary Care Pri-med Meeting, New York, 8/09).
542. Bilezikian JP: New approaches to osteoanabolic therapy. (Presented at the 36th Annual ECTS Meeting, Vienna, Austria, May, 2009).
543. Bilezikian JP: Bone and Mineral: Scientific Overview. (Presented at the ENDO 09 Medical Science Liaison Endocrinology Workshop, June, 2009).
544. Misra B, Bilezikian J, Silverberg S 2009 C-reactive protein is increased in vitamin D deficiency: An association independent of parathyroid hormone. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=74ab0cb9-6039-4000-bfcc-3072b8b7e385>. Accessed October 1, 2009.
545. Binkley N, Krueger D, Lensmeyer G, Wiley C, Morgan S, Cremers S, Bilezikian J, Wiebe D 2009 New insights into 25(OH)D measurement: An assessment of between-laboratory agreement. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=60f82d14-7ecd-45fa-8209-674017a75465>. Accessed October 1, 2009.
546. Bilezikian J, Klemes A, Siris E. 2009 Esophageal cancer reports coincident with risedronate use. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=16f71c49-3da9-4db0-ac90-fcf5a21365ca>. Accessed October 1, 2009.
547. Kulak C, Liu X, Reis L, Jorgetti V, Borba V, Kulak J, Bornschein A, Franco C, Zhou H, Boguszewski C, Bilezikian J, Dempster D, Guo E 2009 Cancellous bone microarchitecture in post menopausal women with chronic obstructive pulmonary disease. J Bone Miner Res 24(Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=06bf03a2-f07b-40cf-9789-91a94932cd27>. Accessed October 1, 2009.
548. Kode A, Rached M, Duncan C, DePinho R, Manavalan J, Bilezikian J, Kousteni S 2009 Mutual regulation of bone mass and oxidative stress in osteoblasts by FoxO1. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=8cc6ac9c-f9ab-4464-add8-d45657c4e8e7>. Accessed October 1, 2009.

549. Walker M, McMahon D, Udesky J, Liu G, Bilezikian J 2009 Indices of bone quality are higher in Chinese American than in Caucasian women. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=384a1978-eb59-4766-b2fd-7d55a68b3520>. Accessed October 1, 2009.
550. Rubin M, Dempster D, Sliney J, Zhou H, Nickolas T, Stein E, Dellabadia M, Shane E, Silverberg S, Bilezikian J 2009 PTH administration reverses abnormal bone remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=42007adc-c2a9-47a6-8700-1ae3277b0da8>. Accessed October 1, 2009.
551. Bilezikian J, Klemes A, Silverman S, Cosman F 2009 Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=0367cfaa-4d0d-47d8-a57a-ff76098839a2>. Accessed October 1, 2009.
552. Stein E, Dempster D, Udesky J, Bilezikian J, Shane E, Silverberg S 2009 Histomorphometric consequences of vitamin D deficiency in primary hyperparathyroidism reflect enhanced actions of PTH. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=5d94c867-814f-4c3f-ad51-ed6fb4ad20d9>. Accessed October 1, 2009.
553. Schafer A, Palermo L, Bauer D, Sellmeyer D, Bilezikian J, Black D 2009 Consistency of biochemical marker of bone turnover and serum calcium responses to parathyroid hormone therapy in postmenopausal osteoporosis. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=219fe1b0-0fd6-4191-9607-64d2c7168781>. Accessed October 1, 2009.
554. Xu L, Rached M, Shah J, Duncan C, Manavalan J, Bilezikian J, Kousteni S 2009 Definition of a cell population with osteogenic potential in the periosteum. J Bone Miner Res 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=c4113fb6-1810-4c39-ac29-47fd88d33ad9>. Accessed October 1, 2009.

555. Fitzpatrick L, Dabrowski C, Cicconetti G, Papapoulos S, Bone H, Bilezikian J 2009 Ronacalaret, a calcium-sensing receptor antagonist: results of a 1 year double-blind, placebo-controlled, dose-ranging phase II study. *J Bone Miner Res* 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=a2c9cbad-2834-4a51-9b49-032e01e0f10c>. Accessed October 1, 2009.
556. Cremers S, Holton K, Wang Y, Dworakowski E, Bilezikian J, Orwoll E f. Study Group 2009 Association between serum levels of whole and intact PTH in men. *J Bone Miner Res* 24 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=39871fc0-785d-449c-8b6e-53aa280c8df0>. Accessed October 1, 2009.
557. Bilezikian JP: Teriparatide in the treatment of glucocorticoid-induced osteoporosis. *Bone* 45: Supplement S130, 2009.
558. Bilezikian JP: Update on rationale and development of new agents for the treatment of osteoporosis. (Presented at the Santa Fe Bone Symposium, 7/31-8/1/09).
559. Kulak CAM, Borba VZC, Liu XS, Reis L, Jorgetti V, Zhou H, Boguszewski CL, Guo XE, Bilezikian JP, Dempster DW: Bone remodeling and microstructure in postmenopausal women with chronic obstructive pulmonary disease. *Brazilian Bone and Mineral Society* (Submitted for Presentation), 2009.
560. Bilezikian JP: Primary hyperparathyroidism: new concepts, new approaches, and new guidelines for 2009. Meet the Professor, ASBMR Annual Meeting, 9/09.
561. Liu XS, Walker MD, Yin PT, Udesky J, Bilezikian JP, Guo XE: Chinese American women have more trabecular plates than Caucasian women indicated by individual trabeculae segmentation-based morphological analyses of HR-pQCT images. *Orthopedic Research Society* (Submitted), 2009.
562. Bilezikian JP: Update on rationale and development of new agents for osteoporosis treatment. Presented at the 2009 Santa Fe Bone Symposium, August, 2009.
563. Bilezikian JP: Osteoporosis in men. *Official Program XX Congresso Chileno de Endocrinologia y diabetes*. p. 55-56, 2009.

564. Bilezikian JP: Primary hyperparathyroidism: new concepts, new approaches, and new guidelines for 2009. Official Program XX Congreso Chileno de Endocrinología y diabetes. p. 30-35, 2009.
565. Bilezikian JP: Catabolic and Anabolic actions of parathyroid hormone. Presented at Parathyroids 2010: From Pathophysiology to the Clinical Use of PTH, Pisa, Italy, 2010.
566. Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism. Presented at Parathyroids 2010: From Pathophysiology to the Clinical Use of PTH, Pisa, Italy, 2010.
567. Costa AG, Cremers S, Rubin MR, Dworakowski E, McMahon DJ, Silverberg SJ, Bilezikian JP: Circulating sclerostin levels in disorders of parathyroid function: primary hyperparathyroidism and hypoparathyroidism. Presented at Parathyroids 2010: From Pathophysiology to the Clinical Use of PTH, Pisa, Italy, 2010.
568. Gonzalez G, Bilezikian JP: Questions and answers about parathyroid disorders. The Chilean Journal of Endocrinology and Diabetes 3(2):150-151, 2010.
569. Bilezikian JP: Using PTH to treat osteoporosis: what takes us so long? Presented at Osteoporosis Management in the 21st Century, Zagreb, Croatia, February, 2010.
570. Bilezikian JP: Workshop Session: Impact of metabolic disorders on bone metabolism - hypoparathyroidism. To be presented at Osteoporosis Management in the 21st Century, Zagreb, Croatia, February, 2010.
571. Bilezikian JP: Advances in the treatment of osteoporosis. Endocrinologia Japonica 57 (Suppl 2) 204, 2010.
572. Bilezikian JP, Borges J, Panelo A, Nino A, Adams P, Jones A, Acosta A, Cobitz A, Fitzpatrick L: In drug-naïve T2DM subjects, RSG/MET FDC is associated with BMD reduction after 80 weeks of treatment. Presented at the ADA, June, 2010.
573. Fitzpatrick L, Dabrowski C, Cicconetti G, Papapoulos S, Bone H, Bilezikian J: Ronacaleret, a calcium-sensing receptor antagonist, fails to increase BMD. Presented at ECCEO, 2010.

574. Bilezikian JP: Stimulators/Inhibitors of bone turnover, together or one after another? *Osteoporosis Int* 21 (Suppl 1), 54, 2010.
575. Bilezikian JP: New approaches to osteoanabolic therapy. Presented at ENDO 2010.
576. Bilezikian JP: Non-traditional features of modern primary hyperparathyroidism. Presented at European Congress of Endocrinology, Prague, 2010.
577. Bilezikian JP: New and emerging therapies for osteoporosis. Presented at the Santa Fe Bone Symposium, August, 2010.
578. Liu XS, Rubin MR, Sliney J Jr, McMahon D, Dempster DW, Bilezikian JP: PTH reverses the imbalance between cortical and trabecular bone compartments in hypoparathyroidism: a three-year longitudinal HR-pQCT study. Presented at the Orthopaedic Research Society, 2011.
579. Bilezikian JP, Kravitz BG, Lewiecki EM, Miller CG, Northcutt AR, Paul G, Cobitz AR, Nino A, Fitzpatrick LA: Effects of rosiglitazone on bone: assessing QCT parameters in a mechanistic study in postmenopausal women with type 2 diabetes mellitus. *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=7c205c95-dbea-4998-9f5f-087b7b8ae934> Accessed November 19, 2010.
580. Costa AG, Cremers S, Rubin MR, Dworakowski E, McMahon DJ, Silverberg SJ, Bilezikian JP: Circulating sclerostin levels in disorders of parathyroid function: primary hyperparathyroidism (PHPT) and hypoparathyroidism (HypoPT). *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b353a574-36d0-47ce-90ec-65f504e8a08a> Accessed November 19, 2010.
581. Liu XS, Walker MD, Zhou B, McMahon DJ, Udesky J, Liu G, Bilezikian JP, Guo XE: Better skeletal microstructure confers greater mechanical advantages in Chinese-American women than Caucasian women. *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6775ae3e-3602-49b4-9947-2c96fb4c4e82> Accessed November 19, 2010.

582. Liu XS, Rubin MR, Sliney J Jr, McMahon DJ, Dempster DW, Bilezikian JP: PTH reverses the imbalance between cortical and trabecular bone compartments in hypoparathyroidism: a three-year longitudinal HR-pQCT study. *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=36622c0a-34a8-4b1a-9697-31bfdee4b910> Accessed November 19, 2010.
583. Walker M, Liu XS, McMahon D, Udesky J, Liu G, Bilezikian JP: Differences in bone quality as determined by HRpQCT in postmenopausal Chinese and Caucasian women. *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=7bb34dda-1cfb-41d5-b44f-8c3c8ca8805e> Accessed November 19, 2010.
584. Silva BCC, Kulak CM, Dias E, Camargos B, Bilezikian JP, Sarquis M: Vitamin D deficiency vs vitamin D insufficiency: an example of how this distinction cannot be made. *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ab3cf696-54fc-4682-b287-3598d5078518> Accessed November 19, 2010.
585. Rubin MR, Zhou H, Silverberg SJ, Sliney J, Dempster DW, Bilezikian JP: PTH regulates the distribution of trabecular and cortical compartments of bone. *J Bone Miner Res* 25 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=319211ec-cc72-4cb4-8616-0d7f989d8412> Accessed November 19, 2010.
586. Liu et al. Age-related differences in trabecular bone microstructure and mechanical competence in Chinese-American and Caucasian women. Presented at the ASBMR Aging Symposium, 2011.
587. Ives R, Sliney J, Korner J, McMahon DJ, Bilezikian JP, Silverberg SJ, Shane E, Kovalevskaya G, Zhang CA, Dworakowski E, Cremers S, Rubin MR: Osteocalcin and glucose homeostasis in hypoparathyroidism. *ENDO*, 2011.
588. Bilezikian JP: New and emerging therapies for osteoporosis. Presented at the 5th International Conference on Osteoporosis and Bone Research, p 65-66, 2010.
589. van Rietbergen CP, Muller R, Rubin MR, Dempster DW, Bilezikian JP, Ito K: Altered bone cell mechanosensitivity can explain the substantially increased bone mass in hypoparathyroidism. *Orthopedic Research Society*, 2011.

590. Bilezikian JP: Primary hyperparathyroidism: Current concepts and controversies. Meet the Professor, ASBMR, 2011.
591. Bilezikian J, Castro ML, Barros ER, Arantes H, Kunii I: Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. J Bone Miner Res 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006158-29 Accessed October 18, 2011.
592. Cusano N, Wang P, Cremers S, Haney E, Bauer D, Orwoll E, Bilezikian J: Subclinical hypoparathyroidism: A new variant based upon a cohort from MrOS. J Bone Miner Res 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006834-52 Accessed October 18, 2011.
593. Seeman E, Libanati C, Austin M, Chapurlat R, Boyd S, Zebaze R, Hanley DA, Zanchetta JR, Grauer A, Bilezikian JP: The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: A distinctive attribute of denosumab therapy. J Bone Miner Res 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006972-62 Accessed October 18, 2011.
594. Cusano N, Rubin M, McMahon D, Ives R, Sliney Jr. J, Bilezikian J: Treatment of hypoparathyroidism with PTH(1-84) is safe and effective for up to 4 years. J Bone Miner Res 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006777-84 Accessed October 18, 2011.
595. Miller CG, Nino AJ, Bilezikian JP, Kravitz B, Paul G, Cobitz AR, Northcutt AR, Fitzpatrick LA: Evaluation of QCT cortical hip parameters in a clinical trial with rosiglitazone: the potential for a new study endpoint? J Bone Miner Res 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11007209-89 Accessed October 18, 2011.
596. Ascenzi MG, Liao V, Lee B, Lindsay R, Cosman F, Nieves J, Bilezikian J, Dempster D: Short-term parathyroid hormone treatment improves cortical bone microstructure. J Bone Miner Res 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006062-89 Accessed October 18, 2011.

597. Cusano N, Wang P, Cremers S, Haney E, Bauer D, Orwoll E, Bilezikian J: Asymptomatic normocalcemic primary hyperparathyroidism: characterization of a new phenotype of normocalcemic primary hyperparathyroidism. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006781-89 Accessed October 18, 2011.
598. Walker M, Saeed I, McMahon D, Udesky J, Liu G, Lang T, Bilezikian J: Chinese women have greater cortical bone density at the hip compared to white women. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11005930-127 Accessed October 18, 2011.
599. Liu X, Walker M, Stein E, Zhou B, Udesky J, Liu G, McMahon D, Shane E, Bilezikian J, Guo X: Pre- and Post-menopausal differences in bone density, microstructure, and mechanical competence in Chinese-American and Caucasian women. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006851-127 Accessed October 18, 2011.
600. Costa A, Rubin M, Sliney Jr J, Lenane Z, Ives R, Zhang C, McMahon D, Cremers S, Bilezikian J: PTH(1-84) lowers circulating sclerostin levels in hypoparathyroidism. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11007406-127 Accessed October 18, 2011.
601. Rubin M, Manavalan JS, McMahon D, Nino A, Northcutt A, Kravitz B, Paul G, Fitzpatrick L, Bilezikian J: Effects of rosiglitazone on circulating osteoblast and osteoclast cell populations in postmenopausal women with Type 2 diabetes mellitus. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006579-127 Accessed October 18, 2011.
602. Boutroy S, Rubin M, Sliney Jr J, Ives R, Bilezikian J: Two-year effects of PTH(1-84) on cortical bone in hypoparathyroidism. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11007633-127 Accessed October 18, 2011.

603. Bilezikian JP, Eastell R, Nino AJ, Northcutt AR, Kravitz B, Paul G, Cobitz AR, Josse R, Fitzpatrick L: Rosiglitazone reduced BMD in women with Type 2 diabetes and the effect was attenuated after switching to metformin. *J Bone Miner Res* 26 (Suppl 1). Available at http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11006203-140 Accessed October 18, 2011.
604. Chapulat et al. ECTS, 2012
605. Gross T, Pahr DH, Muller R, Rubin MR, Bilezikian JP, Zysset PK: Morphology-elasticity relationships in iliac crest biopsies are not affected by hypoparathyroidism. ESB, 2012.
606. Seeman E, Libanati C, Austin M, Chapurlat R, Boyd S, Zebaze R, Hanley D, Zanchetta J, Grauer A, Bilezikian J: Association between transitory increase in PTH following denosumab administration and reduced intracortical porosity is a distinctive attribute of denosumab therapy. Annual Meeting of European Calcified Tissue Society, Stockholm, Sweden, 2012.
607. Costa AG, Cremers S, Dworakowski E, Nickolas TL, Rubin MR, Walker MD, Stein EM, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP: Validation and comparison of two commercially available ELIASs for circulating sclerostin. Annual Meeting of European Calcified Tissue Society, Stockholm, Sweden, 2012.
608. Seeman E, Libanati C, Austin M, Chapurlat R, Boyd SK, Zebaze R, Hanley DA, Zanchetta J, Grauer A, Bilezikian JP: The transitory PTH increase following denosumab administration is associated with reduced intracortical porosity: a distinctive characteristic of denosumab therapy. IOF-ECCEO Annual Meeting, Bordeaux, France, 2012.
609. Zebaze RM, Libanati C, Austin M, Bilezikian JP, Seeman E: Denosumab reduces intracortical porosity more than alendronate in the compact-appearing cortex and outer transitional zone. IOF-ECCEO Annual Meeting, Bordeaux, France, 2012.
610. Hattersley G, Bilezikian J, Guerriero J, Kumar P, Zanchetta J, Lyttle CR, O'Dea L: Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis. Endocrine Society's 94th Annual Meeting, 2012.

611. Bilezikian JP, Mosekilde L, Shoback D, Vokes T, Mannstadt M, Clarke B, Lagast H, Garceau R: Efficacy of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: a randomized, double-blind, placebo-controlled study. Presented at The Endocrine Society Annual Meeting, 2012.
612. Shoback D, Clarke B, Brandi ML, Bilezikian J, Lagast H: Safety and tolerability of recombinant human parathyroid hormone (rhPTH[1-84]) in a randomized, double-blind, placebo-controlled study for the treatment of adults with hypoparathyroidism. Presented at The Endocrine Society Annual Meeting, 2012.
613. Lewiecki EM, Miller PD, Bilezikian JP: Bone density testing interval and transition to osteoporosis. *N Eng J Med*, Letter to Editor 366:1546-1547, 2012.
614. Arantes HP, Bilezikian JP, Lazzaretti-Castro M: Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. *JCEM*, (Letter to Editor) 97:311-325; doi:10.1210/jc.2011-2332, 2012.
615. Walker MD, Cusano NE, Romano M, Sliney Jr J, Zhang C, McMahon DJ, Bilezikian JP: Therapy of male osteoporosis: risedronate, teriparatide or both. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2592bb39-e965-44d4-a0b6-58f24baeaf28> Accessed October 18, 2012.
616. Boutroy S, Silva B, Cusano N, McMahon D, Zhang A, Udesky J, Bilezikian JP: Skeletal microstructural abnormalities in primary hyperparathyroidism by high resolution peripheral quantitative computed tomography. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=55e484c5-d202-45ab-bfe5-56a80c67253c> Accessed October 18, 2012.
617. Boutroy S, Silva B, Rubin MR, Sliney J, Udesky J, McMahon DJ, Zhang C, Cusano NE, Bilezikian J: Primary hyperparathyroidism and hypoparathyroidism show major microstructural differences from each other by high resolution peripheral computed tomography. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ba6242d6-c807-47a0-9277-0ce8694dfafd> Accessed October 18, 2012.

618. Boutroy S, Walker MD, Udesky J, McMahon DJ, Liu G, Bilezikian J: Lower cortical porosity and higher cortical tissue mineral density help to explain stronger bones in Chinese versus Caucasian women. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=a656a6b2-649e-4fef-8295-a7341bd84a3b> Accessed October 18, 2012.
619. Boutroy S, Rubin MR, Cusano NE, Costa AG, Lenane Z, Sliney Jr J, Bilezikian J: Four-year effects of PTH(1-84) on cortical bone in hypoparathyroidism. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=7f608f48-2f9e-4ec6-be9f-206a238c4a05> Accessed October 18, 2012.
620. Costa AG, Cremers S, Rubin MR, Lenane Z, Dworakowski E, Zhang C, McMahon DJ, Sliney Jr J, Castro ML, de Medicina EP, Bilezikian J: Acute and chronic effects of PTH(1-84) on circulating sclerostin levels in hypoparathyroidism. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=88d83f49-a184-496c-8101-50bbad3cfe4d> Accessed October 18, 2012.
621. Costa AG, Cremers S, Dworakowski E, Nickolas TL, Rubin MR, Walker MD, Stein EM, Castro ML, de Medicina EP, Silverberg SJ, Bilezikian J: Measurement of sclerostin in the circulation: validation and comparison of two commercially available ELISAS for circulating sclerostin. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6a89e5ef-3f8d-4671-b9ef-6e2b278e7ab3> Accessed October 18, 2012.
622. Costa AG, Cremers S, Rubin MR, Cusano NE, Dworakowski E, Lenane Z, Zhang C, Sliney Jr. J, McMahon DJ, Castro ML, de Medicina EP, Bilezikian J: Changes in circulating sclerostin reflect changes in bone remodeling dynamics induced by PTH(1-84). *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6410c806-7a1e-468c-9c3d-6d507ccd57bc> Accessed October 18, 2012.
623. Cusano NE, Rubin MR, McMahon DJ, Tulley A, Sliney Jr J, Bilezikian J: Major improvements in quality of life after 1 year of PTH(1-84) therapy in hypoparathyroidism. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ab718176-3118-47e3-9d11-956818a66e96> Accessed October 18, 2012.

624. Cusano NE, Rubin MR, McMahon DJ, Dworakowski E, Cremers S, Tulley A, Sliney Jr J, Bilezikian J: PTH(1-84) in hypoparathyroidism: course as determined by changes in bone turnover markers after 4 continuous years of treatment. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=d9e66e79-0e1a-456f-9836-7a279015dd07> Accessed October 18, 2012.
625. Cusano NE, Maalouf NM, Dworakowski E, Zhang C, Cremers S, Bilezikian J: Epidemiology and natural history of normocalcemic primary hyperparathyroidism and normocalcemic hypoparathyroidism. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=f2015340-d87b-4553-8e24-36fd1d70bd62> Accessed October 18, 2012.
626. Silva BC, Hans D, Zhang CA, Udesky J, McMahon D, Walker M, Boutroy S, Bilezikian JP: Trabecular bone score – TBS - a novel method to evaluate bone microarchitecture in primary hyperparathyroidism. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b4ecbb50-956e-438d-b82c-80bf91e91832> Accessed October 18, 2012.
627. Bilezikian J, Clarke BL, Mannstadt M, Vokes TJ, Shoback D, Lagast H, Garceau R: Effect of recombinant human parathyroid hormone (rhPTH[1-84]) on skeletal dynamics and BMD in hypoparathyroidism: the REPLACE study. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=57591fbc-a2ef-40a0-90da-a4c888d4a230> Accessed October 18, 2012.
628. Maalouf NM, Ayers C, Cusano NE, Silverberg SJ, Bilezikian JP: Does an elevated serum parathyroid hormone increase cardiovascular risk? Comparison of coronary artery calcification in patients with primary hyperparathyroidism versus normocalcemic hyperparathyroidism. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=0ee5ecb4-f227-431b-b0c7-c5fc5d991f54> Accessed October 18, 2012.
629. Agarwal S, Rubin M, Manavalan S, McMahon DJ, Nino A, Fitzpatrick LA, Bilezikian JP: Rosiglitazone affects osteoclast activity in type 2 diabetes mellitus. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=39411a7c-f9ae-4ef4-a8ac-17dce73ec096> Accessed October 18, 2012.

630. Vokes TJ, Shoback DM, Clarke BL, Mannstadt M, Bilezikian JP, Berg J, Lagast H, Garceau R: Efficacy and safety of low dose recombinant parathyroid hormone (rhPTH[1-84]) in hypoparathyroidism: the RELAY Study. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6e25fed9-e7bc-4866-a4a7-e6e39172d61a> Accessed October 18, 2012.
631. Zebaze RM, Libanati C, Austin M, Bilezikian JP, Seeman E: Antiresorptive action is dependent on access to remodeling upon cortical and trabecular surfaces: comparison of denosumab and alendronate. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=70fe42cd-1d35-452a-9bee-4ba984d934c6> Accessed October 18, 2012.
632. Arantes HP, Chiang AY, Bilezikian JP, Lazaretti-Castro M: Correlation between 25 hydroxyvitamin D (25OHD) levels and latitude in a Brazilian postmenopausal population with low bone mass: from the *Arzoxifene Generation Study*. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=335fd416-fe17-4950-99ce-25f46eac104a> Accessed October 18, 2012.
633. Boutroy S, Silva B, Rubin M, Sliney Jr J, McMahon D, Zhang C, Cusano N, Bilezikian J: Skeletal microstructural abnormalities in hypoparathyroidism by high resolution peripheral quantitative computed tomography. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=c26c3a56-a0e2-4b55-8307-d3ff066d5a6c> Accessed October 18, 2012.
634. Seeman E, Libanati C, Austin M, Chapurlat R, Boyd SK, Zebaze R, Hanley DA, Zanchetta J, Grauer A, Bilezikian JP: The transitory PTH increase following denosumab administration is associated with reduced intracortical porosity: a distinctive characteristic of denosumab therapy. ANZBMS, 2012.
635. Clarke B, Bilezikian J, Shoback D, Vokes T, Mannstadt M, Lagast H, Garceau R: Recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of patients with hypoparathyroidism. Annual Meeting of American Academy of Family Physicians, 2012.
636. Gill J, Klimecky L, Zhang Q, Zhou H, Bilezikian J, Dempster D, Ascenzi MG: Differences in cortical micro-structure between hypo- and hyper- parathyroidism in pre- and post-menopausal women. UCLA Orthopedic Hospital, Research Day, 2012.

637. Bilezikian JP: Anabolic therapies in osteoporosis. Clinical Update in Endocrinology and Metabolism, University of Brescia, Brescia, Italy, July, 2012.
638. Shoback D, Mannstadt M, Clarke B, Bilezikian J, Vokes T, Lagast H: Efficacy of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: postsurgical vs nonsurgical etiology. Presented at the American Thyroid Association 82nd Annual Meeting, Quebec City, PQ Canada, September 19-23, 2012.
639. Paschalis EP, Roschger P, Rubin MR, Shane E, Gamsjaeger S, Hofstetter B, Zoehrer R, Misof BM, Dempster D, Sliney J, Compito C, Zhou H, Silverberg SJ, Bilezikian JP, Klaushofer K: Bone material properties in hypoparathyroidism. Presented at the Austrian Bone and Mineral Society, 2012.
640. Seeman E, Zebaze RM, Libanati C, Austin M, Bilezikian JP: Denosumab reduce la porosidad intracortical en mayor medida que alendronato en el hueso cortical compacto y en la porción externa de la zona de transición entre hueso cortical y trabecular. Presented at XVII Congreso de la Sociedad Española de Investigación Ósea y Metabolismo Mineral, Cuenca, 24-26 Octubre 2012.
641. Zhou B, Silva B, Wang J, Stein EM, McMahon DJ, Zhang CA, Udesky J, Boutroy S, Shane E, Bilezikian JP, Guo XE: Dramatic loss in trabecular plates and compromised bone stiffness in postmenopausal women with primary hyperparathyroidism. Orthopedic Res Soc, 2012.
642. Hattersley G, Bilezikian JP, Guerriero J, Kumar P, Zanchetta J, Lyttle CR, O'Dea LS: Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis. Presented at the 94th Annual Meeting of the Endocrine Society, 2012.
643. Bilezikian JP, Brandi ML, Ebeling PR, Melmed S, Tonelli F, Sakurai A, Dralle H, Walls G, Newey P, Thakker RV: MEN1 Guidelines. J Clin Endocrinol Metab (In Press), Letter to the Editor, 2012.
644. Seeman E, Libanati C, Austin M, Chapurlat R, Boyd SK, Zebaze R, Hanley DA, Zanchetta J, Grauer A, Bilezikian JP: The transitory PTH increase following denosumab administration is associated with reduced intracortical porosity: a distinctive characteristic of denosumab therapy. Presented at ECCEO, Florence, Italy, April, 2013.

645. Seeman E, Libanati C, Austin M, Chapurlat R, Boyd SK, Zebaze R, Hanley DA, Zanchetta J, Grauer A, Bilezikian JP: L'augmentation transitoire de la PTH après l'administration du denosumab (DMAb) est associée à une réduction de la porosité intracorticale: une caractéristique distinctive du traitement par denosumab. Presented, Societe francaise de rheum atologie congress Paris, 2012.
646. Vokes T, Shoback D, Clarke B, Mannstadt M, Lagast H, Garceau R, Bilezikian J: Efficacy of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: the REPLACE Study. Presented at The American Association of Endocrine Surgeons 2013 Annual Meeting, Chicago, IL.
647. Clarke B, Mannstadt M, Vokes T, Shoback D, Lagast H, Bilezikian J: Improvements in mineral homeostasis by recombinant human parathyroid hormone (rhPTH[1-84]) treatment in adults with hypoparathyroidism: the REPLACE Study, a multicenter, placebo-controlled, randomized clinical trial. Presented at AACE, 2013.
648. Shoback D, Vokes T, Mannstadt M, Clarke B, Lagast H, Bilezikian J: Safety and tolerability of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: The REPLACE Study, a randomized, double-blind, placebo (PBO)-controlled study. Presented at AACE, 2013.
649. Shoback D, Mannstadt M, Clarke B, Vokes T, Lagast H, Bilezikian J: The effect of recombinant human parathyroid hormone (rhPTH[1-84]) on vitamin (Vit) D metabolism: results from Phase III REPLACE and Phase I Clinical studies. Presented at the The Endocrine Society 2013 Annual Meeting, San Francisco, CA.
650. Clarke B, Shoback D, Mannstadt M, Vokes T, Lagast H, Bilezikian J: The effect of recombinant human parathyroid hormone (rhPTH[1-84]) on phosphate homeostasis in patients with hypoparathyroidism. Presented at The Endocrine Society 2013 Annual Meeting, San Francisco, CA.
651. Fink DA, Raciti PM, Walker MD, Bilezikian JP, Silverberg SJ: Hypercalcemia associated with elevated PTHrP in a patient with a chronic sacral ulcer. Presented at The Endocrine Society 2013 Annual Meeting, San Francisco, CA.
652. Bilezikian JP: Hypoparathyroidism: Pharmacological intervention with parathyroid hormone. Presented at ESCEO-F.I.R.M.O. Symposium, Rome, Italy, 2013.
653. Bilezikian JP: New insights into bone strength in primary hyperparathyroidism. PHPT Symposium at ISCD Annual Meeting, Tampa, Florida, 2013.

654. Ascenzi MG, Gill J, Klimecky L, Hourany T, Zhou H, Bilezikian J, Dempster D: Differences in cortical micro-structure between women and men with hypo- or hyperparathyroidism. Presented at ESB2013.
655. Abraham A, Silva BC, Walker M, Boutroy S, Zhang C, McMahon D, Liu G, Hans D, Bilezikian JP: The trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by cQCT and HRpQCT in Chinese-American and Caucasian women. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=b9cfb77f-5338-4a16-8b09-3db6edbc4228> Accessed April 17, 2014
656. Chiavistelli S, Silva BC, Rubin MR, Cusano NE, Costa A, Zhang C, Sliney J Jr, Anderson LB, Hans D, Bilezikian JP: Two-years effects of PTH (1-84) on bone microstructure in post-menopausal women with hypoparathyroidism. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=0b8c59df-58de-4f08-8de8-dc6328d0317d> Accessed April 17, 2014
657. Costa AG, Lenane Z, Zhang C, Dworakowski E, Cremers S, Lee J, Bilezikian JP: After parathyroidectomy in primary hyperparathyroidism, sclerostin, osteocalcin, and undercarboxylated osteocalcin change rapidly. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=4b7f6934-28de-4045-868a-94d6f49a983a> Accessed April 17, 2014
658. Cusano NE, Silva BC, Zhang C, Nishiyama K, Fan W, Romano M, Bilezikian JP: Skeletal microstructure improves markedly after parathyroidectomy in primary hyperparathyroidism: site- and gender-specific differences. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=0e8dea7e-f73b-422d-90e7-ceae2e8bdb0d> Accessed April 17, 2014
659. Cusano NE, Rubin MR, Silva B, Zhang C, Fan W, Romano M, Anderson L, Sliney J Jr, Bilezikian JP: Parathyroid hormone regulates bone microstructure: reciprocal changes after treatment of hyper- and hypoparathyroid subjects. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=4dc77b7a-13e0-4169-86a5-436e0a263532> Accessed April 17, 2014

660. Bilezikian JP, Hoff L, Vokes T, Rothman J, Clarke BL, Mannstadt M, Lagast H, Shoback D: Changes in bone turnover markers and bone mineral density with recombinant human parathyroid hormone, rhPTH(1-84) in hypoparathyroidism: potential utility as surrogate endpoints for monitoring-the REPLACE study. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=f7964cf6-851e-4ce3-a8f4-5120b7e275ca> Accessed April 17, 2014
661. Toulis K, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP: β -adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, dose, gender and site-specific effects. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=b35495c7-5347-4d79-a209-c103ef0203a3> Accessed April 17, 2014
662. Liu J, Silva BC, Zhao L, He X, Tao B, Sun L, Zhao H, Cusano N, Fan W, Romano M, Ning G, Bilezikian JP: Major changes in the clinical phenotypes of primary hyperparathyroidism in the United States and China over the past 20 years: a tale of two countries. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at <http://www.asbmr.org/education/AbstractDetail?aid=5d37c331-c4f6-4182-b21f-b6ed47c7ad19> Accessed April 17, 2014
663. Rubin MR, Zwahlen A, Dempster DW, Zhou H, Cusano NE, Sliney J Jr, Dellabadia M, McMahon DJ, Muller R, Bilezikian JP: PTH (1-84) administration improves three dimensional cancellous bone structure in hypoparathyroidism early in treatment. *J Bone Miner Res* 28 (Suppl 1). Available at <http://www.asbmr.org/education/AbstractDetail?aid=ed685e42-6df2-47f7-8955-5fd09bc92a3b> Accessed April 17, 2014
664. Silva BC, Cusano NE, Zhang C, Abraham A, Boutroy S, Fan W, Hans D, Bilezikian JP: Changes in bone microarchitectural texture assessed by trabecular bone score after parathyroidectomy in primary hyperparathyroidism. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at: <http://www.asbmr.org/education/AbstractDetail?aid=08f30f9f-a4d9-47dc-a6bf-45da4b563917> Accessed April 17, 2014.
665. Silva BC, Cusano N, Fan W, Romano M, Sliney J Jr, Lenane Z, Anderson LB, Hans D, Rubin M, Bilezikian JP: Major differences in trabecular bone score between primary hyperparathyroidism and hypoparathyroidism remain 1 year after reversal of the abnormal parathyroid state. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at: <http://www.asbmr.org/education/AbstractDetail?aid=425f9019-3d22-415a-b586-1dd4528a63a7> Accessed April 17, 2014

666. Silva BC, Cusano N, Zhang C, Irani D, Sliney J Jr, Lenane Z, Anderson LB, Boutroy S, Hans D, Rubin M, Bilezikian JP: Beneficial effects of PTH (1-84) in hypoparathyroidism as determined by microarchitectural texture assessment (TBS): a 4-year experience. *J Bone Miner Res* 28 (Suppl 1) 2013. Available at: <http://www.asbmr.org/education/AbstractDetail?aid=d1c1e9e9-b2bb-4b86-b123-3ed6114a3c5d> Accessed April 17, 2014.
667. Boutroy S, Walker MD, Liu SX, McMahon DJ, Liu G, Guo XE, Bilezikian JP: Lower cortical porosity and higher tissue mineral density in Chinese-American vs. white women. *Osteoporos Int* 24 (Suppl 1):S33-S67, 2013.
668. Bilezikian JP: New insights into bone strength in primary hyperparathyroidism. Presented at the Inaugural ICHTS-ASBMR International Chinese Musculoskeletal Research Conference, Suzhou, China, May 21-23, 2013.
669. Bilezikian JP: Primary hyperparathyroidism: new insights with a view towards new guidelines in 2013. Presented at the 14th Regional Osteoporosis Conference, Hong Kong, May 25-26, 2013.
670. Bilezikian JP: Treatment of glucocorticoid-induced osteoporosis. Presented at the 8th International Congress on GIO and Other Drug-induced Osteoporosis, Pisa, Italy, 2013.
671. Sliney J Jr, Cusano NC, Rubin MR, Ives R, Lenane Z, Anderson LB, Bilezikian JP: Hypoparathyroidism: overcoming limitations in the study of a rare disease. *J General Medicine, Supplement*, 2013.
672. Bilezikian JP: 40 years of bisphosphonates: A review of benefits and risks. Presented at the 18th Congress of the Argentine Society of Endocrinology, Buenos Aires, Nov 2013.
673. Bilezikian JP: Anabolics in osteoporosis treatment: Rationale for use and perspectives. Presented at the 18th Congress of the Argentine Society of Endocrinology, Buenos Aires, Nov 2013.
674. Bilezikian JP: Meet the expert session: Primary hyperparathyroidism: New guidelines for 2014. Presented at the 18th Congress of the Argentine Society of Endocrinology, Buenos Aires, Nov 2013.

675. Khan A, Bilezikian JP, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Toth M: Cinacalcet normalizes serum calcium in a randomized, placebo-controlled clinical study in patients with primary hyperparathyroidism unable to undergo parathyroidectomy. ICE/ENDO, 2014. Chicago, IL, June 2014.
676. Bilezikian JP: Introduction to emergent management of calcium, phosphate, and metabolic bone diseases. In: Endocrine and Metabolic Medical Emergencies (Matfin, G, ed) The Endocrine Press, Washington DC, 180-181, 2014.
677. Brandi ML, Beckers A, Vokes TJ, Mannstadt M, Bilezikian JP, Clarke BL, Lagast H, Shoback DM: The effect of recombinant human parathyroid hormone, rhPTH(1-84), on Vitamin D metabolism and phosphate homeostasis in patients with hypoparathyroidism: results from Phase III 24-week REPLACE and Phase I clinical studies. European Congress of Endocrinology (ECE) 2014 Annual Meeting, Wroclaw, Poland.
678. Bowlin SJ, Sadowski T, Vokes TJ, Bilezikian JP, Clarke BL, Mannstadt M, Shoback DM, Lagast H: PARADIGHM™: A natural history registry for patients with chronic hypoparathyroidism. European Congress of Endocrinology (ECE) 2014 Annual Meeting, Wroclaw, Poland.
679. Bilezikian JP, Maruani G, Rothman J, Clarke BL, Mannstadt M, Vokes T, Lagast H, Shoback DM: Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1-84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week REPLACE and 8-week RELAY Phase III clinical trials. European Calcified Tissue Society (ECTS) 2014 Annual Meeting, Prague, Czech Republic, 2014.
680. Vokes TJ, Levine M, Warren M, Shoback DM, Bilezikian JP, Mannstadt M, Lagast H, Clarke BL: Long-term safety and efficacy of recombinant human parathyroid hormone, rhPTH(1-84), for the treatment of adults with hypoparathyroidism: one-year data from the RACE study. American Association of Clinical Endocrinologists (AACE) Annual Meeting, Las Vegas, NV, 2014.
681. Mannstadt M, Vokes T, Watts N, Denham D, Shoback D, Clarke BL, Lagast H, Bilezikian JP: Long-term safety and efficacy of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: interim data from the RACE study. International Congress of Endocrinology and Endocrine Society (ICE/ENDO) Meeting, Chicago, IL, 2014.

682. Bowlin SJ, Sadowski T, Vokes TJ, Bilezikian JP, Clarke BL, Mannstadt M, Shoback DM, Lagast H: PARADIGM™: A natural history registry for patients with chronic hypoparathyroidism. International Congress of Endocrinology and Endocrine Society (ICE/ENDO) Meeting, Chicago, IL, 2014.
683. Arantes HP, Chiang AY, Bilezikian J, Lazaretti-Castro M: Serum CTX and P1NP and their correlation with BMD in postmenopausal women with low bone mass: data from Arzoxifene Generation Trial. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Seville, Spain (Submitted), 2014.
684. Tanenbaum JS, Fink DA, Nguyen KT, Rubin MR, Bilezikian JP: Dual mechanisms of hypercalcemia in a patient with adult T-cell leukemia/lymphoma. ICE/ENDO 2014, Chicago, IL, June 2014.
685. Nguyen K, Fink DA, Rubin MR, Wardlaw SL, Bilezikian JP: Uremic leontiasis ossea: a rare disorder of skeletal remodeling due to severe renal osteodystrophy. ICE/ENDO 2014, Chicago, IL, June 2014.
686. Fink DA, Nguyen KT, Kurra S, Ebner SA, Bilezikian JP: Hyperthyroidism and atrial fibrillation after parathyroidectomy. ICE/ENDO 2014, Chicago, IL, June 2014.
687. Bilezikian JP: Primary hyperparathyroidism: new guidelines for 2014. Presented at the 2nd Saudi Osteoporosis Society Meeting, Saudi Arabia, March, 2014.
688. Bilezikian JP: Osteoporosis in men. Presented at the 2nd Saudi Osteoporosis Society Meeting, Saudi Arabia, March, 2014.
689. Bilezikian JP: Monitoring of osteoporosis treatment. Presented at the 2nd Saudi Osteoporosis Society Meeting, Saudi Arabia, March, 2014.
690. Bilezikian JP: How to interpret the DXA scan. Presented at the 2nd Saudi Osteoporosis Society Meeting, Saudi Arabia, March, 2014.
691. Bilezikian JP: Parathyroid carcinoma. 6th Annual Meeting of Skeletal Endocrinology, Brescia, Italy. March, 2014.

692. Bilezikian JP, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C: Denosumab restores cortical bone loss at the distal radius associated with aging and reduces wrist fracture risk: analyses from the FREEDOM extension cross-over group. Submitted to Annual Meeting of the American College of Rheumatology, 2014.
693. Cipriani C, Biamonte F, Diacinti D, Biondi P, Raimo O, Piemonte S, Pepe J, Romagnoli E, Bilezikian J, Minisola S: Clinical presentation of primary hyperparathyroidism: a five-year study. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=7100f8f6-6b4d-4061-aa0e-b6eb1d982d09> Accessed September 26, 2014
694. Cipriani C, Silva B, Cusano N, Costa A, Irani D, Abraham A, McMahon D, Anderson LB, Levy E, Rubin M, Bilezikian J: Beneficial effects of PTH(1-84) in hypoparathyroidism as determined by trabecular bone score (TBS). *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=b3d6a56b-72ab-448e-ba4d-eab3beb02fcd> Accessed September 26, 2014
695. Cusano N, Rubin M, McMahon D, Irani D, Anderson LB, Levy E, Bilezikian J: PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=26c19d04-b5f7-490c-bd41-5f2daf0d3e5b> Accessed September 26, 2014.
696. Tribble MB, Cohen A, De Bakker C, Lappe J, Recker R, Nishiyama K, Rubin M, Bilezikian J, Shane E, Liu X: Increased endocortical formation and periosteal resorption at the distal tibia in premenopausal women with idiopathic osteoporosis treated with 18 months of teriparatide. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=285ef0d5-88b3-4721-816e-543d79daf54b> Accessed September 26, 2014
697. Rubin M, Cusano N, Anderson LB, Irani D, Sliney J, Levy E, Fan W, McMahon DJ, Bilezikian J: PTH(1-84) treatment is safe and effective in hypoparathyroidism for six years. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=79b92bdb-af9a-4ef3-8b5c-1e9030340b9e> Accessed September 26, 2014

698. Clarke BL, Mannstadt M, Shoback DM, Vokes TJ, Warren ML, Levine MA, Lagast H, Bilezikian JP: Long-term effect of recombinant human parathyroid hormone, rhPTH(1-84), on skeletal dynamics in patients with hypoparathyroidism: one-year data from the open-label RACE study. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=c86e8ee3-0c6b-4d90-b43c-c6c16c3fe08f> Accessed September 26, 2014
699. Bilezikian JP, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C: Denosumab restores cortical bone loss at the distal radius associated with aging and reduces wrist fracture risk; analyses from the FREEDOM extension cross-over group. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=3302d1bd-f620-4961-8f72-f3aea8b0bd81> Accessed September 26, 2014
700. Cusano N, Zhang C, Fan W, Costa A, Levy E, Bilezikian J: Skeletal microstructure continues to improve markedly two years after parathyroidectomy in primary hyperparathyroidism. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=28aadabb-60ff-488d-924e-64165b5a2de9> Accessed September 26, 2014
701. Silva B, Babbar R, Liu G, Zhang C, McMahon D, Fan W, Hans D, Bilezikian J, Walker M: Age-related changes in lumbar spine trabecular bone score in Chinese-American men. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=2f1c07ed-781c-4876-b180-eac28cfbf893> Accessed September 26, 2014
702. Abraham A, Zhang C, Silva B, Fan W, Hans D, Cusano N, Bilezikian J: Changes in trabecular bone score up to two years after parathyroidectomy in primary hyperparathyroidism. *J Bone Miner Res* 29 (Suppl 1) 2014. Available at <http://www.asbmr.org/education/AbstractDetail?aid=2fa4e479-13e3-4236-9e72-b22974b84997> Accessed September 26, 2014
703. Bowlin S, Sadowski T, Vokes T, Bilezikian J, Clarke B, Mannstadt M, Levine M, Shoback D, Lagast H: PARADIGHM™: Observational registry of patients with chronic hypoparathyroidism. Presented at the Annual Meeting of the American Thyroid Association, October 2014.

704. Fahrleitner-Pammer A, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Bilezikian JP, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C: Denosumab reversiert altersbedingten kortikalen Knochenverlust am distalen Radius und senkt das Frakturrisiko: Analysen der FREEDOM-Verlängerungsstudie. German Osteology Congress, 2015, (Submitted)
705. Bilezikian JP: Male Osteoporosis. Presented at Meet-the-Professor, Endocrine Society Annual Meeting, March 2015.
706. Bilezikian JP, Clarke BL, Lagast H, Levine M, Mannstadt M, Shoback DM, Vokes TJ, Warren M: Long-term effects of recombinant human parathyroid hormone rhPTH(1-84), on bone remodeling in patients with hypoparathyroidism: 3-year data from the open-label RACE study. European Calcified Tissue Society (ECTS) and International Bone and Mineral Society (IBMS) Joint Meeting, 2015. (Submitted).
707. Fahrleitner-Pammer A, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Bilezikian JP, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C: Denosumab (DMab) restores cortical bone loss at the 1/3 radius associated with aging and reduces wrist fracture risk: analyses from the FREEDOM Extension Cross-over Group. To be Presented at Annual Meeting of ECTS, 2015.
708. Abraham A, Rubin MR, Accili D, Bilezikian JP, Pajvani U: Hypoglycemia secondary to sulfonylurea ingestion in a patient with end stage renal disease (ESRD): results from a 72 hour fast. To Be Presented at the Endocrine Society Meeting, San Diego, 2015.
709. Bilezikian JP: When bone density is not enough: Clinical implications of determining bone microstructure. Santa Fe Bone Symposium Newsletter, 2015.
710. Clarke BL, Mannstadt M, Vokes TJ, Rothman J, Warren ML, Denham DS, Levine MA, Lagast H, Bilezikian JP, Shoback DM: Three-year safety and efficacy data for recombinant human parathyroid hormone, rhPTH(1-84), in the treatment of adults with hypoparathyroidism: The RACE Study. European Congress of Endocrinology (ECE) 2015 Annual Meeting, Dublin, Ireland.
711. Bilezikian JP, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini AF, Libanati C: Denosumab restores cortical bone loss at the 1/3 radius associated with aging and reduces wrist fracture risk: analyses from the Freedom Extension Cross-over Group. Presented at Endocrine Society 97th Annual Meeting, March 6, 2015.

712. Bilezikian JP, Benhamou CL, Lin CJF, Brown JP, Fahrleitner-Pammer A, Franek E, Gilchrist N, Simon JA, Valter I: Denosumab restores cortical bone loss at the distal radius associated with aging and reduces wrist fracture risk: analyses from the FREEDOM Extension cross-over group. Presented at the Australian New Zealand Society of Geriatric Medicine. May, 2015.
713. Mannstadt M, Bilezikian JP, Clarke BL, Vokes TJ, Warren ML, Lagast H, Shoback DM, Levine MA: Bone remodeling in patients with hypoparathyroidism treated for 3 years with recombinant human parathyroid hormone, rhPTH(1-84), in the Open-Label RACE Study. J Bone Miner Res 30 (Suppl 1) 2015
<http://www.asbmr.org/education/AbstractDetail?aid=646e168b-f52b-4509-8b9d-a620ecb9a418> Accessed November 3, 2015
714. Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Bilezikian JP, Lagast H, Shoback DM: Recombinant human parathyroid hormone (rhPTH[1-84]) therapy in hypoparathyroidism and improvement in quality of life. J Bone Miner Res 30 (Suppl 1) 2015. Available at <http://www.asbmr.org/education/AbstractDetail?aid=3e86099e-02d1-49c4-abf3-03b8538be635> Accessed November 3, 2015
715. Abraham A, Cipriani C, Zhang C, Hans D, Bilezikian JP: Changes in BMD and TBS up to 2 years after surgical or medical management of primary hyperparathyroidism. J Bone Miner Res 30 (Suppl 1) 2015. Available at <http://www.asbmr.org/education/AbstractDetail?aid=d0c839ac-db29-480c-abcc-4a5f05ca3f38> Accessed November 3, 2015
716. Cipriani C, Silva B, Rubin M, Cusano N, McMahon DJ, Pepe J, Piemonte S, Fan WW, Rodriguez JK, DeLucia F, Biamonte F, Minisola S, Bilezikian JP: Comparative effect of PTH(1-84) on bone mineral density and trabecular bone score (TBS) in hypoparathyroidism and osteoporosis. J Bone Miner Res 30 (Suppl 1) 2015. Available at <http://www.asbmr.org/education/AbstractDetail?aid=db250ac1-019b-43ca-b9bc-b0a6e1dd6a6b> Accessed November 3, 2015
717. Rubin MR, Cusano NE, Fan W, Delgado Y, Mahdavi F, Rodriguez J, Costa A, McMahon DJ, Bilezikian JP: PTH(1-84) treatment is safe and effective in hypoparathyroidism for seven years. J Bone Miner Res 30 (Suppl 1) 2015. Available at <http://www.asbmr.org/education/AbstractDetail?aid=a66f7d5f-66d4-4d6a-8277-0ca0ba680867> Accessed November 3, 2015

718. Silva B, Fleischer J, Lenane Z, Fan WW, McMahon DJ, Bilezikian J: Spontaneous remission of primary hyperparathyroidism – a case report. *J Bone Miner Res* 30 (Suppl 1) 2015. Available at <http://www.asbmr.org/education/AbstractDetail?aid=8ec97ae3-9fa3-47af-833d-913b8fa76d41> Accessed November 3, 2015
719. Cusano N, Nishiyama K, Zhang C, Rubin M, McMahon D, Guo XE, Bilezikian J: Skeletal microstructure and estimated bone strength in hypoparathyroidism. *J Bone Miner Res* 30 (Suppl 1) 2015. Available at <http://www.asbmr.org/education/AbstractDetail?aid=eb8a406e-97eb-4370-aea4-a57a0fea47d8> Accessed November 3, 2015
720. Hutchings N, Bilezikian JP, Grigoryan A: Identifying risk factors for fragility fractures among elderly Armenians: initiating treatment and prevention strategies. Presented at the 4th International Medical Congress of Armenia, Yerevan, Armenia, July 3, 2015.
721. Cipriani C, Silva B, Rubin M, Cusano N, McMahon DJ, Pepe J, Piemonte S, Fan WW, Rodriguez JK, De Lucia F, Biamonte F, Minisola S, Bilezikian JP: Comparative effect of PTH(1-84) on bone mineral density and trabecular bone score (TBS) in hypoparathyroidism and osteoporosis. Submitted for Presentation at the Italian Society of Internal Medicine, 2015.
722. Bilezikian JP, Benhamou CL, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C: Denosumab restores cortical bone loss at the 1/3 radius associated with aging and reduces wrist fracture risk: analyses from the FREEDOM Extension cross-over group. 6th Central European Congress on Osteoporosis and Osteoarthritis, Krakow, Poland, September 25-26, 2015.
723. Bilezikian JP: Primary hyperparathyroidism update. ASBMR Meet the Professor Handout, October 2015.
724. Benhamou CL, Bilezikian JP, Lin CJF, Brown JP, Daizadeh NS, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C: Le denosumab inverse le processus de perte osseuse corticale au radius distal associée a l'âge, et réduit le risque de fracture du poignet: analyses des données du groupe *de novo* de l'extension de FREEDOM. Submitted to French Society of Rheumatology Annual Congress, December, 2015.

725. Compston J, Bilezikian JP: Bone mineral density and bone quality in diabetes mellitus. Presented, Skeletal Endocrinology, Brescia, Italy, September, 2015.
726. Bilezikian JP: Advances in treatment of osteoporosis: osteoanabolics. Presented, Skeletal Endocrinology, Brescia, Italy, September 2015.
727. Brandi ML, Bilezikian JP, Clarke BL, Fraser WD, Krasner A, Lagast H, Li B, Mannstadt M, Rejnmark L, Shoback DM, Vokes TJ: Similarities in postsurgical vs nonsurgical patients with hypoparathyroidism: Post hoc analysis from recombinant human parathyroid hormone (rhPTH[1-84], Parathyroid Hormone rDNA) REPLACE Study. (Submitted for Presentation), 2016.
728. Bilezikian JP: Treatment of glucocorticoid-induced osteoporosis: state of the art and perspectives. Presented at 9th International Congress: GIOSEG Glucocorticoid and Drug-Induced Osteoporosis, Rome, Italy, March 19, 2016.
729. Bilezikian JP: Primary hyperparathyroidism; New concepts and new guidelines. Presented at 4th Seoul International Congress of Endocrinology and Metabolism; 35th Annual Meeting of the Korean Endocrine Society, April 28-May 1, 2016.
730. Bilezikian JP: Current concepts in the therapy of osteoporosis. Presented at 4th Seoul International Congress of Endocrinology and Metabolism; 35th Annual Meeting of the Korean Endocrine Society, April 28-May 1, 2016.
731. Bilezikian JP: PTH: Good, bad, but not ugly. To be presented at the National Osteoporosis Society Osteoporosis Conference 2016, Birmingham, England, November 7-9, 2016.
732. Bilezikian JP: What's new in primary hyperparathyroidism. Presented at meeting of the ICE-CSE, Parathyroid Disorders – An Update, Beijing, China, September, 2016.
733. Bilezikian JP: New concepts in hypoparathyroidism. Presented at meeting of ICE-CSE, MTE Hypoparathyroidism, Beijing, China, September, 2016.
734. Bilezikian JP, Bone HG, Clarke BL, Denham DS, Lee HM, Levine MA, Mannstadt M, Peacock M, Rothman JG, Shoback DM, Vokes TJ, Warren ML, Watts NB, Krasner A: Recombinant human parathyroid hormone, (rhPTH[1-84], parathyroid hormone rDNA) decreases elevated urinary calcium levels in patients with hypoparathyroidism: 3 year analysis from RACE study. Presented at ENDO 2017, 99th Annual Meeting of the Endocrine Society, Orlando, FL, April 1-4, 2017.

735. Mannstadt M, Brandi ML, Bilezikian JP, Clarke BL, Fraser WD, Krasner A, Lagast H, Lee HM, Rejnmark L, Shoback DM, Vokes TJ: Similarities in postsurgical vs nonsurgical patients with hypoparathyroidism: post hoc analysis from recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) REPLACE study. To be presented at ENDO 2017, 99th Annual Meeting of the Endocrine Society, Orlando, FL, April 1-4, 2017.
736. Bilezikian JP: Tribute to Larry Raisz, MD, the Founding Editor of JBMR. *J Bone Min Res*, 31(9)1632, 2016.
737. Vokes TJ, Bilezikian JP, Bone HG, Clarke BL, Denham DS, Lee HM, Levine MA, Mannstadt M, Peacock M, Rothman JG, Shoback DM, Warren ML, Watts NB, Krasner A: Recombinant human parathyroid hormone, (rhPTH[1-84], Parathyroid Hormone rDNA) decreases elevated urinary calcium levels in patients with hypoparathyroidism: 3 year analysis from RACE study. (Submitted for Presentation) ENDO, 2017.
738. Nys K, Clarke BL, Mannstadt M, Vokes TJ, Rothman J, Warren ML, Denham DS, Levine MA, Krasner A, Bilezikian JP, Shoback DM: Three-year safety and efficacy data for recombinant human parathyroid hormone, rhPTH(1-84), in the treatment of adults with hypoparathyroidism: The RACE Study. (Submitted for Presentation) Dutch Endocrine Meeting, 2017.
739. Vokes TJ, Bilezikian JP, Bone HG, Clarke BL, Denham DS, Lee HM, Levine MA, Manstadt M, Peacock M, Rothman JG, Shoback DM, Warren ML, Watts NB, Krasner A: Recombinant human parathyroid hormone (rhPTH[1-84], Parathyroid Hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study. (Submitted for Presentation) 19th European Congress of Endocrinology, Lisbon, Portugal, 2017.
740. Hutchings N, Tovmasyan I, Qefoyan M, Baghdasaryan S, Bilezikian JP: Analysis of Armenian neonatal hypothyroid screening data. Presented at the Armenian Medical World Congress, Buenos Aires, 2017.
741. Hutchings N, Aghajanova E, Baghdasaryan S, Manoukian M, Gerasimov G, Bilezikian JP: Investigating iodine nutrition in Armenia. Presented at the Armenian Medical World Congress, Buenos Aires, 2017.
742. Hutchings N, Tovmasyan I, Qefoyan M, Baghdasaryan S, Bilezikian JP: Analysis of Armenian neonatal hypothyroid screening data. Presented at the Armenian Medical World Congress, Buenos Aires, 2017.

743. Hutchings N, Baghdasaryan S, Qefoyan M, Bilezikian JP: Investigating iodine nutrition in Nagorno Karabakh. Presented at the Armenian Medical World Congress, Buenos Aires, 2017.
744. Bilezikian JP: Treatment of primary hyperparathyroidism with a calcimimetic. Presented at the 3rd International Symposium on: The Calcium-Sensing Receptor (CaSR), Florence, Italy, May, 2017.
745. Hutchings N, Aghajanova E, Baghdasaryan S, Qefoyan M, Manoukian M, Gerasimov G, Bilezikian JP: Investigating iodine nutrition in Armenia. Columbia University College of Physicians and Surgeons Student Research Day, (Presented), 2017.
746. Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP: Impact of geographic region on health-related quality of life in patients treated with recombinant human parathyroid hormone: post hoc analysis of REPLACE. (Submitted for Presentation) ASBMR Annual Meeting, Denver, CO, September, 2017.
747. Gamsjaeger S, Eriksen EF, Glorieux FH, Rauch F, Dempster D, Zhou H, Shane E, Cohen A, Bilezikian JP, Rubin M, Moreira C, Brozek W, Fratzl P, Klaushofer K, Paschalis EP: Pyridinoline collagen cross-link content at actively forming trabecular surfaces is associated with fragility fracture incidence independent of BMD and the clinical diagnosis. (Submitted for Presentation) ASBMR Annual Meeting, Denver, CO, September, 2017.
748. Bilezikian JP, Fitzpatrick LA, Williams GC, Hu M, Hattersley G, Rizzoli R: Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: results of ACTIVEExtend. (Submitted for Presentation) ASBMR Annual Meeting, Denver, CO, September, 2017.
749. Cusano NE, Rubin MR, Piccolo R, Krasner A, Bilezikian JP: Maintenance of key biochemical parameters with recombinant human parathyroid hormone (1-84) in patients with hypoparathyroidism: An analysis of a long-term, open-label, single-center study. (Submitted for Presentation) ASBMR Annual Meeting, Denver, CO, September, 2017.
750. Tay Y, Cusano N, Williams J, Omeragic B, Bilezikian JP: Influence of obesity on trabecular bone score remains after parathyroidectomy in primary hyperparathyroidism. (Submitted for Presentation) ASBMR Annual Meeting, Denver, CO, September, 2017.

751. Rubin MR, Cusano NE, Zhou H, Majeed R, Omeragic B, Dempster DW, Bilezikian JP: Long-term administration of rhPTH(1-84) results in marked and sustained improvements in skeletal indices by bone histomorphometry in hypoparathyroidism. (Submitted for Presentation) ASBMR Annual Meeting, Denver, CO, September, 2017.
752. Bilezikian JP: Vitamin D in primary hyperparathyroidism and hypoparathyroidism. To be presented at the 1st International Conference on Controversies in Vitamin D, Pisa, Italy, June, 2017.
753. Hutchings N, Aghajanova E, Baghdasaryan S, Qefoyan M, Sullivan C, He X, Manoukian M, Gerasimov G, Braverman L, Bilezikian JP: Iodine nutrition in Armenia: a model of representative surveillance. To be Presented at the 87th Annual Meeting of the American Thyroid Association, October, 2017.
754. Burrillo E, Clarke BL, Mannstadt M, Vokes TJ, Rothman J, Warren ML, Denham DS, Levine MA, Krasner A, Bilezikian JP, Shoback DM: Datos de seguridad y eficacia a tres años en el tratamiento de adultos con hipoparatiroidismo con la hormona paratiroidea humana recombinante, rhPTH(1-84),: el estudio RACE. Submitted for Presentation at SEIOMM 2017, October 2017.
755. Orti LG, Mannstadt M, Brandi ML, Bilezikian JP, Clarke BL, Fraser WD, Krasner A, Lagast H, Lee HM, Rejnmark L, Shoback DM, Vokes TJ: Comparativa entre los pacientes con hipoparatiroidismo postquirúrgico y los no-quirúrgicos: Análisis “Post-Hoc” del estudio REPLACE (Recombinant Human Parathyroid Hormone (rhPTH[1-84], Parathyroid Hormone rDNA)). Submitted for Presentation at SEIOMM 2017, October 2017.
756. Bilezikian JP: Introduction to emergent management of calcium, phosphate, and metabolic bone diseases. In: Endocrine and Metabolic Medical Emergencies (Matfin, G, ed) The Endocrine Press, Washington DC, (In Press), 2017.
757. Hutchings N, Baghdasaryan S, Qefoyan M, Manoukian M, Atayan K, Bilezikian JP: Investigating iodine nutrition in Nagorno, Karabakh. To be Presented at the 87th Annual Meeting of the American Thyroid Association, October, 2017.
758. Bilezikian, JP: Disorders of the parathyroid glands: 4 decades of new concepts and insights. *Lectio Magistralis*, University of Pisa, Pisa, Italy, 2017.

759. Saag KG, Miller PD, Cosman F, Fitzpatrick LA, Hattersley G, Gut R, Mitlak B, Bilezikian JP, Dore RK: Persistent fracture reduction and BMD increases with abaloparatide-SC (TYMLOS™) followed by alendronate. Am Col of Rheum (To be Presented) 2017.
760. Bilezikian JP: Bone metabolism and skeletal complications of hypoparathyroidism. To Be Presented: Defining, Achieving, and Maintaining Disease Control in Hypoparathyroid Patients, Vienna, Austria, 9/29-9/30/2017.
761. Bilezikian JP: Long-term outcomes with parathyroid hormone therapy. To Be Presented: Defining, Achieving, and Maintaining Disease Control in Hypoparathyroid Patients, Vienna, Austria, 9/29-9/30/2017.
762. Bilezikian JP: Advances in osteoanabolic therapeutics with the advent of a new therapy: Abaloparatide. To Be Presented: 17th Congress of the Italian Society of Osteoporosis and Mineral Metabolism, Bologna, Italy, October 2017.